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Abstract 
Background and Objective: 
Diagnosis of liver fibrosis - a chronic disease that may develop into cirrhosis 
and hepatocellular carcinoma - relies on histological examination of liver biopsy, 
which is labor intensive and invasive. A non-invasive diagnostic approach is urgently 
needed to monitor disease progress regularly. Since liver is responsible for the 
production of majority of serum glycoproteins, therefore any abnormal changes in 
patterns of total serum A^-glycome may faithfully reflect the disease status of liver, and 
can be used as biomarkers for liver diseases. 
The objective of this research is to develop a methodology for high-throughput, 
quantitative analysis of A^-glycome by using MALDI-TOF mass spectrometric 
approach, and to apply the methodology for non-invasive diagnosis of liver fibrosis in 
chronic hepatitis B patients. 
Research Plan and Methodology: 
First, we aimed to develop a method for quantitative A^-glycome profiling. It 
was focused on the optimization of the enzymatic cleavage of A^-glycans from total 
glycoproteins in serum, detection of A^-glycans, and the evaluation of the quantitative 
aspect of MALDI-TOF MS in analysing A^-glycans. 
Next, we aimed at demonstrating the feasibility of applying such technology in 
liver fibrosis diagnosis. Forty-six liver fibrosis patients with chronic hepatitis B 
infection were involved. Their degrees of liver fibrosis were assessed by Ishak score 
based on histological examination of liver biopsy. The A^-glycomic features obtained 
from the pilot study were subjected to bioinformatic and statistical analysis, in order 
to identify A^-glycomic features with diagnostic value and construct a diagnostic 
model. 
Finally, we aimed to further verify the diagnostic value of serum A^-glycomic 
biomarkers and A^-glycome fingerprinting in liver fibrosis by involving a larger 
sample group, and to determine if A^-glycomic biomarkers were able to monitor 
fibrosis development during treatment. The verification study involved 167 liver 
fibrosis patients with chronic hepatitis B infection. Samples were collected before and 
after antiviral drug treatment. Pre- and Post-treatment samples were splited into two 
groups for biomarker discovery and independent validation. Data obtained from 
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biomarker discovery groups were analyzed in the same fashion as in pilot study, and 
the result was validated by validation groups. 
Result: 
A quantitative method for A^-glycan profiling was successfully developed by 
using MALDI-TOF MS. The relationship between concentration of an A^-glycan and 
its peak intensity in the mass spectra was highly linear; intra-assay and inter-assay 
coefficient of variations of our assay were found to be less than 8% and 17%, 
respectively. Total serum A^-glycome profile could be obtained from as low as 2 of 
serum. 
Total serum A/-glycome profiles from 46 patients with chronic hepatitis B were 
obtained accordingly. Bioinformatic analysis had identified 17 differential A^-glycans 
that were significantly associated with fibrosis stages. Four A^-glycans (m/z 1341.5, 
1829.7, 1933.3 and 2130.3) were selected by linear regression method and used to 
generate the diagnostic model. Leave-one-out cross-validation showed that the model 
could detect both liver fibrosis and cirrhosis with sensitivities and specificities > 83% 
with areas under ROC curve in both diseases above 0.91. 
In the verification study, we had identified 12 and 5 differential A^-glycans in 
the pre-treatment samples and in the post-treatment samples respectively. When these 
A^-glycans were used to construct 2 diagnostic models for classifying pre- and post-
treatment independent validation samples, these models attained areas under ROC 
curve of 0.84 and 0.78 for liver fibrosis, and 0.89 and 0.85 for liver cirrhosis 
respectively. For the treatment naive patients, the sensitivity and specificity of the best 
model was 79% and 84% respectively. For the post-treatment patients, the sensitivity 
and specificity of the best model was 75% and 69% respectively. Their diagnostic 
performances were comparable with other well established non-invasive diagnostic 
biomarkers developed by other research groups. We had identified 1 diagnostic N-
glycan (m/z 1829.8) in the verification study that was also found in the pilot study. 
Two diagnostic A^-glycans (m/z 1752.5, m/z 1829.8) were found in both pre-treatment 
samples and post-treatment samples. 
The structures of differential glycans were predicted by searching their m/z 
values against iV-glycan mass database. Glycans with core fucosylation and bisecting 




We had developed a high-throughput methodology for quantitative profiling of 
both glycoprotein preparations and whole serum A^-glycome by using MALDI-TOF 
MS technology. We had identified a panel of differential A^glycans with diagnostic 
value in liver fibrosis patients with chronic hepatitis B infection in a pilot study. In the 
verification study, we had confirmed the value of whole serum A'-glycome in the 
diagnosis of liver fibrosis and cirrhosis, and identified two different panels of 
differential iV-glycans for treatment-naive and post-treatment patients. We had 
constructed and compared different linear regression models for the detection of liver 
fibrosis in different set of patients. Our models developed for treatment naive and 
post-treatment patients were able to detect liver fibrosis with area under curve of 0.84 
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A^-glvcan Representation: 
Representation of A^-glycan was made according to the nomenclature adopted 
by Consortium for Functional Glycomics (CFG). Details can be found at the 
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CFG guideline was attached in the reference section in this thesis. 
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Introduction 
Liver fibrosis refers to the gradual accumulation of ECM molecules in liver due 
to chronic hepatic damages. It is one of the risk factors for the development of liver 
cirrhosis and hepatocellualr carcinoma. Currently the diagnosis of liver fibrosis is based 
on histological examination of liver biopsy, which is an invasive procedure with certain 
degree of risk or complication. Therefore, it is also not ideal for long term disease 
monitoring or screening. A reliable, non-invasive biomarker is urgently needed for liver 
fibrosis. Recently, several research groups had developed serum based, non-invasive 
diagnostic tests for liver fibrosis, including FibroTest and FibroSpect. Most of these tests 
included direct or indirect biomarkers related to liver fibrosis, and achieved an area 
under ROC curve of approximately 85%. Despite of this, histological examination of 
liver biopsy is still currently the gold standard for the diagnosis of liver fibrosis, and yet 
no serum biomarkers developed so far had achieved sufficient sensitivity and specificity 
to replace it. 
Liver was responsible for the production of a majority of serum glycoproteins. 
Therefore, the total serum glycome depends on the normal liver function. Any changes 
in liver disease status will affect the serum glycome. Previous researches had showed 
that the glycosylation status of serum transferrin was affected by alcoholic hepatitis, and 
that of alpha-fetoprotein was affected by hepatocellular carcinoma. We hypothesized that 
liver fibrosis can also affect serum glycome, and such changes can be utilized as a 
disease biomarker. Callewaert et al in 2004 had demonstrated the use of total serum N-
glycome in detecting liver cirrhosis - an advance stage of liver fibrosis - with 
approximately 90% accuracy. In this project, we aimed to utilize a similar approach and 
to use total serum A^-glycome profile as a liver fibrosis biomarker. 
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Review of Literatures 
5.1 Introduction to Liver Fibrosis 
Liver fibrosis refers to the wound-healing response by the liver due to chronic 
damage, which leads to accumulation of ECM molecules in liver and ultimately loss of 
hepatic function (1, 2). The annual probability of developing liver cirrhosis for patients 
with hepatitis B virus (HBV) infection was reported to be 0.1% - 1.0%, while the annual 
probability for liver cirrhosis patients to deteriorate into hepatocellular carcinoma (HCC) 
was between 1% to 6% (3，4). Liver cirrhosis and HCC were the leading cause of 
death and 3�� l e ad ing cancer cause of death respectively (5). There are several risk 
factors for liver fibrosis including alcohol abuse (6)，chronic viral hepatitis (7)，steatosis 
and non-alcoholic steatohepatitis (NASH, 8). Among these, alcohol abuse and NASH 
were considered as the most common cause of liver fibrosis in Western industrial 
countries (9，10); while chronic HBV infection was considered as a common 
epidemiological factor in South-East Asia and Africa (7)，where HBV infection is 
endemic. Liver fibrosis is mainly characterized by the increased stiffness of liver due to 
excess accumulation of ECM molecules, and subsequent hepatocyte apotosis, portal 
hypertension and loss of liver function. While the reversibility of liver fibrosis or early 
liver cirrhosis is still under hot debate (7, 11), there is little doubt that the only treatment 
option for advance cirrhosis is liver transplantation. 
5.1.1 Pathnpenesis of Liver Fibrosis 
Although the exact pathway leading to hepatic stellate cell (HSC) activation may 
vary in different etiologies (1)，the pathogenesis of liver fibrosis is similar which include 
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the activation of HSC and subsequent active secretion of extracellular matrix (ECM) 
molecules, portal hypertension and hepatocyte apotosis, loss of hepatic function and 
cirrhosis (11, 12, 13)，regardless of the cause of the chronic damage. HSC is formerly 
known as Ito cells, lipocytes or fat-storing cells responsible for vitamin A storage (11), 
and is a type of perisinusoidal cell accounting for 5-8% of hepatic cell population (14). 
The transdifferentiation of quiescent HSC into myofibroblast-like HSC is the pivotal 
point of liver fibrosis, as a majority of fibrotic ECM, namely collagen, proteoglycan and 
glycoprotein (2)，are of myofibroblast-like HSC origin. In fibrotic liver, the content of 
ECM can increase three- to six-fold (2, 15), and is the main cause of liver stiffness and 
portal hypertension. In its quiescence state, HSC resides in the perisinusoidal space (also 
called Space of Disse) between hepatocyte and sinusoid. During the activation process, 
HSC gradually lost its lipid content, and its morphology changes from more circular 
star-like shape into elongated myofibroblast-like shape with prominent intracellular 
contractile fiber. Activated HSC is characterized by the elevated expression and 
secretion of ECM, most prominently collagen I，III，IV and fibronectin, and the 
disturbed balance between matrix metalloproteinase (MMP) and tissue-inhibitor of 
metalloproteinase (TIMP). The deposition of ECM by HSC is a natural, programmed 
and dynamic response towards chronic liver injury; and fibrogenicity only becomes 
pathological when ECM degradation cannot compensate for the ECM accumulation, and 
the action of myofibrotic HSC becomes self-perpetuating (16). 
Upon liver parenchymal injury, HSC is activated by its neighboring cells 
including hepatocytes, Kupffer cells, and endothelial cells, through the action of a series 
of signaling cascade in a paracrine fashion. Reactive oxygen species and cytokines are 
released by apoptotic hepatocytes, recruiting inflammatory lymphocytes and 
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macrophages, which release major HSC activation molecules including transforming 
growth factor-pi (TGF-pi) and platelet-derived growth factor (PDGF) (11，15). TGF-pl 
stimulates secretion of ECM biomolecules from HSC; and PDGF from Kupffer cells 
promotes the loss of lipid droplet and vitamin A in HSC, both of which are important 
functional changes during the transdifferentiation process of HSC into myofibroblast-
like cells (11). 
5.1.2 Changes of liver architecture - basis of biopsy examination 
The natural history of liver fibrosis progress from chronic inflammation, to liver 
fibrosis, compensated cirrhosis, decompensated cirrhosis, and ultimately ends with liver 
failure and patient death with or without HCC. In order to aid physicians in designing 
appropriate therapeutic regimen for patients, it is inevitable to grade liver fibrosis into 
certain number of stages so as to semi-quantitatively indicate the progress of disease. 
Since severity of liver fibrosis is defined by abnormal deposition of ECM in liver, the 
most reliable grading method is through histological examination of liver biopsy, which 
is also the gold standard of liver fibrosis diagnosis (17). 
Currently, several grading methods are available for fibrosis grading, including 
Ishak (18), METAVIR (19) and Knodell's Histological Activity Index (HAI, 20). In 
general, depending on the purpose of grading, the former two are the most common 
grading systems for liver fibrosis. METAVIR scoring system is used for simple patient 
management, while Ishak scoring method is used for HBV-associated liver fibrosis and 
for more sophisticated purpose such as large scale evaluation and statistical analysis (17). 
Ishak score is a modified grading and staging method for chronic hepatitis based on HAI 
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system. It takes into account the degree of fibrosis, architectural disturbance and 
cirrhosis for fibrosis stage assessment. Ishak scoring system divides liver fibrosis into 6 
stages, from no fibrosis (Ishak = 0) to probable or define cirrhosis (Ishak = 6). 
METAVIR score, on the other hand, is an algorithm for grading liver fibrosis in chronic 
hepatitis C. Since it is based on histological features such as piecemeal necrosis, lobular 
necrosis, portal inflammation and bridging necrosis, its use is not limited to chronic 
hepatitis C but to all liver fibrosis with similar etiology. METAVIR system divides liver 
fibrosis into 5 stages, from no fibrosis (F=0) to cirrhosis (F=4). 
Since histological staging systems for liver fibrosis inevitably rely on 
pathologists' own experience, preference, and the quality of biopsy, there is considerable 
inter-observer and sample variation. In order to evaluate such variation, kappa statistics 
was designed to measure the reproducibility of a scoring system, of which a value of 
0.81-1.00 means perfect agreement and 0.00-0.20 slight agreement (21). Ishak and 
METAVIR system have a kappa statistics ranging from 0.57-0.69 and 0.59 respectively, 
showing moderate agreement between observers (22，23). Though there are slight 
differences in the choice of fibrosis criteria, both systems were used frequently as "gold 
standard" of fibrosis staging in both the context of liver fibrosis diagnosis and biomarker 
researches. 
j .2 Ciirrent Diagnosis of Liver Fibrosis - from Biopsy Examination to Serum Test 
Although histological examination of liver biopsy remains the "gold standard" of 
fibrosis diagnosis, there exist several drawbacks of such diagnostic approach. One of the 
most obvious drawbacks is the observer variation. It was revealed that the reliability of 
METAVIR system, which also applies to Ishak system, was more heavily influenced by 
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the academic background, experience, and location of practices than realized before (23). 
Therefore, the precise staging of liver biopsy depends on the background of pathologists. 
Secondly, liver biopsy is obtained by laparoscopy which is an invasive procedure. A 
summary of three studies from 1966 to 1994 indicated that laparoscopic liver biopsy 
carries 0.57%-2.5% chance of complications (0.57%-0.87% chance of complication if 
the study in 1966 is excluded), and 0.03%-0.05% lethality (24). Common complications 
include biliary peritonitis (0.02% to 0.2%) and bleeding from biopsy site (0.2%) (25). 
Long term monitoring of liver fibrosis will therefore increase the risk of complication, 
and bring discomfort and annoyance to both patients and physicians. 
Given the fact that diagnosis of liver fibrosis is subjective to observer variation 
and routine monitoring is not feasible with liver biopsy, there is an urgent need for a 
standardized, objective and non-invasive method to diagnose and stage liver fibrosis 
precisely and accurately. In the past decade, many different diagnostic approaches have 
been developed including the use of ultrasound to probe for liver stiffness, and the use of 
circulating biomolecules that are related to the pathogenesis of liver fibrosis or liver 
function. 
Ultrasonography, or transient elastography (TE) or FibroScan®，refers to the use 
of low frequency (50 Hz) ultrasound (5-7.5 MHz) to measure the liver stiffness, which 
reflects the extent of fibrogenesis and liver fibrosis (26). A study conducted in 2007 
involving 170 patients with CHB suggested that FibroScan® has a sensitivity of 66% 
and specificity of 83% in detecting significant fibrosis (27). Further more, a meta-
analysis across 9 studies has shown that FibroScan® has a similar sensitivity of 70% and 
specificity of 84% in detecting intermediate fibrosis (28). These results suggest that TE 
is a promising approach for non-invasive assessment of liver fibrosis. However, it must 
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be noted that TE has several technical limitations, including difficult measurement in 
patients with obesity and ascites. Failure rate on average is around 4.5% (29). Moreover, 
there is no consensus over the diagnostic threshold (cut-off point) when using TE for 
diagnosis of liver fibrosis, which makes interpretation of results across different centres 
difficult (28). A non-invasive, objective diagnostic method for liver fibrosis is still 
required, and serum marker has been considered one of the promising candidates. 
Great efforts have been made in using serum biochemical parameters to predict 
liver fibrosis since most of them have been shown to correlate with liver fibrosis stages 
(30). Direct markers or class I markers are linked with the biochemistry of ECM 
accumulation, which is a direct cause of fibrogenesis. Indirect markers or class II 
markers are linked with liver function or damage, which is an indirect consequence of 
fibrogenesis. Direct markers have the potential of more faithfully and specifically 
reflecting the actual fibrotic status of liver fibrosis than indirect markers. However, their 
presence in serum indicates the development of already advance stage fibrosis or 
cirrhosis; therefore they are not useful in early monitoring of the disease. Direct markers 
include ECM-related enzymes, collagen products, matrix-metalloproteinase and 
glycosaminoglycan. On the other hand, indirect markers are less specific to liver fibrosis, 
but they can be easily detected at early stage of diseases and allow early intervention. 
Several well-known indirect serum markers include alanine transaminase (ALT), 
asparatate transaminase (AST), bilirubin level and platelet count (31). In the past decade, 
various serum tests have been developed; notable examples include FibroTest (32), 
Fibrometer test (33) and FibroSpect (34). FibroTest made use of a2-macroglobulin, 
haptoglobin, Gamma-Glutamyl Transpeptidase (yGT), total bilirubin and apolipoprotein 
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A1 to detect liver fibrosis in patients with hepatitis C virus (HCV) infection; Fibrometer 
test used platelet count, prothrombin index, AST, a2-macroglobulin, hyaluronate, urea 
and age as detection parameters; and FibroSpect used a2-macroglobulin, hyaluronic 
acid and TIMP-1 for diagnosis of liver fibrosis. It is worth noting that a2-macroglobulin, 
a proteinase inhibitor expressed by hepatocytes and stellate cells, was included in all 
three types of diagnostic models which was also included in other models such as 
Hepascore and PGAA-index (35, 36). The sensitivities of these tests range from 75% to 
81%, and specificities range from 73% to 85%. While these tests have shown a higher 
performance than TE, most of them were targeted towards limited spectra of liver 
diseases, and the accuracy of these tests might be reduced in large group of patients with 
different aetiologies. Both Fibrotest and FibroSpect were based on patients with HCV 
infection, and while Fibrometer test was developed from a mix of chronic liver diseases, 
the diagnostic accuracy for alcoholic liver diseases was markedly higher than viral liver 
diseases (0.92 versus 0.821，33). Therefore, a novel serum biomarker which is 
independent on disease aetiology is needed in order to diagnose liver fibrosis. 
The majority of serum glycoproteins are of hepatic origin. The close relationship 
between liver and serum glycoproteins suggests that liver abnormalities associated with 
aberrant glycosylations can be reflected by the changes in serum glycoprotein 
glycosylation patterns. For example, the degrees of fucosylation on certain serum 
glycoproteins, such as haptoglobin (37), cholinesterase (38) and alpha-1 acid 
glycoprotein (39)，were increased in liver cirrhosis. Microheterogeneity with 
concanavalin A affinity of serum transferrin was observed in patients with alcoholic 
liver disease (40). Altered glycosylation pattern of serum transferrin can be observed in 
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patients with alcohol abuse. Carbohydrate deficient transferrin is a well established 
biomarker for detecting alcohol abuse (41, 42, 43). 
Haptoglobin is a serum glycoprotein carrying sialylated complex type 
biantennary A/^-glycan, and is also included in FibroTest diagnostic model. Changes in 
the haptoglobin glycosylation pattern have been studied as early as 1992 in ovarian 
cancer (46) and surprisingly in canine diseases in the past decade (44’ 45). Serum 
haptoglobin level was found to be elevated in serum of HCC patients (47)，and the 
fucosylated glycoform of haptoglobin with altered sialylation was found to be associated 
with tumor progression, enhancing its value as HCC biomarkers (47). Recently 
aberrantly glycosylated haptoglobin has been shown to be a potential biomarker for 
other cancer types, including non-small cell lung cancer (48)，prostate cancer (49) and 
pancreatic cancer (50). Based on these findings, it is therefore postulated that whole 
serum glycome profile is closely linked with liver health status, and can be used as a 
novel liver fibrosis biomarkers. 
5.3 Glycomics and Its Potential as Biomarkers 
Glycosylation is one of the most common post-translational modifications in 
eukaryotes, and a majority of cellular proteins are glycosylated through either N- or O-
glycosylation, or through glycophosphatidylinositol anchor pathway which connects the 
protein with 2 fatty acid chains. Other important glycoconjugates include 
glycosphingolipids, lipopolysaccharides and peptidoglycans. The attachment of 
polysaccharides or glycans to biomolecules depends on the physiological status of the 
cells (51) and the protein sequence (52). Glycosylation changes have been identified in 
various diseases, ranging from systemic genetic diseases like congenital disorders of 
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glycosylation syndrome (CDG, 53) to localized malignancy like ovarian cancers (54). 
There has been a long history in applying glycobiomarkers for disease diagnosis and 
prognosis. Because of their diverse structures and the information they carry, glyeans 
provide a valuable source of biomarkers. In this "Omics" Era, the concept of glycomics 
has been evolved. In the past, research was restricted to glycosylation analysis of 
individual glycoproteins, and large scale glycome screening at tissue level was not 
possible due to technical difficulties. With the recent advances in analytical technologies, 
glycomics and glycoproteomics have been gaining momentum in biomarker researches. 
Glycans with specific sequence are recognized as antigens in immune system. 
Besides the ABO blood group antigens, one of the famous examples is the Lewis antigen 
(Le) present on the plasma membrane of red blood cells. Lewis antigen belongs to a type 
of cell adhesion molecules expressed by leukocytes and some circulating cancer cells. 
Lewis antigen is recognized by selectin, a family of lectins expressed by vascular 
endothelial cells, and assists the adhesion of leukocytes and cancer cells to endothelia. 
Four types of Le antigen are identified: Le^ (Gaip 1 -3(Fuca 1 -4)GlcNAc), Le'' (Fucal-
2Galp 1 -3(Fuca 1 -4)GlcNAc), Le" (Galpl-4(Fucal-3)GlcNAc) and Le^ (Fucal-2Gal(31-
4(Fucal-3)GlcNAc). Le®，LeX and their sialylated (Neu5Aca 1 -3Galp 1 -4(Fuca 1 -
3)GlcNAc) and sulphated (S043-0Gaip 1 -4(Fuca 1 -3)GlcNAc and Neu5Acal-3Gal(31-
4(Fuca 1 -3)(S046-0)G1CNAC) variants are commonly associated with cancer cell 
adhesions. Previous studies have shown that inhibition of Le^ and Le" antigen 
expressions in cancer cells greatly reduce their adhesion to endothelial cells or selectin-
expressing cells in vitro, and the expression of sialyl Le^ and sialyl Le^ is associated with 
tumor progression and metastasis (55). Due to the connection between sialyl Lewis 
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antigen and tumorigenicity, it is not surprising that the expression of sialyl Le® is a 
useful prognostic factor in cancers, for example for colorectal carcinomas (56, 57, 58). H. 
pylori also expresses Le'' and Le^ antigens on its cell surface as part of the 
lipopolysaccharide to mimic the cell-surface glycoconjugate molecules of human gastric 
endothelial cells (59). They are responsible for the adhesion of Helicobacter pylori, the 
infection and colonization of which cause chronic gastritis and gastric cancer. 
The relationship between glycosylation and immunoglobulin (Ig) is also of great 
interest. Immunoglobulin is a well-known circulating glycoprotein found in serum. It is 
glycosylated at the conserved location in heavy chains and less conserved location in 
light chains. Immunoglobulins are produced and secreted specifically by 
immunoglobulin-secreting cells and play important roles in the immune system. 
Glycosylation plays a critical role in modulating the structure and function of 
immunoglobulins. Alterations in glycan structures of immunoglobulin has been 
observed in a variety of autoimmune diseases, such as rheumatoid arthritis and systemic 
lupus erythematosus (60，61)，as well as immune-related diseases like IgA nephropathy. 
Abnormal hypogalactosylated 0-glycosylation on the fragmentation of crystallization 
region in IgA molecules is known to cause mesangial IgA deposition in kidney in IgA 
nephropathy, leading to glomerular damage (62). 
Alteration in glycosylation of glycoproteins and glycolipids is a common feature 
in various cancers, and may be aggressively involved in numerous ways in 
carcinogenesis, such as progression, differentiation, cell-cell interaction, adhesion and 
metastasis. For examples, down-regulation of beta-1,3-A^-acetylglucosaminyltransferase-
T2 expression was observed in invasive human bladder transitional cell carcinomas 
compared with their non-invasive counterparts, suggesting that down-regulation of this 
11 
glycosylation enzyme may be involved in cancer progression (63). In colorectal cancers, 
mRNA expressions of various glycosyltransferase are significantly altered (64). 
Elevated mRNA expression of alpha 1-6 fucosyltransferase in human hepatoma tissues 
was associated with the production of tumor-specific fucosylated AFP glycoform (65). 
The changes of glycosylation machinery in the cancer cells can be reflected in the blood 
circulation by tracing the changes in the glycosylation of the proteins released by the 
tumor (66). 
The poor specificity of a tumor marker is often due to the fact that it is also 
produced by normal cells under other pathological conditions. As tumor cells have 
different glycosylation machinery, it is hypothesized that identification of tumor-specific 
glycoforms should improve the specificity of a tumor marker. This hypothesis has been 
supported by various studies showing that identification of tumor-specific glycoforms 
can improve the diagnostic value of serum alpha-fetoprotein (AFP). AFP is an N-
glycosylated serum glycoprotein carrying a biantennary complex type glycan (67), and 
is a well documented up-regulated biomarker for HCC. However, it was also found to be 
elevated in chronic liver diseases, reducing its specificity in diagnosis HCC. By using 
lectin-affinity electrophoresis, an elevated level of core alpha 1-6-fucosylated AFP 
glycoform called AFP-L3 can differentiate between chronic liver diseases and HCC, 
demonstrating the application of altered glycosylation in biomarker discovery (65，68). 
Apart from AFP-L3, a monosialylated glycoform of AFP termed msAFP was also found 
to be able to differentiate between early stage HCC with non-diagnostic AFP level and 
liver cirrhosis patients with similar total serum AFP level (69). These studies have 
shown that although total serum AFP alone was not sufficient to differentiate HCC and 
chronic liver diseases, the qualitative and quantitative information of the 7V~glycosylation 
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pattern of serum AFP have significantly improved the performance of AFP as a HCC 
specific biomarker. Besides AFP, it has been reported that serum levels of fucosylated 
glycoforms of alpha-1 antitrypsin and transferrin in patients with HCC are significantly 
higher than with liver cirrhosis (70，71，72). 
5.3.1 Overview of Biochemical and Functional Characteristics of Glycan 
Compared with DNA molecules and polypeptides, glycans attached to 
glycoconjugates have three fundamental differences, which are i) non-template based 
synthesis, ii) branching primary structures and iii) variable linkages between the basic 
units, i.e. monosaccharides. In contrast to the production of DNA molecules or 
polypeptides, which requires the present of complementary DNA strands or mRNAs, 
there is no template or blue-print molecule for the production of oligosaccharides to be 
based upon. The synthesis of a glycan depends on the activity of a set of glycosidases 
and glycosyltransferases in rough endoplasmic reticulum and Golgi apparatus, and the 
target molecule. To-date, it is st川 impossible to predict the structure(s) of the 
glycosylation side chain(s) based on the protein sequence. While the primary structures 
of DNA molecules and proteins are linear and relatively straight-forward, the branching 
property allows glycans to have exceedingly large number of isomeric primary 
structures even if only 6 basic units are concerned (73). In contrast to DNA molecules 
and proteins, the bonding between two monosaccharide residues can have a variety of 
configurations and linkages. There are two different stereochemical configurations of 
glycosidic bonds—an alpha linkage and a beta linkage. The only difference between the 
alpha and beta linkages is the orientation of the linked carbon atoms. Furthermore, each 
carbon in a monosaccharide can participate in such bonding. This flexibility and 
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complexity cannot be addressed by using conventional analytical approaches in 
genomics and proteomics. 
Glycosylation alters the biochemical properties of a glycoprotein in a number of 
ways, including isoelectric point (74)，conformational stability (75)，thermal and pH 
stabilities (76, 77), susceptibility to inorganic solvent and proteolysis (78), and lectin 
binding behavior (79). In general, glycosylation increases the thermal stability and 
reduce the susceptibility of protein to proteolysis, as demonstrated by various 
deglycosylated glycoenzymes (80). However, the removal of glycosylation does not 
always change the biochemical properties of different glycoproteins in the same way 
(80). Therefore, functional changes brought about by glycosylation not only depend on 
the structure of a glycan, but also the characteristics of the protein concerned. It is 
almost impossible to predict the functional changes brought by the glycans based solely 
on their glycan structures. Moreover, a single glycoprotein molecule may have several 
glycosylation sites with various susceptibilities to glycosylation, and may carry different 
glycan chains independently, leading to considerable number of glycoforms with subtle 
differences in their properties. For example, serum haptoglobin is a tetramer composed 
of two alpha-subunits of 9.1kDa and two beta-subunits of 40kDa. The carbohydrate 
content of haptoglobin is found exclusively as 'complex, AMinked glycans on the beta-
subunit only (81). There are 4 AMinked glycosylation sites on the beta-subunit. The 
glycans are either biantennary or triantennary, both terminating with sialic acid 
residue(s). Fucose is linked to the core N-acetylglucosamine residue (GlcNAc) at either 
alpha-1,6 position or alpha-1,3 position (82). In our recent study, we observed a total of 
18 glycoforms with slight differences in molecular weight (ranging from 35 — 44kDa) 
and pi value (ranging from 4.6 - 5.8) (47). Given such complicated relationships 
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between proteins and glycosylations, it is inevitable in glycoproteomics to isolate and 
study structures of glycan motifs. This is especially important in biomarkers research 
because glycosylation is usually tissue or disease specific (83). These allow 
identification of glycoproteins with tissue-specific glycosylations, or tracing back the 
origin of disease-related differential glycoproteins. 
5.3.2 A^ -1 inked and 0-1 inked Glycosylations - A Valuable Source of Biomarkers 
There are two major types of glycoprotein glycosylation concerned and studied 
extensively in biomarker discovery: AMinked and 0-1 inked glycosylations. It is because 
they are commonly associated with secretory glycoproteins found in the blood. 
Glycosylphosphatidy I inositol (GPI)-anchored glycoproteins, on the other hand, is bound 
to plasma membrane by two fatty acid chains and less readily detected in body fluids. 
The structural and physiological characteristics of these two types of glycans are more 
diverse than those of GPI-anchored glycoproteins. 
AMinked glycan is covalently bonded with the amide group on asparagine residue 
of proteins. The asparagine residue is located in a consensus Asn-X-Ser/Thr sequence in 
which X can be any amino acid except proline. In some rare cases the serine or threonine 
residue can be replaced with a cysteine, giving an Asn-X-Cys glycosylation site, as 
found in epidermal growth factor receptor (85), a minor glycosylation site in human 
transferrin (86) and CD81 molecules (87). A^-glycans can be classified into 3 classes 
based on the composition and sequence of oligosaccharides: high-mannose, complex and 
hybrid. High-mannose AMinked glycan is composed of mainly polymannosyl residues in 
all branches. Complex type glycans have a characteristics A^-acetyllactosamine Gal((31-
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4)GlcNAc in every branches. Hybrid-type glycan carries both high mannose branches 
and complex branches. Regardless of classes, all AMinked glycans share the common tri-
mannosyl core Mana 1 -6(Mana 1 -3)Manp 1 -4GlcNAcp 1 -4GlcNAc. Each mannose 
residues of the tri-mannosyl core at the non-reducing termini can be extended in an 
independent manner by oligomannose (high-mannose type) or //-acetyllactosamine 
(complex type), or linked up with 2 more branches (antennae). A single A^-glycan can 
therefore carries up to 4 branches (tetra-antennary). The branching mannose residue in 
the core is susceptible to the addition of bisecting //-acetylglucosamine through (31-3 
bond through the action of A^-acetylglucosaminyltransferase-III, while the asparagines-
linked A^-acetylglucosamine may be fucosylated through a l - 6 bond through the action 
of a 1 -6-fucosyltransferase (88，89). 
The expression of A^-acetylglucosaminyltransferase-III and a l -6-
fucosyltransferase have been found in or related to various diseases, such as human 
leukemia, hepatitis and hepatoma, thus showing disease-related and tissue-related 
alteration. These two types of modifications hence are particularly of interest to 
biomarker discovery. The A^-acetylglucosamine residue in the branches can be further 
modified by a 1-3 fucosylation, forming various antigenic structures which will be 
covered in the following section. 
0-linked glycans, on the other hand, have more complex and less defined 
structures than TV-linked glycans. 0-linked glycan is linked to the hydroxyl side chain 
group on the serine or threonine residue in the protein. The two most contrasting 
differences between O- and AMinked glycans are the absent of common tri-mannosyl 
core and a consensus amino acid sequence on the glycosylation site. In most of 0-linked 
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glycoproteins, the glycans are of mucin type which carries the core sugar N-
acetylgalactosamine, followed by a galactose, A^-acetylgalactosamine or N-
acetylglucosamine residue. Unlike AMinked glycans, 0-1 inked glycans are less branched 
and usually carry at most 2 antennae, branching at the core A^-acetylgalactosamine by 
galactoses. 
In both types of glycosylations, the main monosaccharide residues encountered 
are usually hexoses and their A^-acetylated derivatives, including A^-acetylglucosamine 
and iV-acetyllactosamine. Pentoses are rarely found in human glycosylation system 
except xylose in O-Iinked glycans, and their presence is usually allergenic (90). Sialic 
acid, or A^-acetyIneuraminic acid, is another important constituent of glycans. It is a 
nine-carbon acidic monosaccharide usually found at the termini of various glycans, and 
on the plasma membrane of vertebrates and invertebrates. Sialic acid can link up with 
the terminal galactose in a2-3 or a2-6 configuration, depending on the cell-type, tissue-
type, developmental stages and environmental factors (91). a2-8 linkage is also found in 
the terminal polysialic acid chain in AMinked and O-linked glycans, and in ganglioside 
(92，93). The present of sialic acid on plasma membrane increases the hydrophilicity and 
negative charges of the cell, and mask the galactose residue in the internal sequence to 
avoid binding of it with specific receptors (91). It is also commonly expressed in 
microbial pathogen as molecular mimicry, as sialic acid is heavily related with cell 
surface glycoproteins and cells recognition system (91’ 94). 
5.3.3 Glycomics - An Uprising Approach for Biomarker Discovery 
Glycome is referred to a repertoire of glycans in a tissue/cell type. Glycomics is 
the study of glycome. Glycomics is becoming a hot research field in the recent years. 
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There have been considerable advances in mass spectrometry (MS) technologies and 
oligosaccharide analysis technologies, including techniques in derivatization, fluorescent 
labeling, capillary electrophoresis (CE) and high-performance liquid chromatography 
(HPLC)，making glycomics study possible. Recent advances of analytical technologies 
also allow more effective differentiation of isomeric and anomeric glycans, which can 
visualize the glycome with higher resolution. Similar to genomics and proteomics 
studies, glycomics studies rely on high-throughput screening to identify a panel of 
distinguishable glycomic features simultaneously. Glycomics study usually involves 
large scale systemic analysis of glycan pools, which usually contain several subtypes 
such as AMinked and O-linked glycans, and glycans from glycolipid. Among these 
glycan subgroups, their structural properties, such as sequences and extent of branching 
and sialylation, differ from each other significantly as mentioned above. The analytical 
approaches for these subgroups hence are also different. 
Moreover, as mentioned in the last section, glycans have been recognized as a 
valuable source of biomarkers for various diseases and cancers. Glycomic analysis 
allows rapid global comparison of glycome within body fluids or tissues of interest, 
which would allow identification and application of a new type of biomarkers for cancer 
diagnosis and to monitor cancer development and treatment. With the establishment of 
powerful high-throughput technologies, the analysis of glycome - a complex mixture 
with significant biological importance - has become a surmountable task. Unlike 
genomic or proteomic biomarkers, which directly or indirectly rely on transcriptional or 
translational information, glycomics allows biomarker researches to utilize the post-
translational events within the cell to facilitate disease prediction and diagnosis. 
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It should be pointed out that there are several differences between 
glycoproteomics and glycomics. Glycoproteomics aims to enrich, quantify, separate and 
identify low abundant glycoproteins with specific glycosylation. Therefore, 
glycoproteomics focuses on a subset of proteome characterized by the presence of 
glycosylation on proteins, and proteins remain the main subject of study (95). In 
glycoproteomics study, a specific glycoform of a glycoprotein, such as monosialylated 
AFP, will be identified as a biomarker. Glycomics, on the other hand, focuses on 
structures and sequences of glycan motifs, and the conjugated molecules are not the 
main concern. 
In August 2007, the National Cancer Institute (NCI) of the National Institutes of 
Health, United States, had funded a $15.5 million initiative consisting of seven projects 
designed for glycomic biomarkers research with aims to discover novel cancer 
biomarkers and to improve preexisting one. All seven projects are focused on either 
serum glycomic biomarkers or anti-glycan autoantibodies. A majority of these projects 
focused mainly on cancers with poor prognosis including pancreas cancer and breast 
cancer. This campaign has highlighted the importance of glycomics in biomarker 
discovery, and the advent of glycomics in this Post-Genome Era. 
5.3.4 Human Proteome Organisation Human Disease Glvcomics/Proteome Initiative 
Human Disease Glycomics/Proteome Initiative (HGPI) was launched by Human 
Proteome Organization (HUPO). The major aim of HGPI is to identify disease-related 
glycobiomarkers in biological fluids mainly by undertaking functional glycomics and 
high-throughput mass spectrometry approaches. To achieve this, HGPI has attempted to 
develop a common data and analytical standard method of A^-glycans for various 
19 
diseases. Ultimately, a common database platform will be developed. Since October 
2004, several projects were carried out by HGPI, including the development of standard 
methodology for glycome analysis of glycans carried by human transferrin and IgG, and 
the development of a diagnostic program for CDGs. The result of method development 
was note-worthy. It made a comprehensive and quantitative comparison between the 
merits and drawbacks of different analytical approaches (96). The on-going CDG 
program, on the other hand, aims to complement traditional methods for classification of 
the syndrome through genetics and to discover new subtypes of the syndrome. This 
anticipation by the global proteomics community clearly illustrates the worldwide 
awareness of the importance of glycomics in biomarker research. 
5.3.5 Recent Applications of Glycomics to Biomarker Discovery 
Owing to technological limitations to elucidate the complex information of 
various glycans including sequences, structures and quantities, early studies of 
glycosylation remained at the level of separation of protein glycoforms based on 
isoelectric focusing or lectin affinity electrophoresis, and subsequent identification by 
immunoblotting (41, 42, 43, 68). Recently, the development and maturation of more 
sophisticated analysis platforms like mass spectrometry and bioinformatics allow more 
in-depth studies and high-throughput analyses on glycosylations. These have accelerated 
the utilization of glycosylation as a new source of biomarkers, since differential glycans 
can now be assessed more accurately and precisely at larger scale. Aberrant 
glycosylation has gained much attention in biomarker researches, especially in liver 
diseases and cancers. 
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The number of glycomic researches and glycobiomarker studies has been 
gradually rising in the beginning of this century. A brief summary of all articles 
published in relation with glycomics was given in this review to provide an overview of 
this growing field. In 2004, the global pattern of desialylated AMinked glycans from 
whole serum proteins, was successfully profiled by using a DNA sequencer as a CE 
instrument, and subsequently used to detect liver cirrhosis (83). Four glycomic features 
were found to be significantly different in liver cirrhosis patients compared with control, 
and all up-regulated features were shown to be fucosylated and carry a bisecting 
GlcNAc. Log ratio of two of these features gave a Receiver Operating Characteristics 
(ROC) curve area of 0.87 in classifying mild fibrosis and compensated liver cirrhosis. In 
2007，the same approach was applied to identify A^-glycomic changes in HCC patients 
with HBV induced liver cirrhosis (97). Two fucosylated glycomic features, one of them 
carrying bisecting GlcNAc, were found to be associated with HCC. The log ratio of 
these two features gave an ROC curve area of 0.81 in diagnosing HCC, which is 
comparable with that of using AFP. 
Apart from CE, Matrix-assisted laser desorption/ionization time-of-flight mass 
spectrometry (MALDI-TOF MS) has been successfully applied to obtain the profile of 
AMinked glycans from the whole serum proteins (98). In the study, the released N-
glycans released were purified by HPLC on graphitized carbon columns, and 
subsequently subjected to either desialylated or methyl-esterified prior to MALDI-TOF 
MS analysis. MALDI-TOF MS was also used in conjunction with a novel type of 
sepharose beads to profile total serum A^-glycan (99). The sepharose bead was 
functionalized with a hydrazide polymer to facilitate the immobilization of free glycans 
through hydrazone bond, which allowed on-beads methyl-esterification of sialic acid. 
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The technology was applied to study 3 types of diseases: CDG, HCC and prostate cancer. 
It was able to identified serum glycomic features that could differentiate type 1 and type 
2 CDG from healthy normal controls and HCC from health normal controls. The method 
also allowed analysis of total cellular glycan profiles of human prostate cancer cells and 
normal human prostate epithelial cells. 
Apart from A^-glycans, total serum 0-glycomic pattern was also profiled by 
matrix-assisted laser desorption/ionization Fourier transform ion cyclotron resonance 
mass spectrometry (MALDI-FTICR-MS), and applied to discovering biomarkers for 
ovarian cancer (100). A unique serum 0-glycomic profile containing 16 cancer-specific 
signatures was obtained from patients with ovarian cancer. Infrared multiphoton 
dissociation was applied to glycan sequencing. The diagnostic features identified in the 
spectra were confirmed to be oligosaccharides but not peptides. Later the same approach 
was applied to search for potential biomarkers for breast cancer in mouse and human 
(101). Principle component analysis of the 0-glycomic profiles had successfully 
distinguished breast cancer samples from normal samples. 
5.4 Current Technologies for Quantitative Profiling of Tissue Glvcome 
5.4.1 MALDI-TOF MS 
MALDI-TOF MS is one of the most commonly used techniques to visualize the 
relative abundance of different molecules within a mixture based on their molecular 
weight. The choice of matrix is critical in order to achieve good quality spectra for 
biomarker identification. At least 13 matrix chemicals have been found to be effective in 
free oligosaccharide analysis (102). The combinations of matrix chemicals and analysis 
parameters have been extensively investigated and reviewed. When using positive mode, 
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2，5-dihydroxybenzoic acid (DHB) is the most common matrix of choice for the analysis 
of glycans. DHB can be supplemented with 2-hydroxy-5-methoxybenzoic acid (HMB) 
to give "super 2，5-DHB" (SDHB). This matrix can enhance the sensitivity of up to 2 to 
3 fold. However, care must be taken because these matrices are also capable of ionizing 
peptides and proteins (103)，which may contribute to artifacts and a more complicated 
spectrum. Other supplement options include 1 -hydroxyisoquinoline, spermine, a-L(-)-
fucose and aniline. When negative mode is used to analyze negative charged sialylated 
or sulphated glycans, 2，4，6-trihydroxyacetophenone is commonly used. 
Sialic acid units are easily lost during laser ionization during laser ionization or 
flight due to the instability of the a-glycosidic bond between sialic acid and its adjacent 
monosaccharide (102，104). Even if sialic acids are not lost in the process, formation of 
multiple cation sialic salts will complicate the interpretation of mass spectra. This 
phenomenon is usually avoided by either treating the glycome with sialidase before 
MALDI-TOF MS, or protecting the sialic acid by methyl esterification (105). Sialidase, 
or neuraminidase and exo-a-sialidase, is a hydrolase (EC 3.2.1.18) that cleaves at the 
a2-3, a2-6 and a2-8 glycosidic bond between the terminal sialic acid residues in 
oligosaccharides. Sialidase treatment therefore effectively pools various species of 
glycans that share the same structures with different degrees of sialylation into one 
single desialylated species. Although the sialylation information about the glycome is 
lost through this treatment, it allows analysis of glycans that differ only in sialylation as 
one single species, therefore increasing the sensitivity to the changes in structures like 
fucosylation. Methyl esterification of sialic acid involves the transfer of methyl group 
from donor molecules like methyl iodide (106) to the carboxyl group at CI position on 
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sialic acid. This modification stabilizes the a-glycosidic bond of the sialic acid and 
avoid lost due to pH or laser ionization. Recently a solid-phase esterification 
methodology was developed by using Affi-Ge丨 Hz as solid support and 3-methyl-1-p-
tolyltriazene as the donor molecule (107). However, care must be taken when 
interpreting the mass spectra obtained because of the mass shift of sialylated glycans by 
15 Da per sialic acid due to methyl esterification. 
MALDI-TOF MS has been successfully applied to profile serum A^-glycomic 
features in liver cirrhosis. Serum A^-glycome was released from 10 |j.l of serum using 
PNGase F solution-phase deglycosylation approach, followed by graphitized carbon 
column clean up. The A^-glycome pool was divided into two equal fractions for methyl 
esterification and chemical desialylation. MALDI-TOF MS analysis was carried out by 
using 2, 5-dihydroxybenzoic acid as matrix in positive mode. A portion of A^-glycan was 
permethylated for Electrospray Ionization (ESI)-MS structural characterization and Gas 
Chromatography (GC)-MS linkage analysis (98). Twenty-six A^-glycans were identified 
from human serum with their structures elucidated. Although differential //-glycans 
were not identified in this study because of lack of samples, it provided an overview on 
the complexity of total serum A^-glycome and the candidate biomarkers, which are those 
with a bisecting GlcNAc residue at the branching mannose. A^-glycome profiling has 
also been adapted to identify serum 7^-glycomic biomarker in liver cirrhosis patients and 
was utilized as biomarkers (83). 
MALDI-TOF MS has also been used to profile total serum 0-glycome to 
identify glycomic biomarkers for ovarian cancer (100). Total serum 0-glycans were 
released by using p-elimination，followed by graphitized carbon column (GCC) clean up. 
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2, 5-dihydroxybenzoic acid and 2, 5-dihydroxyacetophenone was used as MALDI 
matrix in both positive and negative mode respectively. Structural information was 
determined by infrared multiphoton dissociation (IRMPD). Twenty-three neutral O-
glycans where found to be of ovarian origin and related with ovarian cancer. The result 
was validated by comparing with 0-glycome from condition media obtained from 4 
ovarian cancer cell lines. A similar approach was utilized to identify serum O-glycomic 
biomarkers for breast cancer by using conditioned media from 4 breast cancer cell lines, 
serum from rodent with breast cancer and 4 human patients (101). In this study, O-
glycomes from different sources were fractionated by graphitized carbon column for MS 
analysis. Although both serum O-glycomic studies did not have sufficient patient 
samples for diagnostic model construction, these have provided pilot studies 
demonstrating the potential of serum glycomic biomarkers. 
5.4.2 Lectin microarray 
Lectin is a group of glycans-binding proteins that recognizes glycans by their 
structural information. Different types of lectins recognize different oligosaccharide 
structures, terminal residue and linkage (109). For example galectins are specific 
towards galactose residue (110); siglecs are a group of sialic acid-recognizing 
immunoglobulin (111) and selectins are expressed by leukocytes and endothelial cells to 
recognize sialyl Lewis antigens (112). When immobilized onto solid-support in a 
microarray format, they allow simultaneous detection of glycans based on their 
interaction with different lectins. Lectin microarray was first developed in 2004 (113). It 
has been shown that a lectin microarray constructed from 9 lectins was already capable 
of giving distinct glycoprofiles for different glycoproteins (114). In the experiment, 
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lectin microarray was interrogated by Cy3-tagged glycoproteins, followed by washing 
and scanning. The experiment outcome was a pattern of different lectins that interact 
with the glycans of glycoproteins. Structures of glycans can then be interpreted based on 
the specificity of those lectins. When compared with other detection methods such as 
MS and HPLC, lectin microarrays provide the information about the biological 
information of glycans-proteins interaction in high-throughput format (115). Moreover, 
since the interaction depends only on the characteristics of lectins and the structural 
information of glycans, glyroproteins can be applied directly to the array without 
deglycosylation and desialylation. This simplifies the experimental process, allows more 
labeling options and downstream analysis, and simultaneous analysis of 0-linked, N-
linked and glycolipid glycans (114). Although the affinity of lectins to glycans was 
relatively low (Kd = lO""^  to lO'^M) compared with antibody-antigen interaction (Kd = 10' 
8 to lO'^^M), various techniques have been developed to avoid lost of analyte during 
washing, and to probe such weak interactions such as evanescent-field fluorescence 
detection (115) and ratiometric approach (116). Evanescent-field is a weak electric field 
that only propagates wavelength distance from the sensor surface. It allows real-time 
detection during the interaction event between lectins and glycans, thus omitting the 
need of washing. Ratiometric approach utilized dual fluorescence colors similar to DNA 
microarrys for different samples, allowing ratiometric comparison between glycomes. 
This approach was also shown to be able to analyze complex mixture including the total 
glycome of whole cell lysates. 
To the best of our knowledge, no application of lectin microarrays in glycomic 
biomarker discovery has been done so far. However, this novel technology has been 
applied to profile glycome from mammalian whole cell lysates (116) and plasma 
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membrane of mammalian cell (117) and bacterial cell (118). It has been shown that, 
when combined with evanescent-field fluorescence detection method, intracellularly 
fluorescence labeled mammalian cells can be applied directly to the lectin microarray 
with similar quantitative performance and specificity compared with those of 
glycoproteins. Because samples were not fractionated and fluorescence tags not directly 
labeled to glycoconjugates, glycome contributed by glycolipid was also profiled. In this 
case, the dynamic multivalency of cell surface glycome was successfully retained (117). 
A similar approach was applied to differentiate strains of E. coli with different 
pathogenicities and S, typhimurium by cell surface glycoprotein profiling (118). The 
glycomic patterns acquired for each cells in these studies were mostly consistence with 
previous findings. It is worth noting that in these studies, different lectin microarrays 
were able to provide differential glycomic features of, and distinguish between wild type 
and mutant mammalian cell lines, primary cell cultures and bacteria of different species, 
strains and pathogenicities, making it crucial in biomarker discovery. 
5.4.3 Liquid Chromatography (LC) 
Chromatographic method has been used for oligosaccharides analysis since 1939 
(119). It has been demonstrated that glucose and fructose, after esterified with 
azobenzene-/7-benzoic acid, can be separated into distinct band by a mixture of 
chloroform, benzene and petroleum on normal-phase silica column (119). Charcoal has 
also demonstrated to be able to resolve mono-, di- and trisaccharides (120), presumably 
by adsorption onto graphitized carbons and to lesser extent through hydrophobic 
interaction and electron acceptor-donor interaction (121). Charcoal column was later 
developed into graphitized carbon column (GCC) with more refined performance. Prior 
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to LC analysis, fluorescent tagging by reductive amination is usually required because of 
the lack of chromophores or fluorophores in oligosaccharides. Thirteen commonly used 
fluorescent tags have been comprehensively reviewed (122), most of them also 
compatible with MS analysis. Glycans separated in LC are characterized by their 
retention time on chromatogram, or more commonly by glucose unit (GU) based on the 
retention time of oligomaltoses of various length or dextran hydrolysate (123). The use 
of glucose unit allows identification of glycans across LC runs with different conditions. 
Unlike lectin microarray and MS, which characterize glycans by their structural 
information and molecular weight, LC characterize glycans by their interaction with the 
stationary phase and the interaction is influenced by various factors including number of 
constituents, hydrophobicity and degree of branching. As a consequence, LC cannot 
provide structural information about glycans alone, and is usually coupled with MS 
instrument for more solid glycans characterization. 
Normal phase HPLC was shown to be able to separate free plasma membrane 
glycans from cancer cells labeled with 2-aminobenzoic acid after being fractionated by 
serotonin affinity chromatography (124). In combination with MALDI-TOF MS, it was 
found that histocytic lymphoma cells express several unique glycomic features on the 
plasma membrane, namely the present of polylactosamine residues and 
hyperfucosylation. LC-MS approach was used in 2006 to elucidate the sorting of hepatic 
glycoproteins into bile duct by two-dimensional mapping HPLC and MALDI-TOF MS 
(125). After sialidase treatment, A^-glycomes released from bile and serum were 
separated by reverse phase Shim-packed CLC-ODS HPLC column. Each peak obtained 
was further separated by normal phase amide-80 HPLC column to resolve overlapping 
peaks in reverse phase HPLC. Glycan structures were identified by exoglycosidase 
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treatment in terms of glucose unit, and confirmed by MALDI-TOF MS. (The high 
abundance of fucosylated glycoproteins in bile suggests that fucosylation is a bile duct 
sorting signal, which is confirmed by Fut8-deficient mice and immunohistochemistry). 
In 2007, a parallel-column system consists of 2 independent graphite and C18 reverse 
phase capillary columns was developed to analyze free, underivatized A^-glycans and 
trypsinized serum peptides respectively and simultaneously, followed by an on-line ESI-
MS/MS instrument for A^-glycans structures determination and sequencing, and protein 
identification (126). The system has successfully profiled and identified 41 unique N-
glycans and 84 proteins from albumin-depleted human serum. Both neutral and 
sialylated A^-glycans were detected by using positive and negative mode. In another 
study, 2-AB labeled acidic glycosphingolipids in colon adenocarcinoma tissues were 
profiled and identified by using similar 2-dimension technique utilizing normal and 
reverse phase column, followed by structural characterization by ESI-MS/MS analysis 
and exoglycosidase sequencing (127). This study shown that co-eluting glycans in 
normal phase column can be further separated by using reverse phase column. A total of 
22 glycosphingolipid-linked glycans were identified and characterized. 
5.4.4 Capillary electrophoresis (CE) 
The use of capillary zone electrophoresis to analyze A^-glycans was first applied 
in 1991 (128) on 'W-gIycomapping" of fetuin, and the technology was reviewed by 
Suzuki and Honda in 1998 for carbohydrate analysis (129). Although MS is a common 
technique to give a glycomic profile of a mixture of glycans in relatively short time, 
other techniques are often required to distinguish isomeric glycans in the mass spectrum. 
Moreover, since MS is not designed for sample fractionation, MS techniques represent a 
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certain end of analysis from which no further retrieval of analytes from MS instrument is 
currently feasible. Therefore, it is not possible to obtain glycans from a particular mass 
peak of interest for further analysis. Apart from LC, CE is another alternative approach 
to these problems. Similar to chromatographic methods, fluorescence labeling at 
reducing end by reductive elimination is required for CE, not only because of increasing 
the sensitivity of detection, but also to provide charges for electrophoresis to take place. 
The earliest fluorophore used for glycans in CE was 3-(4-carboxybenzoyl)-2-
quinolinecarboxaldehyde (CBQCA). Since then, more fluorescent tags were developed 
for the derivatization of carbohydrates (122). One of the most commonly used 
fluorophore in glycan analysis was 8-aminopyrene-l, 3，6-trisulfonic acid (APTS, 130). 
The methodology of using DNA sequencer as CE device to analyze 
oligosaccharides obtained from wheat, glycogen and potato starch was developed by 
O'Shea and Morell in 1996 (131). The procedure of profiling and sequencing //-glycans 
was first described by Callewaert et. al in 2000 (132), utilizing the high-throughput 96-
well plate A^-glycans release method developed by Papac et, al in 1998 (133). APTS 
was used to as fluorescent tag for A^-glycans and Sephadex G10 was used as size-
exclusion medium for post-derivatization clean up. The study had shown the application 
of DNA sequencing equipment in A^-glycomic profiling and exoglycosidase sequencing 
of bovine thyroglobulin and oti-acid glycoprotein, and its ability in resolving isomeric N-
glycans on electrophorogram. The technology was further applied on serum samples 
from liver cirrhosis patients in an attempt to identify serum A^-glycomic biomarkers (83) 
and on rat with CCU-induced liver fibrosis (134). Though DNA sequencing instruments 
in general are low throughput, efforts are being made by various research groups to 
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reduce the analysis time of CE equipment. In 2006, a microfluidic device was designed 
to profile total human serum A^-glycome, with comparable sensitivity with that of ABI 
377 DNA sequencer (135). The device was shown to be able to detect similar liver 
cirrhosis A^-glycomic biomarkers from the previous study (83) in 12 minutes. 
5.4.5 Quantitative Profiling of Tissue Glycome 
Quantitative profiling is essential for the identification of differential features in 
biomarker discovery. Among the technologies mentioned above, HPLC and CE are 
well-known for their quantitative performance. The detection methods of glycans in 
these systems are based on the measurement of fluorescent signal of the derivatized 
glycans. As long as there is neither detector saturation nor substrate bias during 
derivatization, the signal intensity should be proportional to amount of analytes. CE has 
been demonstrated to be quantitative in analyzing native and derivatized 
glycosaminoglycans (136). 
The quantitative aspect of glycans analysis in MALDI-TOF MS is affected by 
various parameters including analyte derivatization, types of laser, spotting protocol, 
choice of matrix, and acquisition protocol of spectrum. Structure of glycans, on the other 
hand, does not significantly affect the quantitative performance of MALDI-TOF MS 
(137)，although it has been suspected that an extra antenna may promote post-source 
decay (96). In order to obtain a quantitative profile of glycome by MALDI-TOF MS, 
methyl-esterification is usually required to stabilize sialic acid. In proteomic study, it 
had been shown that the reproducibility of MALDI-TOF mass spectra was greatly 
affected by the spotting methods, such as direct mixing, overlaying and sandwich (138). 
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Similarly, such parameter should also dictate the quantitative performance of MALDI-
TOF MS in glycan analysis. 
The reproducibility of the signal intensity of a glycan depends on i) the quality of 
the glycan-matrix co-crystal on the sample spot and ii) the laser scanning protocol. The 
variation of signal intensities can be minimized by obtaining more mass spectra over 
different area on the sample spot and averaging the resulting spectra. From a multi-
institutional study, the intra-assay and inter-assay coefficient of variation (CV) 
percentage of glycans released from human IgG were below 10 % and 4.2% for major 
species, and 34% and 13% for minor species (96). This suggests that the quantitative 
performance of MALDI-TOF MS is comparable to chromatography in terms of relative 
quantity. However, the multi-institutional study it clearly illustrated that there were 
considerable variations between different centers. More efforts have to be made to 
standardize the protocols and instrumentation to obtain comparable mass spectra from 
different research centers. The major shortcoming of MALDI-TOF MS is its incapability 
to provide concrete structure information of the glycan detected, although it is possible 
to predict structures of glycans based on molecular weights obtained from MS (154). In 
the future, similar approach could be carried out with a MALDI-TOF/TOF MS system 
to allow direct structure analysis by tandem MS. Besides combined use of MALDI and 
TOF MS, MALDI has been combined with FTICR-MS to obtain quantitative glycomic 
profiles (100, 101). However, the reproducibility of the MALDI-FTICR-MS in 
quantitative glycomic profiles has not been systematically evaluated. 
Comparable to gene expression microarray and antibody microarray, lectin 
microarray was a newly developed technology for glycomics and glycoproteomics 
studies. Lectins are highly specific carbohydrate-binding biomolecules that recognizes 
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glycans by their structural information. Different types of lectins recognize different 
oligosaccharide structures, terminal residue and linkage (109). For example galectins are 
specific towards galactose residue (110); siglecs are a group of sialic acid-recognizing 
immunoglobulin (111) and selectins are expressed by leukocytes and endothelial cells to 
recognize sialyl Lewis antigens (112). Lectins have been widely used to study and 
isolate glycoproteins. LCA lectin has been applied to isolate flicosylated AFP 
glycoforms associated with HCC (139). RCA lectin was applied on monitoring the 
desialylation of glycoproteins in murine B16 melanoma cells (140), and on investigating 
the degree of galactosylation of glycoproteins in human astrocytoma (141). Sambucus 
Nigra Agglutinin was used to measure the degree of 2,6-sialylation of glycoproteins in 
human colon cancer (142). Binding of Helix Pomatia Agglutinin to human cutaneous 
malignant melanoma was found to be associated with metastasis formation (143). Peanut 
Agglutinin was used to measure levels of mucin-type 0-glycan in the human benign and 
malignant colorectal tissues (144). 
In the lectin microarray technology, a panel of lectins is immobilized onto solid-
support in a microarray format. This allows simultaneous detection of glycans based on 
their interaction with different lectins. Lectin microarray was first developed in 2004 
(113). It has been shown that a lectin microarray spotted with 9 lectins was already 
capable of giving distinct glycoprofiles for different glycoproteins (114). In the 
experiment, lectin microarray was exposed to fluorescence-tagged glycoproteins, 
followed by washing and scanning. The experiment outcome was a pattern of lectins that 
interact with the glycans of glycoproteins. When a purified glycan or glycoprotein is 
analyzed with the lectin microarray, structure of the glycan can then be interpreted based 
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the interaction pattern. Moreover, lectin microarrays can used to study glycan-lectin 
interaction in a high-throughput manner (115). 
Because the affinity of lectins to glycans was relatively low (Kd = 10"^  to lO'^M) 
compared with antibody-antigen interaction (Kd = 10'^  to various techniques 
have been developed to avoid lost of analyte during washing, and to probe such weak 
interactions such as evanescent-field fluorescence detection (115) and ratiometric 
approach (116). Evanescent-field is a weak electric field that only propagates 
wavelength distance from the sensor surface. It allows real-time detection during the 
interaction event between lectins and glycans, thus omitting the need of washing. 
Ratiometric approach utilized dual fluorescence colors similar to DNA microarrys for 
different samples, allowing ratiometric comparison between glycomes. This approach 
was also shown to be able to analyze complex mixture including the total glycome of 
whole cell lysates. The quantitative performance of lectin microarray has been well 
evaluated (114). The signal intensity was linear for glycoproteins in the range of 
50|Lig/ml to 300|ig/ml. Coefficient of variation of signal intensities was within 10% to 
20% (115). 
Although lectin microarray also detects fluorescence signal given by analytes, 
there are several ways different from the approaches based on HPLC or CE. Firstly, in 
the lectin microarray technology, fluorescent tags are attached to protein portions of the 
glycoconjugates, instead of the glycan molecules. Hence the glycoproteins or 
glycoconjugates can be applied directly to the array without deglycosylation and 
desialylation. This simplifies the experimental process, and allows more labeling options 
and downstream analysis as well as simultaneous analysis of 0-linked, AMinked and 
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glycolipid glycans (114). Secondly, lectin microarray belongs to the type of competition 
assays. Different glycoproteins having the same glycan structures will compete for the 
same group of lectins. It is not uncommon that different glycoproteins are labeled with 
different number of fluorescent tag, leading to variations in the signal intensities 
between experiments. Furthermore, a single lectin molecule can bind to glycan 
molecules with different structures, but at different affinities. When a mixture of 
glycoproteins or glycoconjugates is subjected to a lectin microarray analysis, a highly 
complex pattern of competition and interaction among glycans and lectins will be 
resulted. 
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Project Rationales and Objectives 
An overview of current invasive and non-invasive diagnostic methods for liver 
fibrosis shows that each approach has its own limitations and drawbacks. Invasive 
diagnostic approach (histological examination of liver biopsy) is not suitable for routine 
monitoring, and non-invasive diagnostic approach (TE and serum biochemical markers) 
is still immature and requires large scale validation using cases with different aetiologies. 
While glycomics is also a relatively new area in biomarker research, both global 
tissue glycome profile and individual protein glycosylation profile have been proven to 
be a promising biomarker in a variety of diseases, ranging from alcoholic hepatitis to 
ovarian cancer. It was also shown to be a biomarker candidate for mouse liver fibrosis 
and human liver cirrhosis with good diagnostic value. In the light of these evidences, the 
objective of this research project is as follow, 
1. To develop a high-throughput methodology for the quantitative profiling of 
whole serum TV-glycomic using MALDI-TOF MS technology. 
2. To develop a whole serum "-glycome based non-invasive diagnostic approach 
for HBV-induced liver fibrosis. 
3. To further verify our approach by using more samples, and to evaluate the 
performance of our approach on treatment-naive and post-treatment patients. 
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Section 1: Method Development of Quantitative N-glycomic Profiling 
1. Introduction 
In most A^-glycomic research project, the usual workflow is to first release all N-
glycans from glycoprotein by using PNGase F, followed by purification of iV-glycans. 
The released iV-glycans are then subjected to subsequent quantitative analysis. 
PNGase F is a 36 kDa amidase that cleaves the glycosylamine bond between N-
acetylglucosamine at the reducing end of the glycan and asparagine residue on the 
glycoprotein. PNGase F releases the A^-glycan intact from the glycoprotein, in which the 
asparagine is deaminated to aspartic acid (145). Moreover, the activity of PNGase F is 
not restricted by the composition of oligosaccharide branches unless the A^-glycan is 
modified by a a l - 3 fucose at the asparagine-linked A^-acetylglucosamine (146), which is 
only found in plant species, and it is capable of releasing all types of human A^-glycan. 
Because of the absence of substrate bias in PNGaseF action, it is almost universally used 
when complete A^-deglycosylation is needed. 
Various methods have been developed to accelerate and to achieve higher 
through-put in the deglycosylation process by using PNGase F, most of which were 
based on the solution-phase protocol developed in 1985 (145). Fifty microgram of 
glycoproteins were first heat-denatured by using 1% (v/v) SDS, neutralized by 0.6% (v/v) 
NP-40 and followed by addition of 6 mU of PNGase F. Denaturation of glycoproteins 
prior to digestion was shown to give higher extent of deglycosylation, probably because 
steric hindrance was reduced. This was further confirmed by comparing the extent of 
reaction in the present of detergent, after trypsinization, and after reductive alkylation 
(147). The result showed that PNGase F catalyzed deglycosylation was much more 
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efficient after denaturation of glycoproteins and trypsinization. Trypsin breaks down the 
substrate into glycopeptides, further reduces the effect of steric hindrance. While the use 
of detergent was avoided in trypsinization (147)，the peptide side-products do interfere 
with downstream analysis, especially for MS because the mass of peptides and glycans 
overlap each other (148). The presence of either detergent or salt is still a nuisance for 
downstream analysis. Several methodologies were developed to overcome this problem. 
A^-glycans were successfully released from immobilized recombinant-type plasminogen 
activator in polyvinylidene fluoride (PVDF)-coated 96-well plate (133). Glycoproteins 
were first adsorbed onto microtitre plate coated with PVDF, followed by treatment with 
8M urea buffer and reductive-alkylation by dithiothreitol (DTT) and iodoacetamide 
(lAA). To avoid the non-specific loss of PNGase F onto PVDF membrane due to 
hydrogen bonding, polyvinylpyrrolidone 360 was used to block the membrane prior to 
the addition of PNGase F. The reaction products can be readily desalted by cation-
exchange resin and analyzed by MALDI-TOF MS. On the other hand, "-glycans had 
been successfully desalted and purified by using Sepharose 4B (149). Free A^-glycans 
bind with Sepharose 4B via hydrophilic interaction in the present of manganese chloride. 
The column was washed by a mixture of butanol/ethanol/water and glycans were eluted 
by 10% ethanol. Hydrophilic interaction chromatography sorbent was also shown to be a 
useful alternative (150). 
Currently, several different methods can be used to quantitatively profile N-
glycome including MALDI-TOF MS (137)，LC and capillary electrophoresis (136). 
Although LC and capillary electrophoresis are two well-established methods for 
glycome analysis, their through-put performances have limited their use in routine 
testing. Because the aim of the study was to develop a routine laboratory test for liver 
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fibrosis, throughput performance was a key factor in choosing the analytical platform of 
A^-glycome. MALDI-TOF MS was chosen because of its high-throughput performance, 
sensitivity and quantitative performance. 
In this section, we aimed to optimize the condition for PNGase F digestion, 
hydrophilic chromatographic purification of free A^-glycans, and analysis of free N-
glycans by using MALDI-TOF MS. Moreover, the quantitative aspect of MALDI-TOF 
MS on 7V-glycan analysis was also evaluated. 
2. Materials and Methods 
Unless otherwise specified, all chemicals and organic solvents were supplied by 
VWR and Amresco, and all plastic wares were supplied by Axygen. All chemicals and 
organic solvents were of at least HPLC grade or higher. 
2.1 Evaluation for the quantitative aspect of MALDI-TOF MS on A^-glvcan analysis 
The condition of A^-glycan profiling was designed as followed. A^-glycan samples 
and matrix chemical were added on an 8-spot gold ProteinChip array (Ciphergen 
Biosystems) by undertaking a sandwich spotting approach. Super 2，5-DHB in the 
presence of sodium chloride was used as the matrix chemical. A stock solution of SDHB 
(Sigma-Aldrich, consist of 13.5 g/L DHB, 1.5 g/L HMB in pure ethanol) was prepared 
and stored at -30�C. A working solution of SDHB was prepared on the day of MS 
analysis by mixing 10 of SDHB stock solution with 90 of 11 mmol/L sodium 
chloride. First, 0.5 jiil of SDHB working solution was spotted and vacuum-dried. Then 
0.5 \il of 0.02 mmol/L A^-glycan preparation was spotted and vacuum-dried, followed by 
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sequential addition and vacuum drying of 0.5 |LI1 of 50 % v/v acetonitrile and 0.5 of 
SDHB working solution. Finally, 0.5 |LU of 50 % v/v ethanol was spotted over the 
spotting area and vacuum-dried to achieve a homogeneous layer of analyte-matrix co-
crystals. The gold ProteinChip arrays were read over the 900-^000 m/z interval on the 
ProteinChip PBS II reader of a Protein-Chip Biomarker System (Ciphergen Biosystems). 
The ProteinChip reader was equipped with a nitrogen laser operating at 337 nm 
wavelength and at 5 |LIJ pulse. The mass spectra were acquired at a positive ion mode 
and an optimized interval of 1200-3000 m/z. Mass spectrum of each glycans ample was 
a mean of 610 mass spectra obtained over the sample spot at 61 acquisition positions. 
Four standard A^-glycans (CalBiochem) were used during evaluation. Structural 
information of the standard A^-glycans is listed in Table 1. M3N2 was the tri-mannosyl 
core common to all 7V-glycans and represented small molecular weight analytes; MANS 
was a high-mannose A^-glycans containing a total of 8 mannose, and represent 
intermediate molecular weight analytes; A2 was a disialylated, complex type 
biantennary A^-glyeans; NA4 was a non-sialylated, complex type biantennary A^-glycans. 
Both of these two A^-glycans represent high molecular weight analytes. Intra-assay and 
inter-assay CV percentage, and the linear relationship between glycan quantity and 
relative signal intensity were evaluated. Intra-assay CV% was determined from 32 
identical sample-matrix spots in one single day by using the same preparations of matrix 
chemical and reagents. For the inter-assay CV%, the standard glycan mixture was 
measured in duplicate for 12 consecutive days by using different batches of matrix 
chemical and reagents, which were prepared freshly on the day of the experiment. 
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Identity of standard o “ ^ Molecular 1 Structures … . / r ^ � AT-glycans Weight (Da) 
M3N2 Glycan ^ ^ ^ • • 910.8325 
MANS Glycan : { • • 1721.5445 
A2 Glycan 身 • • 2224.0231 
• o i n T 
NA4 Glycan _ • • 2372.1821 
I y n 
Table 1: Structure of individual iV-glycan standard. 
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Linearity test was carried out by varying amounts of single A^-glycan from 5 to 
20 pmol while fixing the amount of the other 3 A^-glycans at 10 pmol. In all three tests, 
normalized peak intensity was used for calculation, which was derived as followed, 
�T , , . , .. Signal intensity of interested peak , 
Normalized peak intensity = Total peak intensity ^ 100% 
All mass spectrometric data analysis was carried out by using Ciphergen 
ProteinChip Software 3.1.1 (Ciphergen Biosystems). 
2.2 Optimization for release of A^-glvcans from serum glycoproteins using PNGase F 
A solution phase deglycosylation protocol was adopted and modified for this 
study (145). One hundred microgram of human holo-transferrin (Sigma-Aldrich, Cat. 
No. T0665) was denatured at 56°C in 20 of 12.5 mmol/L sodium phosphate buffer 
(pH8.3) containing 2.5 mL/L beta-mercaptoethano 1 (Sigma-Aldrich) and 1.25g/L 
sodium dodecyl sulphate (SDS, Sigma-Aldrich) for 1 hour, followed by addition of 5 [i\ 
of 100 mL/L Triton X-100 (Sigma-Aldrich) which neutralized the denaturing effect of 
the SDS on PNGaseF. Twenty-five microliter of 50 mmol/L sodium phosphate buffer 
(pH 8.3) containing 0，0.1，0.25 or 0.5 units of PNGase F (Sigma-Aldrich, Cat. No. 
G5166) was added to the mixture, followed by incubation at 37°C for 24 hours. 
According to Sigma-Aldrich product specification, 1 unit of PNGase F was defined as 
the amount of enzyme required to release A^-glycans from 1 nmol of denatured 
ribonuclease B in one minute at 37°C at pH 7.5 as monitored by sodium dodecyl 
sulphate-polyacrylamide gel electrophoresis (SDS-PAGE), and is equivalent to 1 lUB 
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milliunit. Five microliter of digestion mixture containing 10 [ig of PNGase F-treated 
transferrin was aliquoted at 0，1，2, 4，8，and 24 hours and subjected to SDS-PAGE 
analysis for reaction monitoring. 
Aliquotes of digestion mixture were transferred into 0.5 ml microcentrifuge tube, 
followed by addition of 1.32 i^l of 20X XT reducing agent (Bio-Rad) and 20 of 1.25X 
Sampling buffer (Bio-Rad). The mixtures were then incubated at 95®C for 10 minutes 
and separated on 4-12% Bis-Tris polyacrylamide gel (Bio-Rad) at 150 V for about 1 
hour and 30 minutes. Deglycosylation event was identified as a shift of transferrin 
protein band from approximately 75-76 kDa to 70 kDa (151). Protein bands were 
visualized by using SilverQuest silver staining kit (Invitrogen) according to the 
manufacturer protocol. After electrophoresis, polyacrylamide gels were scanned by 
using GS-800 Calibrated Densitometer (Bio-Rad), and the image analysis was carried 
out by using Quantity One® Software (Bio-Rad). The extent of deglycosyslation was 
evaluated by the relative quantity of each transferrin glycoform (fully glycosylated, 
mono-glycosylated, deglycosylated), and the relative quantity of released A^-glycans. 
Relative transferrin glycoform quantity was calculated as follow, 
Relative transferrin Color intensity of the interested protein band X jqqo/ 
glycoform quantity 一 Total color intensity of 3 transferrin glycoform bands ° 
Relative quantity of released A^-glycan was calculated by first assessing the 
quantity of A^-glycan bound to tranferrin，which was represented as follow, 
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^ •.‘ , , , , Percentage of double- , Percentage of singly-
Quantity of bound TV-glycans = giy^sylated transferrin x 2 + glycosylLd transferrin x 1 
Quantity of bound A^-glycans at different time point relative to time point zero 
was calculated as follow, 
Relative quantity of = Quantity of bound A -^glycans at particular time point 
bound A -^glycans — Quantity of bound TV-glycans at 0 hour X 1UO / � 
Relative quantity of released A^-glycans at different time point was calculated as 
follow, 
Relative quantity of released iV-glycans = 1 - Relative quantity of bound A/-glycans 
The changes of relative quantity of released A^-glycans over time would indicate 
the amount of TV -^glycans accumulated over time, and the rate of deglycosylation at 
different time point. Table 3 summarize the changes of relative quantitiy of released N-
glycans over 24 hours. 
2.3 Purification of free A^-glvcans by using Sepharose 4B 
A protocol originally developed for hydrophilic purification of glycopeptide was 
adopted and modified for this project (152). Ten milligram of preswollen Sepharose 4B 
gel (GE Healthcare Life Sciences) was equilibrated twice with 0.5 ml of binding 
solution (Butanol: ethanol: 7 mmol/L manganese chloride solution = 5:1: 1，v/v/v), 
followed by addition of 8 of the enzymatic digest in 200 \x\ binding solution. The 
mixture was incubated at room temperature for 30 minutes on an end-to-end rotator. 
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Afterward, the mixture was transferred to a Spin-X column (Coming) and washed 4 
times with 0.5 ml of washing solution (Butanol: ethanol: water = 5:1:1, v/v/v). The N-
glycans were eluted by 200 |il of 10% ethanol (v/v), followed by centrifugal vacuum 
drying at 60 for 1 hour and 30 minutes (Eppendorf Concentrator 5301). The N-
glycans were reconstituted with 5 |xl of 10% ethanol (v/v) and stored at -30�C until MS 
analysis. 
2.4 Quantitative A^-glvcome profiling of human transferrin and whole serum 
After optimizing the condition for A^-glycan release, purification and quantitative 
A^-glycan profiling by using single glycoprotein preparation and standard A^-glycans, we 
next applied this technology on normal human serum, which contains a more complex 
mixture of glycoproteins and biomolecules. Since the total protein concentration of a 
normal human serum is approximately 65 g/L and a majority of serum protein is 
glycosylated, we estimated that 2 of serum would provide roughly 130 |ig of 
glycoproteins. Based on the result from previous section, this would be sufficient for 
quantitative A^-glycan profiling using MALDI-TOF MS. In order to prepare for under-
and over-estimation, we have halved and doubled the amount of serum used in two other 
preparations for comparison. One, two or four microliters of human serum were 
denatured and enzyme-treated as previously mentioned, followed by hydrophilic 
purification and MALDI-TOF MS analysis. Deglycosylation was identified by 
observation of A^-glycan peaks on mass spectrum. 
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2.5 A^-glycan structure prediction by database search. 
The possible structures of A^-glycans were predicted by searching the acquired 
mass-to-charge value (m/z value) in mass spectra against online A^-glycan database and 
prediction program. CFG Glycan Structures Database (Consortium of Functional 
Glycomics, Nature Publishing Group, 153) and ExPASy GlycoMod tool (Swiss Institute 
of Bioinformatics, 154) were used respectively. When using GlycoMod, only hexose, N-
acetylhexosamine, deoxyhexose and sialic acid were included as possible 
monosaccharide residues. The predicted A^-glycan compositions from GlycoMod tool 
were confirmed by the search result from CFG database, and only those from Homo 
sapiens source were used. 
On the mass spectra, each non-sialylated glycan appeared as a single peak with 
an m/z value equivalent to the average molecular mass plus 1.0 mass unit (mass of a 
proton). For the sialylated glycans, sodium salts were expected to form and detected as a 
group of consecutive peaks with a step-wise increment of 22 m/z (Figure 1). Therefore, 
when n+1 consecutive peaks were detected, the first peak was predicted to be a 
sialylated glycan with n sialic acid residues. 
3 . Result 
3.1 MALDI-TOF MS was quantitative in profiling 7^-glvcans 
For all 3 standard A^-glycans M3N2，MAN8 and A2, the intra-assay CV% of the 
normalized peak intensities were around 8.7%, 8.7% and 8.2% respectively; the inter-
assay CV% were 17.2%, 18.5% and 15.8% respectively (Table 2). In the linearity test, a 
non-sialylated, tetraantennary (both tetraantennary and tetra-antennary were used) N-
















































































































































































































"Glycan M3N2 MANS A2 
Iiitra-assay CV% 8.7 — 8.7 8.2 
Inter-assay CV% 17.2 18.5 15.8 
Table 2: Intra-assay and inter-assay CV% of different standard A^-glycans, illustrating 
the reproducible result from MALDI-TOF MS. 
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analytes. The test showed that the normalized peak intensity was directly proportional to 
the relative quantity of that particular A^-glycan, with an R^ value greater than 0.95 for 
low and intermediate molecular weight standard A^-glyeans, and 0.99 for high molecular 
weight standard A^-glycans (Figure 2). A representative mass spectrum of 4 standard N-
glycans at 10 pmol each is showed in Figure 3. 
The spotting protocol used in this section incorporated a vacuum drying method 
to ensure the formation of homogeneous layer of analyte-matrix co-crystals on the 
MALDI target. The appearance of the co-crystal layer with or without vacuum drying 
method was showed in Figure 4 for comparison. 
3.2 Deglvcosvlation of human holo-transferrin using PNGase F 
Since human holo-transferrin was well-known to carry 2 disialylated, complex type 
biantennary A^-glycans of 〜2 kDa each, deglycosylation event can therefore be easily and 
confidently visualized on polyacrylamide gels, and therefore it was used as a standard 
glycoprotein for methodology development. Several different amount of PNGase F were 
used in order to optimize the condition required for deglycosylation, and the extent of 
deglycosylation was represented by the shift of transferrin protein band on 
polyacrylamide gels. Table 3 and Figure 5 summarized the relative quantity of each 
transferrin glycoform bands in 24 hours. From the result of negative control, it was 
shown that no or only negligible amount of deglycosylated glycoform was found in the 
transferrin preparation, and no deglycosylation event took place in the absence of 
PNGase F over 24 hours. Relative quantity of fully glycosylated transferrin in the 
presence of 0 unit, 0.1 unit and 0.2 units of PNGase F were 63%, 22% and 12% 
respectively after 24 hours incubation. No fully glycosylated transferrin remained after 
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24 hours incubation with 0.5 units of PNGase F. Under these conditions, 43%, 53% and 
64% of A^-glycans were released by 0.1 units, 0.25 units and 0.5 units of PNGase F 
respectively. 
From Figure 5，we had observed a product inhibition phenomenon when using 
0.5 units of PNGase F at 24 hours. First, the rate of reaction was gradually decreasing 
and eventually reach plateau phase at 24 hour-time-point. Secondly, the yield of the 
reaction did not double even when the amount of PNGase F doubled from 0.5 units to 
0.25 units. 
Figure 6 showed that when heat-inactivated PNGase F was used, no significant 
peaks were detected. This finding indicated that the majority of the peaks in the mass 
spectra were contributed by the A^-glycans released from the whole serum proteins, and 
peaks contributed by potential contaminants including glycosphingolipids were 
negligible. We observed that 5 freeze-thaw cycles did not significantly affect the serum 
A^-glycome profiles (Figure 7). 
3.3 Purification of free A^-glvcans bv using Sepharose 4B. 
Sepharose 4B had been used previously by other group to purify 
glycopeptide (152), and was used in this project to purify free "-glycans in the PNGase 
F digest. Sepharose 4B is a bead-formed agarose-based gel filtration matrix (155) that 
can provide hydrophilic surface for A^-glycan adsorption in the present of organic solvent. 
Eight micro-liter of PNGase F digest containing 16 fig of transferrin and 




















































































































































































































































































































































































































































































































































Figure 4: Appearance of analyte-matrix co-crystal on the MALDI target A) with vacuum 















































































































































































































































































































































































































































































































































































































































































































































































































































































It was postulated that after reconstitution, the final concentration of A^-glycan was 
roughly 54 pmol/|Lil, which was sufficient for MALDI-TOF MS analysis. 
In summary, we had optimized the deglycosylation condition as followed. One 
hundred micrograms of glycoproteins were heat-denatured by beta-mercaptoethanol and 
SDS，followed by treatment with 0.5 units ofPNGase F and incubation at 37°C for 24 
hours. Eight microliters of the digest was subjected to Sepharose 4B hydrophilic 
purification, and the extracted A^-glycans were reconstituted in 5 j^l of 10% ethanol. The 
concentration of such A^-glycan was approximately 54 pmole/|al. MALDI-TOF MS 
analysis was carried out by using 0.5 \i\ of the reconstituted A^-glycan sample and SDHB 
matrix. 
3.4 Analysis of human transferrin and whole serum A/-glvcome. 
The representative mass spectra of human transferrin and total serum A^-glycome 
profiles were shown in Figure 8 and 9 respectively. Six 7V-glycan peaks were identified 
in human transferrin samples, and 13 A^-glycan peaks were identified in human serum 
samples from m/z 1400 to m/z 3500, and their structures were listed in Table 4 and 5 
respectively. 
From the result of human transferrin A^-glycome profile, a majority of the N-
glycans was predicted to be either complex type biantennary or complex type 
triantennary glycans, most of them were sialylated. Only one minor biantennary species 
was non-sialylated. A l l predicted structures were fully galactosylated. From the result of 
human serum A^-glycome profile, a majority of serum iV-glycans were predicted to be 
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Figure 7: Effect of (A) 1 freeze-thaw cycle, (B) 3 freeze-thaw cycles, and (C) 5 freeze-
thaw cycles on the quality of serum A^-glycome profile obtained by MALDI-TOF MS. 
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Only 3 species were non- or partially galactosylated. No hybrid or high-mannose 
type, or tetraantennary A^-glycans were detected. Of the 13 A^-glycans, 4 were fully 
sialylated, and 3 were mono-sialylated. 
In both samples, no tetraantennary, hybrid type or high-mannose type TV-glycans 
were detected. Mass deviation between observed and theoretical mass value was less 













































































































































































































































































































































, , T» J. ^ J ex ^ Mass Deviation in Da 
m/z value Predicted Structure � 
Chm<i 
1641.8 \ > - B H [ 0.31 (0.019%) 
o - m - o 
1932.6 • 0.15 (0.008%) 
O O i H S ^ : 
2224.1 0.09 (0.004%) 
O o - B - g 
2442.9 O I 1 ( 0 . 0 5 4 % ) 
O o ^ 
2880.8 / N n f ^ ^ n • • 0.20 (0.007%) 
^ o X c r ' ^ ^ l 
Table 4: A^-glycans identified in normal human transferrin, ranging from m/z 1400 to 
m/z 35 
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in^ ： T T T T c Z T T Mass Deviation 丨 Predicted Structure . / n / � value in Da (%) 
1463.36 0.01 (0.001%) 
1625.50 〇 { 0.01 (0.001%) 
1641.37 ^ ^ ^ ^ V M �.12(_7%) 
o - m < j u 
1787.43 0.20 (0.011%) 
1828.63 〇 ^ 0.05 (0.003%) 
1932.39 O { = : ^ ^ X H U I 0.36 (0.019%) 
1990.47 | i H > - B H I 0.36 (0.018%) 
O l h c r 
2078.75 • { = : 0.91 (0.044%) 
Table 5: A^-glycans identified in normal human serum, ranging from m/z 1400 to m/z 
3500. 
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m/z J. ^ . Ox X. Mass Deviation , Predicted Structure . ^ ,。，� value in Da (%) 
O O B ^ 
2224.15 0.14 (0.006%) 
O O X T 
O o - m < i ^ 
2369.80 0.35 (0.015%) 
2443.61 0.62(0.0250/0) 
2880.56 0.04 (0.0010/0) 
^ o X o 
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Although MALDI-TOF MS has been widely used to characterize the structure of 
A^-glycans, we have also shown that MALDI-TOF MS is also applicable to quantitative 
profiling of a complex mixture of glycans. To achieve this quantitative capability, 2 
important measures were taken, one to ensure a homogeneous layer of glycan-matrix co-
crystals and the other to scan the glycan-matrix spot to obtain 610 mass spectra, the 
mean of which was used as the final mass spectrum for each glycan sample. Previous 
report had showed that both measures were important to obtain a quantitative mass 
spectrum for profiling a mixture of protein/peptide molecules (138). Vacuum drying 
method was used to ensure rapid drying of sample-matrix chemical on the gold chip 
support. This could reduce the formation of large sample-matrix co-crystal on the 
sample spot and the variation in the quality of crystals. As a further precaution, the final 
mass spectrum was the average of 610 mass spectra obtained over 61 acquisition 
position on the sample spot. This would avoid the variation of MS signals from different 
sample-matrix co-crystal. 
Different standard A^-glycans were used to give a more representative mixture 
when optimizing MALDI-TOF MS analysis condition. The presence of sialylated N-
glycan A2 in the mixture was particularly important because it was widely believed that 
MALDI-TOF MS in positive mode would not be able to ionize the negatively charged 
acidic glycans effectively for quantitative analysis. Moreover, previous evidence had 
shown that there would be extensive sialic acid residue loss during MALDI-TOF MS 
analysis in the absent of methylesterification process. From the result, we observed that 
the extent of sialic acid loss was low, since the signal intensities of the possible single 
loss products (monosialylated) m/z 1932 was marginally detectable and that of double 
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loss product (desialylated) m/z 1641 was negligible (Figure 10). On the other hand, it 
must be noted that the standard A2 A/-glycan obtained was 90% pure by HPLC; 
therefore we could not confirm whether these products (m/z 1932, m/z 1641) were 
indeed fragmentation products due to MALDI-TOF MS analysis or contaminants in the 
A^-glycan preparation. Based on these two points, it follows that the extent of sialic acid 
loss we observed might be an over-estimate. Nevertheless, in this study we have 
demonstrated that MALDI-TOF MS was quantitative in analyzing sialylated A^-glycans 
with sufficient quantitative performance, with CV% less than 8.2% in intra-assay, 16% 
in inter-assay and R value of 0.99. 
In this section, we aimed to develop a methodology for deglycosylation of 
glycoprotein and purification of A^-glycans for MALDI-TOF MS analysis. We have 
optimized various parameters, namely the amount of PNGase F used, incubation time 
required for deglycosylation, amount of enzymatic digest needed for purification, and 
amount of A^-glycans required for quantitative MALDI-TOF MS analysis. 
Transferrin was used as our standard glycoprotein during methodology 
development. Transferrin was an iron-transporting glycoprotein produced by liver, and 
is abundant in human serum. It has 2 different glycosylation sites, and is able to carry 
either biantennary or triantennary A^-glycans, each with different degree of sialylation. 
Therefore, there are theoretically 64 glycoforms available for transferrin. It was found 
that in normal human serum, there are two predominant types of transferrin glycoform, 
both of them fully glycosylated at both glycosylation sites: type 1) a biantennary fully 
sialylated A^-glycan and a triantennary fully sialylated A -^glycan，and type 2) two 
biantennary fully sialylated A^-glycans (156). Since biantennary and triantennary fully 






























































































































































































































































successful deglycosylation would shift the transferrin protein band from 76 kDa to 69-70 
kDa, the difference of which could be sufficiently resolved by SDS-PAGE. Since 
different glycoproteins are known to have different susceptibilities toward PNGase F 
treatment due to steric hindrance, trypsinization or heat denaturation are usually required 
to expose the TV^glycans to the enzyme. In our approach, heat denaturation was chosen in 
order to avoid the generation of tryptic peptides which would overlap with "-glycan 
peaks in mass spectra. Nonetheless, hydrophilic chromatography was used to purify N-
glycans before MS analysis. Sodium dodecyl sulphate and beta-mercaptoethanol were 
commonly used for heat denaturation in electrophoresis and PNGase F deglycosylation 
(145). However, since SDS was also one of the inhibitor of PNGase F (157), non-ionic 
detergent like Triton X-100 and NP-40 was required to neutralize the effect of SDS on 
PNGase F. From the experiment, we have demonstrated that 0.5 units PNGase F was 
capable to completely release 64% of A^-glycans from transferrin 24 hours, which was 
21% and 11% higher than those using 0.1 unit and 0.25 units respectively (Table 3). We 
did not further attempt to achieve 100% completion for 3 reasons. First, as observed 
from Table 3, the rate of reaction was greatly reduced and was approaching plateau 
phase after 24 hours incubation, possibly due to end-product inhibition. This was 
supported by the fact that doubling the amount of PNGase F used (from 0.25 units to 0.5 
units) did not double the yield at 24 hours. Second, once end-product inhibition happens, 
it can only be overcome by increasing the unit of PNGase F used and the volume of 
reaction to huge amount. It would tremendously increase the cost per reaction and rate of 
reaction, and as a whole increase the time required for the whole TV-glycomic profiling 
assay for routine liver fibrosis diagnosis. Third, as observed from the mass spectrum, the 
reaction condition had generated enough A^-glycans for analysis even at 64% yield, and 
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the predicted structures and relative quantities of the A^-glycans observed matched the 
predominant types of iV-glycans of transferrin reported previously (Table 4，152, 156). 
This is consistent to the expectation that PNGase F could release different A^-glycans 
from human glycoprotein in a fair manner, regardless of their structures. Therefore, we 
concluded that the current deglycosylation condition was sufficient for the purpose of 
this study. 
In this study, Sepharose 4B was used to purify hydrophilic A^-glycans from 
PNGase F digest. Sepharose is a class of cross-linked agarose in bead format. Since 
agarose by itself is a hexose-based polymer, we speculated that there should be 
sufficient hydrogen bonding between hydroxy 1 groups of sehparose beads and A^-glycans 
for specific binding. The principle of such bonding between hydroxyl groups would also 
ensure that our A^-glycans could be purified without structural bias. On the other hand, 
the protein portion of our digestion mixture is hydrophobic, and therefore was unlikely 
to bind specifically to sepharose or to survive the hydrophobic washing procedure. 
Moreover, the glycoproteins were denatured prior to deglycosylation. The exposed 
functional groups would strengthen the hydrophobicity of proteins. While there was no 
previous study concerning the principle of binding between sepharose and A^-glycans, 
our speculation was based on a sound scientific assumption on the chemistry of 
oligosaccharide, and this method was already applied successfully on glycopeptide (152). 
In this study, this approach was also successful in purifying A^-glycans from the 
digestion mixture of human transferrin. However, since human serum is a complex 
mixture of different biomolecules, it was possible that such purification approach would 
also purify other low molecular weight, hydrophilic molecules that could be analyzed by 
MALDI-TOF MS, thus contaminating our TV-glycome mass spectra and giving false 
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positive results. One of the most prominent contaminant anticipated was 
glycosphingolipids (GSLs), which carries an oligosaccharide chain and has a molecular 
weight of approximately 2 kDa, thus making it possible to be purified by Sepharose 4B 
and analyzed by MALDI-TOF MS within our acquisition range. Parry et al. in 2007 had 
demonstrated that the glycan portion of GSL could be analyzed by using DHB matrix 
chemical and MALDI-TOF MS (158). In their study, GSLs were extracted from human 
serum by using chloroform and methanol extraction, and the glycan portion was released 
by treatment with ceramide glycanase, followed by purification on C.ig Sep-Pak column 
and MALDI-TOF MS analysis using DHB matrix. From their result, molecular weight 
of permethylated glycans derived from glycosphingolipid (GSL) were shown to range 
from 838 Da to 2370 Da, which overlap with our acquisition range (1300 Da to 3500 
Da). When the lipid portion was taken into account, a majority of 
gangliotetraosylceramide (molecular weight approximately 1800 Da, 159) and GM2 
(molecular weight approximately 1400 Da, 160) would also overlap with our acquisition 
range. Therefore, even i f there was no fragmentation in the structure of GSL molecules, 
either the whole GSL or only the glycan portion of GSL could potentially be ionized and 
resolved within the acquisition range of A^-glycome profile. To evaluate such potential 
contamination problem, we had prepared heat-inactivated PNGase F control (Figure 6). 
The result showed that no significant peaks were detected in the mass spectrum, 
suggesting that no obvious GSL contamination was detected. 
When using MALDI-TOF MS to analyze the A^-glycan released from transferrin, 
5 A^-glycans were detected in the mass spectrum (Table 4). Four out of five of them were 
sialylated to different degrees. A^-glycans with m/z 2224.1 was predicted to be 
biantennary, fully sialylated and that of m/z 2880.8 was triantennary, fully sialylated. 
70 
These structural predictions were consistent with the A^-glycan structures of transferrin 
as reported (156). Moreover, the signal intensities of these A^-glycans also matched their 
distribution in transferrin glycoforms, with m/z 2224.1 being the dominant type. A low 
abundance A^-glycan of m/z 2880.8 was also observed in the mass spectrum. Since the 
glycoform information regarding the transferrin preparation was not available from the 
supplier, it was unknown whether the glycan composition of the transferrin preparation 
was consistent with previous studies. Nonetheless, the identity of A^-glycans observed in 
the mass spectrum was consistent with other research finding. 
We have identified 13 A^-glycan peaks in human serum A^-glycome profile. From 
the search result of GlycoMod and CFG database, 7 of them were at least partially 
sialylated. This result was confirmed by their respective numbers of sodium adducts on 
the mass spectrum. On the other hand, no sodium adducts peaks were found for those 6 
asialylated A^-glycans. Moreover, a similar human serum A^-glycomic study was 
conducted in 2007 by Kita et al (147) and a total of 34 iV-glycans were identified. 
Except m/z 2443.61, all A^-glyeans identified in our study were also found in their study. 
This observation confirmed that most of the A^-glycans detected in MALDI-TOF MS 
analysis were indeed serum A^-glycans, and thus provided a validation of our study 
approach. 
5. Conclusion 
In this section, we had optimized a protocol for quantitative profiling of human 
serum A^-glycome using MALDI-TOF MS. Total A^-glycans were released from 2 [i\ of 
human serum using 0.5 units of PNGase F. Sample clean-up and concentration was done 
by using Sepharose 4B hydrophilic purification. MALDI-TOF MS analysis was carried 
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out by using approximately 20 pmol of analyte and SDHB matrix supplemented with 10 
mmol/L sodium chloride. 
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Section 2: Serum iV-glycomic Profile as Biomarker for Liver Fibrosis - Pilot Study 
1. Introduction 
Liver fibrosis is accompanied by hepatocyte apoptosis, buildup of scar tissue, 
disruption of liver morphology and loss of liver function. Since a majority of serum 
protein is produced by the liver, it is inevitable that the serum proteome profile is altered 
by such pathological changes. 
In 2005, Poon et al had made use of serum proteome and peptidome profile to 
classify liver fibrosis and cirrhosis using Surface Enhanced Laser Desorption/ionization 
(SELDI) technology. Briefly, 2 of serum was first diluted, denatured and then bound 
to weak cationic exchange SELDI chip in acidic (pH 4) or alkaline (pH 9) conditions 
followed by several washing. The samples were then subjected to SELDI-TOF MS 
analysis. Mass spectra were obtained from 0.9 kDa to 250 kDa. The group had 
successfully identified a total of 794 proteomic features in two conditions; 81 of them 
were significantly different between normal and fibrosis/cirrhosis group; 30 out of these 
81 differential features correlated with degree of fibrosis significantly. When this panel 
of 30 proteomic features was used in Artificial Neural Network (ANN) analysis, the 
model generated could detect liver fibrosis with 89% sensitivity and specificity, and 
could detect liver cirrhosis with 94% sensitivity and 86% specificity. Furthermore, about 
50% of the liver fibrosis-associated proteomic features were showed to be correlated 
with liver function or liver inflammation, indicating that the features identified also have 
clinical meanings as well (161). 
Beside serum proteome and peptidome, it was expected that the serum glycome 
would also be affected by liver diseases. Callewaert et al. had reported a liver cirrhosis 
diagnostic model in 2004 using the logarithmic intensity ratio of 2 serum TV -^glycans. In 
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their work, total serum A^-glycome profile was obtained from 248 liver cirrhosis patients 
by using capillary electrophoresis. Briefly, 5 joJ of serum was applied to PVDF-coated 
96-well plate that immobilize serum proteins. After APTS-derivatization and 
desialylation, total serum A^-glycans were released by PNGase F and subjected to 
capillary electrophoresis. A total of 14 A^-glycan peaks were detected and 5 of them 
showed positive or negative correlation with severity of liver cirrhosis (normal, chronic 
liver disorder, compensated cirrhosis, decompensated cirrhosis). The structures of N-
glycans were elucidated by sequential exoglycosidase sequencing method. It was found 
that the logarithmic intensity ratio of 2 serum A/^glycans (A/^ -glycan 1: GlcNAcpl-4 
(Galp 1 -4GlcNAcp 1 -2Mana 1 -3) (Galpl-4GlcNAc pi-2Manal-6) Manpi-4GlcNAc(31-
4 (Fucal-6) GlcNAc; A^-glycan 2: Gaipi-4GlcNAcpl-2 (Gal|31-4GlcNAcpi-4) Manal-
3 (Galpl- 4GlcNAcpl-2Manal-6) Manp 1 -4GlcNAcp 1 -4GlcNAc) could distinguish 
between chronic liver disease and compensated cirrhosis with 79% sensitivity and 89% 
sensitivity; and between chronic liver disease and decompensated cirrhosis with 100% 
sensitivity (83). 
Apart from human liver cirrhosis, Desmyter et al. in 2007 had also applied a 
similar technology to detect carbon tetrachloride-induced liver fibrosis and its regression 
by interferon-y in rat model. Briefly, A^-glycans from 5 |il of rat serum was released and 
analyzed by capillary electrophoresis using the same methodology developed by 
Callewaert et al Three A^-glycan peaks were identified as correlated with liver fibrosis 
stages, and were showed to be liver specific, fibrosis stages-specific, and respond well to 
antifibrotic therapy (134). 
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In this section of our study, we hypothesized that total serum 7V~glycome profile 
would reflect the status of liver fibrosis and cirrhosis, and had the potential to be used as 
an accurate disease biomarker. The methodology developed in section 1 was used to 
obtain total serum A^-glycome profile in liver fibrosis patients, and the profile obtained 
would be subjected to bioinformatics and statistics analysis in order to identify liver 
fibrosis or cirrhosis associated features. This would serve as a pilot study to demonstrate 
the feasibility of such diagnostic method. While such approach could be deemed as 
untargeted A^-glycomic study, which aims to find differential features between normal 
and disease groups regardless of the positive identity of those features, the A^-glycan 
structure prediction method used would give a certain confidence that the features 
identified were not artifact generated during the experiment. Moreover, correlation 
between A^-glycans identified and serological markers would be examined to ensure that 
the A^-glycans identified do have biological meanings. As a result, we believe that this 
approach would produce a reliable liver fibrosis biomarker. 
2. Methods and Materials 
2.1 Patient Materials 
Liver biopsies were obtained from consecutive patients with chronic hepatitis B 
in the Prince of Wales Hospital, Hong Kong, in 2002 and 2003. Patients included those 
who had been recruited or screened for other therapeutic trails, as well as patients who 
were suspected of having active liver disease on the basis of laboratory or radiologic 
investigations. No patients were undergoing treatment at the time of liver biopsy or had 
compensated liver disease at the time of recruitment. After obtaining informed consent, 
we collected fasting blood samples by venipuncture before liver biopsy. Serum was 
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stored at -70 Randomly selected serum samples from 46 patients (35 males and 11 
females; mean (SD) age: 48.3 (9.2) years) were archived for this study. The same set of 
samples had been subjected to proteomic profiling in previous study in 2005 (161). Age 
was calculated to the date of biopsy. Used of these clinical samples for biomarker 
discovery was approved by the University ethics committee. Hematologic and 
biochemical parameters (complete blood screens, coagulation tests, bilirubin, total 
protein, albumin, ALT, alkaline phosphatase (ALP)) were measured by a Modular 
Analytic system (Roche Diagnostics). AFP level was measured by two-site sandwich 
chemiluminometric immunoassay (ACS 180 analyzer; Chiron Diagnostics). 
Liver biopsies were obtained with 16-gauge Temno needles (Bauer Medical). 
The specimens were fixed with formalin, embedded in paraffin, and stained with 
hematoxylin-eosin. Al l specimens were at least 15 mm in length with a minimum of five 
portal tracts. Hepatic fibrosis was assessed by use of the Ishak fibrosis score by a single 
pathologist blinded to the clinical and proteomic data. The mean (SD) Ishak Fibrosis 
score was 3.5 (1.9). Ten patients had minimal fibrosis (Ishak score = 1)，9 had mild 
fibrosis (Ishak score = 2)，10 had moderate fibrosis (Ishak score = 3 or 4)，8 had severe 
fibrosis and incomplete cirrhosis (Ishak score = 5) and 9 had probable/definite cirrhosis 
(Ishak score = 6). 
2.2 Total Serum A^-glvcome Profiling 
Total //-glycans were released from the 46 patient serums and subjected to 
MALDI-TOF MS analysis using the optimized protocol as mentioned in section 1. 
Briefly, 2 foJ serum was denatured and treated with 0.5 units of PNGase F in 50 fj,l at 37 
for 24 hours. Eight micro-liters of the digest was subjected to hydrophilic purification, 
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and concentrated down to 5 \i\. After purification, 0.5 |j.l of purified A^-glycans were 
subjected to MALDI-TOF MS analysis. A negative control was included in which 
PNGase F was heated-inactivated at 90 for 30 minutes prior to be used for 
deglycosylation. MALDI-TOF MS analysis of "-glycans was carried out by using 
SDHB matrix, sandwich spotting method with vacuum drying, and Ciphergen 
ProteinChip PBS I I Reader. A l l patients' serum A^-glycome profiles were acquired by 
using same batch of enzyme preparation and matrix chemicals, and measured with 
MALDI-TOF MS in duplicate for more accurate measurement. The structures of N-
glycans were predicted as mentioned in section 1. 
2.3 Identification of Potential Diagnostic A^-Glvcans for Liver Fibrosis/Cirrhosis. 
Two criteria were used to identify the A^-glycans associated only with disease. 
First, the normalized peak intensities must be significantly higher/lower in patients with 
typical fibrosis/cirrhosis (Ishak score = 3，4’ 5, 6) than in individuals with minimal 
fibrosis (Ishak score =1 ,2 ) . Second, the normalized peak intensities must correlate with 
the degree of fibrosis. The significance analysis of microarray (SAM) algorithm 
(Stanford University, 161，162) was used to identify the glycans that were significantly 
higher/lower in patients with fibrosis/cirrhosis by comparing the A^-glycome profiles of 
the cases with minimal fibrosis (Ishak score = 1) with those for cases with typical 
fibrosis/cirrhosis (Ishak score > 3) at a median false discovery rate of 2.5%. In the 
significance analysis of microarray analysis, "2-classed, unpaired data" were selected as 
the data type, and 5000 permutations were performed. Correlations between the degree 
of fibrosis (Ishak scores) and the peak intensities of the significant glycans were 
analyzed by the Spearman rank order correlation test using SPSS 10.0 (SPSS Inc.). 
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2.4 Construction of 7V-glvcan-based Diagnostic Model 
Log2 values of the age, potential diagnostic A^-glycans and serological markers 
(total protein, albumin concentration, international normalized ratio (INR), activated 
partial thromboplastin time (APTT), ALT, total bilirubin, ALP, AFP, haemoglobin, 
leukocyte count, and platelet count) were included as independent variables, and Ishak 
score was set as the dependent output variable. Forward stepwise linear regression 
analysis was performed using prediction values for constructing a diagnostic model to 
calculate the Fibro-Glyco index. Leave-one-out cross-validation (LOOCV) was 
performed to evaluate the performance of the diagnostic model in detecting significant 
liver fibrosis (Ishak score > 2) and cirrhosis (Ishak score > 4). 
2.5 Association between A^-glycans and Clinical Parameters 
The Spearman rank order correlation test was used to examine correlation 
relationships between the A^-glycan peak intensities and the clinical/biochemical 
variables. The sensitivity and specificity were calculated according to the standard 
formulas. Receiver Operating Characteristic (ROC) curves were constructed for 
differentiating patients with or without significant liver fibrosis (Ishak score > 2) and for 
differentiating patients with or without liver cirrhosis (Ishak score > 4). The likelihood 
ratios (LRs) were calculated by use of the standard formulas: 
Positive LR (LR+) = sensitivity / (100% - specificity) 
Negative LR (LR-) = (100% - sensitivity)/specificity. 
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3. Results 
3.1 Serum A^-glvcome Profile and Liver Fibrosis-Associated Fingerprint 
The representative serum A^-glycome mass spectra of serum samples from a 
healthy individual, a patient with minimal liver fibrosis, and a patient with significant 
fibrosis are shown in Figure 11, A-C. 
We found that 55 A^-glycomic features were matched among the serum samples. 
At a median false-discovery rate of 2.5%, we identified 15 features that were 
significantly higher and 8 features that were significantly lower in the patient group of 
typical fibrosis/cirrhosis. Among these 23 significant //-glycomic features, 13 were 
positively correlated with degree of fibrosis, and 8 were negatively correlated (all P 
value < 0.05; Figure 12). Therefore, only 21 A^-glycomic features were significantly 
associated with liver fibrosis. ROC curve analyses showed that 17 of these liver fibrosis-
associated A^-glycans had potential value in the detection of either liver fibrosis and/or 
liver cirrhosis (all P value < 0.05). The m/z 1829.7 glycan (Area under the curve (AUC) 
=0.90) was the best marker for detecting significant liver fibrosis, and the m/z 1444.7 
glycan (AUC = 0.83) was the best marker for detecting liver cirrhosis. The results for the 
17 potential diagnostic glycans are listed in Table 6. 
3.2 Construction of Linear Regression Model for Detecting Liver Fibrosis and 
Cirrhosis 
Among all the dependent variables (potential diagnostic A^-glycans, serological 
markers, and age), only A^-glycans of m/z 1341.5, 1829.7，1933.3 or 2130.3 (all P < 0.05) 
were selected as biomarkers with independent diagnostic values and included in the 
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Figure 11: The representative MALDI-TOF mass spectra of serum A^-glycome profile of 
(A) a healthy individual; (B) a chronic hepatitis B patient with minimal liver fibrosis and 
(C) a chronic hepatitis B patient with significant fibrosis. 
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Figure 12: Representative mass spectra showing peak intensities of 2 diagnostic N-
glycans in the patients with different degrees of liver fibrosis. The m/z 1933.3 glycan 
and m/z 2130.3 glycan were negatively and positively associated with liver fibrosis, 
respectively. The molecular weights of the neutral molecules are marked in the mass 
spectra. 
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Figure 12 (con't): Representative mass spectra showing peak intensities of 2 diagnostic 
A^-glycans in the patients with different degrees of liver fibrosis. The m/z 1933.3 glycan 
and m/z 2130.3 glycan were negatively and positively associated with liver fibrosis, 






















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































linear regression model for calculating the Fibro-Glyco index. Leave-one-out cross 
validation showed that the Fibro-Glyco index significantly correlated with degrees of 
liver fibrosis (r = 0.784，P = 0.01). Furthermore, the index was useful in the detection of 
liver fibrosis and cirrhosis. The ROC curve areas for the Fibro-Glyco index in detection 
of liver fibrosis and in detection of liver cirrhosis both were 0.91 (P < 0.001，Figure 13). 
At 85% specificity, the sensitivity for detecting liver fibrosis was 82%, the overall 
accuracy was 83%, and the LR+ and LR- were 5.47 and 0.21 respectively. At 85% 
specificity, the sensitivity for detecting liver cirrhosis was 77%, the overall accuracy was 
80%, and the LR+ and LR- were 5.13 and 0.27 respectively. 
3.3 Correlations between the A^-glvcan Peak Intensities and Serological Markers. 
Among the 17 potential diagnostic A^-glycans, 5 were correlated with albumin 
concentration (r = 0.417 to 0.490 and -0.292 to -0.348; all P values < 0.05); 5 were 
correlated with total protein (r = 0.329 to 0.351 and -0.292 to -0.343; all P values < 0.05); 
1 was positively correlated with APTT (r = 0.326; P = 0.027), and 3 were negatively 
correlated (r = -0.322 to -0.356; all P values < 0.05); 4 were correlated with INR (r = 
0.304 to 0.403 and -0.380 to -0.450; all P values < 0.05), resulting in lOA^-glycans 
significantly correlated with liver function. Concerning liver inflammation, only the m/z 
2606.9 iV-glycan was negatively correlated with ALT concentration (r = -0.366; P = 
0.012). Concerning liver damage, 17V-glycan was positively correlated with total 
bilirubin (r = 0.319; P = 0.031), whereas 1 //-glycan was negatively correlated (r = -
0.316; P = 0.032). None of the A^-glycans were correlated with ALP. Three A^-glycans 
were positively correlated with AFP (r = 0.327 to 0.431; all P values < 0.05). As a result, 
76% (13 of 17) of the liver fibrosis-associated A^-glycans potentially reflected the 
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Figure 13: ROC curves of the Fibro-Glyco index in the detection of significant liver 
fibrosis (A) and cirrhosis (B). The 95% CIs of the AUC values are shown in parentheses. 
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physiological state of the liver. Finally, it is well known that platelet count is negatively 
correlated with degrees of fibrosis. We found that 8 7V-glycans were correlated with the 
platelet count (all P values < 0.05). Therefore, 82% (14 of 17) of the iV-glycans forming 
the liver fibrosis fingerprint were significantly correlated with the serologic markers that 
directly reflect the liver physiology and/or with those that are well known to be altered 
in patients with liver fibrosis (Table 6). 
3.4 Structural prediction of diagnostic A^-glvcans 
The predicted structures of all these A^-glycomic features were listed in Table 7. 
4. Discussion 
A^-glycans are different from peptides or proteins in terms of sequence-structure 
analysis. Because human AMinked glycans all contain the same chitobiose core (2 N-
acetylglucosamines (GlcNAc) attached to a trimannose) and are synthesized by a well-
defined pathway, an accurate mass measurement wil l generally permit prediction of 
structure (154). 
In this section, using the serum A/-glycome profiling assay, we successfully 
identified a panel of serum A^-glycans as potential markers for detecting liver fibrosis 
and liver cirrhosis. Two criteria were used to ensure that the A^-glycans identified were 
not only correlated with degree of liver fibrosis, but also shown significant differences in 
serum level between minimal fibrosis group and severe fibrosis group. Seventeen N-
glycans were found to be potential markers for detecting liver fibrosis. We have 
‘ predicted the structures of the 17 differential A^-glycans from their mean m/z values with 
an acceptable error tolerance < 0.05%. Moreover, 82% (14 of 17) of the glycans with 
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Mass Spearman Correlation 
Deviation in with Ishak Score 
‘ m/z Predicted Structures Da (%) (P value) 
‘ 1341.4 N/A “ 0.3 (0.022) 0.447 (0.002) 
Oom<i 
1363.8 y ^ 1.4 (0.100) 0.441 (0.002) 
二 1444.7 N/A - -0.560 (< 0.001) 
1465.5 1.1 (0.075) -0.370 (0.011) 
二 1488.6. N/A - -0.483 (0.001) 
1829.7 0.0 (0.000) 0.517 (< 0.001) 
1933.3 : 0.5 (0.026) -0.478 (0.001) 
1992.0 | H > S - a 0.2 (0.010) 0.327 (0.027) 
O J K / 
112130.3 N/A — 0.1 (0.033r" 0.380 (0.009) 一 
s o ; - c > B - c r OR 
2159.0 . UK 1.0 (0.046) 0.355 (0.016) 
O o H B - g 
2284.6 I ^ D - n - B 0.5 (0.022) 0.292 (0.049) 
^ 
Table 7: Predicted structures of 17 potential diagnostic A^-glycans. 
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Mass Spearman Correlation 
Deviation in with Ishak Score 
m/z Predicted Structures Da (%) (P value) 
2431.0 m W • _ 0.7 (0.028) 0.328 (0.026) 
II"2606.9 N/A - -0.310 (0.036) 
2780.4 0.8 (0.029) 0.383 (0.009) 
一 
2881.4 ^ O ^ ^ ^ - m - m 0.2(0.007) -0.437 (0.002) 
^ J o ? / 
3027.6 ^ - O - M ^ ^ - m - X 1.0(0.033) 0.357 (0.015) 
113285.0 N ^ I - I -0.357 (0.015) 
Table 7 (con't): Predicted structures of 17 potential diagnostic A^-glycans. 
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potential diagnostic values were significantly correlated with the serological markers 
that directly reflect liver physiology and/or with those that are well known to be altered 
in patients with liver fibrosis. These findings also served as indirect evidence indicating 
that identified diagnostic glycans have clinical meanings associated with the disease 
being studied. 
Linear regression was used to select A^-glycans with independent diagnostic 
value for model building. The final diagnostic model comprised of 4 A^-glycans was able 
to detect liver fibrosis and cirrhosis with 85% accuracy. With the predicted structures, 
we found that 3 diagnostic A^-glycans (m/z 1341.5，1829.7, 2130.3) showing positive 
correlations with fibrosis stages contain a proximal fucose and/or a bisecting GlcNAc. 
Because liver cirrhosis is the severe stage of liver fibrosis, our prediction was consistent 
with the observations that degrees of fucosylation on certain serum glycoproteins were 
increased in liver cirrhosis (37, 38，39). Morelle et al. also observed that certain serum 
尽glycan species containing proximal fucose and/or a bisecting GlcNAc were increased 
in liver cirrhosis (98). One of these (m/z 1829.7) was found in the present study. 
Callewaert et al. had also found that a biantennary A^-glycan with a proximal fucose and 
a bisecting GlcNAc was increased in liver cirrhosis and was a major diagnostic marker 
of liver cirrhosis (83). When only considering those 7V~glycans with positive structure 
prediction, 8 out of 11 A^-glycans identified (m/z 1465.5, m/z 1829.7, m/z 1992.0, m/z 
2159.0, m/z 2284.6，m/z 2431.0 and m/z 3027.6) were also core fucosylated and/or 
modified with a bisecting GlcNAc residue, and 7 of them (except m/z 1465.5) were up-
regulated with degree of liver fibrosis significantly. 
Four A^-glycans were selected in the Fibro-Glyco Index detection model. While 
we had successfully predicted the structures of two out of four 7V~glycans，we were not 
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able to predict the structure of the remaining A^-glycans with m/z 1341.5 and 2130.3 
either by using GlycoMod tools or CFG database. A^-glycans with m/z 1341.5 was found 
to be significantly positively correlated with degree of liver fibrosis (r = 0.447，P = 0.002, 
n = 46). However, its normalized peak intensity in the mass spectrum was low compared 
with the other three diagnostic A^-glycans, and its molecular weight marginally 
overlapped with those of matrix cluster. Together with the result of structure prediction, 
we suspected that this A^-glycomic feature might be a MALDI-TOF MS artifact. 
However, it must be noted that the statistics and bioinformatics result suggested this N-
glycomic feature was closely related with degree of liver fibrosis and had independent 
diagnostic value in linear regression model. Nonetheless, we did not have enough 
evidence to further support either side of the argument. We therefore had decided to 
include this A^-glycomic feature in the linear regression model so as to avoid missing out 
any important biological information. 
A^-glycan with m/z 2130.3 was found to be up-regulated with degree of liver 
fibrosis. Although there was also no structure available, we believed that this was a 
genuine A^-glycan in human serum instead of possible artifact as m/z 1341.5 for 2 
reasons. First, the mass-to-charge ratio of this A^-glycan was well beyond the region of 
matrix cluster, therefore it was unlikely to be due to matrix noise. Second, the signal-to-
noise ratio of this //-glycan was comparable with or even higher than some of genuine 
A^-glycans, meaning that this feature could be reproducibly detected and distinguished 
from background noise. In this study, while it was not correlated with any serological 
parameters, it was effective in distinguishing minimal and typical liver cirrhosis, with 
‘ area under ROC curve of 0.719. More work would be needed to elucidate the structure 
of this A^-glycan. 
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Another A^-glycan with m/z 1829.8 was also selected as diagnostic A^-glycan. Its 
structure was predicted to be asialylated, mono-galactosylated complex type biantennary 
glycan, modified with core fucosylation and a bisecting GlcNAc. The modification 
observed in this A^-glycan was a common characteristic shared by other liver fibrosis 
associated A^-glycan reported previously (83，134). This A^-glycan was found on human 
sphingolipid activator protein 1 (SAPl, also termed saposin B, 163), human serum IgG 
(164, 165), and a similar A^-glycan structure was found in the asialylated transferrin from 
human cerebrospinal fluid with double galactosylation (166). On the other hand, this N-
glycan was also commonly found in various sources including placental fibronectin 
(167)，human IgA in myeloma patients (168)，and also in the serum of various 
vertebrates (169). Because it was a common A^-glycan species shared by many different 
glycoproteins, its quantity in serum was likely to be contributed by many glycoproteins 
from different sources. In the following, we attempted to illustrate two potential 
contributors that were related to liver fibrosis. Saposin B was a house keeping enzyme 
commonly found in various organs including liver, and was necessary for lysosomal 
hydrolysis process. It shall be noted that apart from the A^-glycan with fucosylation and 
bisecting GlcNAc, one of the A^-glycans found on saposin B also had the same 
asialylated, mono-galactosylated complex type structure without the core fucosylation 
and bisecting GlcNAc. Saposin B was associated with ganglioside metabolism in liver 
(170)，which was increased during acute phase response and inflammation as reported 
by Memon et al in 1999 (171). Hepatitis B virus and the associated liver fibrosis were 
capable of inducing liver inflammation and may cause up-regulation of saposin B in 
liver. This was consistent with our observation that //-glycans on saposin B was up-
regulated with liver fibrosis, and down-regulated with liver function (Table 6). However, 
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to the best of our knowledge, there is currently no report concerning the changes of 
glycosylation on saposin B during liver diseases. Therefore, their relationships remained 
to be confirmed. 
The A^-glycan with m/z 1829.8 was also found on human serum IgG. It was 
worth noting that the serum level of human IgG and IgM was elevated during chronic 
HBV infection, possibly in response to HBV surface antigen and HBx (172, 173). 
Although human immunoglobulin was mainly produced by B cells and was not directly 
related with liver physiology, the serum level of IgG and IgM was showed to be up-
regulated during chronic HBV infection, which was one of the risk factors and causes of 
liver fibrosis. Thus it was consistence with our observation that the serum level of this 
A^-glycan was also up-regulated with degree of liver fibrosis, and the fact that all of our 
samples were CHB infection patients. 
Another diagnostic A^-glycan with m/z 1933.3 was down-regulated with degree 
of liver fibrosis. It was predicted to be a mono-sialylated, biantennary complex type N-
glycan with no abnormal modification. It was found to be conjugated to human 
interferon-pl (174), plasminogen (175), transferrin (43) and AFP in HCC patient serum 
(176). Isailovic et al. in 2008 had found that this A^-glycan was able to differentiate 
between patients with HCC and normal control (177), suggesting that it was strongly 
associated with liver diseases. This postulation was consistent with our observation that 
it was significantly correlated with liver function. 
Apart from the four diagnostic iV-glycans, there were several other A/^ -glycans 
worth mentioning with regards to their predicted structures. An up-regulated A^-glycan 
with m/z 1363.8 was predicted to be a monosialylated, truncated A^-glycan at both 
trimannosyl core and one of the branches. A GlcNAc residue at the reducing end was 
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missing, and one branch was truncated at the core mannose residue, giving a unique 
monoantennary structure. Since PNGase F was not able to release iV-glycans with single 
GlcNAc residue at the reducing end, we postulated that this species of TV-glycan was 
present in human serum before PNGase F treatment. While the structure contains a rare 
monoantennary structure with atypical core, this A^-glycan was reported and found by 
Strecker et al in 1977 and van Pelt et al in 1989 in the urine of patients with sialidosis 
(178) and galactosialidosis (179). Endo-acetylglucosaminidase F (Endo F) is capable of 
trimming the asparagines-linked GlcNAc at the reducing end of A^-glycans (180). 
Brassart et al in 1987 had reported such type of Endo-acetylglucosaminidase in 
lysosome that can tolerate the sialylated branch structures while retaining the reducing 
end trimming property (181). It was possible that such exoglycosidase was a part of N-
glycan lysosomal degradation pathway and was responsible for the production of this 
truncated A/-glycan. 
Another up-regulated A^-glycan with m/z 2159.0 was predicted to be sulphated 
and sialylated at termini. Since there was no sulphate or sulphating agent in our system, 
the sulphate group in this A^-glycan was unlikely to be a side product generated during 
the analysis. We believed that, i f our prediction was correct, this was a genuine A^-glycan 
found in human serum glycoprotein. This A^-glycan was also found to be present on 
Tamm-Horsfall glycoprotein, which is originated from kidney and found in urine (182, 
183). A similar structure with sulphation at GlcNAc was also found in keratan sulfate 
(184). However, there was no previous report on finding such structures (Gal6Spl-
4GlcNAc) in serum glycoprotein. Further experiments are needed to confirm these 
“ predicted structures, such as tandem MS analysis (98) and glycosidase sequencing (185). 
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Our serum A^-glycome profiling assay has several advantages. The assay can 
easily be performed by laboratories already equipped with the SELDI ProteinChip 
system, and only 2 fo-l of serum is needed for profiling the serum A^-glycome. The assay 
is high-throughput, so a maximum of 96 serum samples can be examined in duplicate 
within 2 working days. As with the serum proteomic profiling assay, it is not necessary 
to know the structure of a diagnostic glycan, because a diagnostic A^-glycan can be 
reproducibly recognized and quantified through its unique m/z value. When a MALDI-
TOF/丁OF MS or MALDI Quadrupole-TOF (Q-TOF) MS instrument is used instead of 
the MALDI-TOF MS instrument, the structures of the glycan be can further obtained by 
tandem MS analysis. 
In addition to liver fibrosis, our assay has the potential to be applied to the 
diagnoses of other diseases, such as CDG. Multiple serum glycoproteins with abnormal 
glycosylation have been observed in patients with CDG (186, 187). Furthermore, our 
assay can be modified for other applications, such as quantitative profiling of glycans on 
a single protein. For example, quantitative profiling of the //-glycans detached from 
transferrin should be useful in detecting alcohol abuse. Quantitative analysis of specific 
A^-glycans on haptoglobin may be useful in the diagnosis of liver cancer (47). 
5. Conclusion 
In conclusion, we have applied a high-throughput quantitative A^-glycome 
profiling method and discovered 17 differential A^-glycans in human serum that were 
correlated with liver fibrosis stages, and had significant difference between minimal and 
severe fibrosis. We have constructed a diagnostic model by using 4 of these A^-glycans 
that could detect liver fibrosis and cirrhosis with approximately 82% accuracy. The 
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results of this pilot study strongly suggest that serum //-glycome profiling is a useful 
approach for discovery of biomarkers for diagnosis of liver fibrosis and cirrhosis. 
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Section 3: Serum 7V-glycome Profile as Biomarker for Liver Fibrosis - Verification 
Study 
1. Introduction 
In the previous section, we have demonstrated that total serum //-glycome profile 
can be used as a liver fibrosis biomarker with 85% accuracy. Seventeen A^-glycans were 
identified to be correlated with degree of liver fibrosis, and showed significant 
difference in signal intensities between minimal and typical liver fibrois patients. Most 
of the up-regulated A^-glycans were found to be core a 1-6 fucosylated or modified by a 
bisecting GlcNAc at the trimannosyl core. The result was consistent with previous 
similar studies carried out by other groups (37，38，39，83, 98). 
In this section, we aimed to verify the value of serum A^-glycome profiling in 
diagnosis of liver fibrosis with a larger independent cohort of approximately 170 
patients with chronic hepatitis B infection. The second objective was to identify N-
glycan biomarkers that were not affected by drug treatments using post-treatment serum 
samples. The result obtained would further consolidate the value of serum A^-glycomic in 
diagnosing liver fibrosis. The third objective was to investigate whether the result of the 
verification study was compatible with that of pilot study, i.e., whether the diagnostic N-
glycomic biomarkers generated from the verification study was relevant to that of pilot 
study. 
Currently, lamivudine and peginterferon a2b were used for the treatment of liver 
fibrosis with chronic hepatitis B infection. Lamivudine is a potent nucleoside analog 
reverse transcriptase inhibitor which could be utilized to suppress hepatitis B viral 
replication (188). Peginterferon a2b, on the other hand, is an antiviral cytokine mainly 
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used for the suppression of serum viral load (189) and can induce cellular immune 
response against hepatocytes infected by HBV. Some evidences have suggested that 
pegylated interferon monotherapy was as effective as lamivudine monotherapy (190). 
However, previous studies have shown that in terms of hepatitis B antigen 
seroconversion, HBV suppression and lamivudine resistance, the use of combined 
therapy of lamivudine and peginterferon a2b in hepatitis B antigen positive patients 
performed better than that of monotherapy of lamivudine (189). 
Maxwell et al in 2005 had demonstrated that there were changes of diagnostic 
serological biomarkers after long-term treatment with lamivudine. The group examined 
the level of ALT, amino-terminal propeptide of type I collagen (PINP) and carboxy-
terminal telopeptide of type I collagen (ICTP) in the serum of 39 patients on daily 
lamivudine treatment. It was found that while only PINP/ICTP ratio was both effective 
in diagnosing liver fibrosis before treatment, both the serum level of ALT and 
PINP/ICTP ratio had diagnostic abilities after 24 weeks of treatment (191). This 
suggested that there were changes in serological parameters after lamivudine treatment. 
Desmyter et al in 2006 had showed that serum glycomic was able to reflect 
degree of liver fibrosis in CCU-treated rat before and after treatment with in-house 
produced interferon 乂 (134). Their group had identified 3 A^-glycan peaks that could 
monitor degree of liver fibrosis, and showed difference in serum level in pre- and post-
treatment groups. Although the group had established a significant correlation 
relationship between the potential "-glycomic biomarkers and degree of liver fibrosis, 
no detail information regarding the diagnostic performance of these A^-glycans was given. 
Therefore, it was unknown i f the serum TV-glycans could monitor the patients' response 
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to interferon treatment, i.e. the degree of liver fibrosis before and after treatment. In this 
section, we would also take a similar approach to identify A^-glycans that could diagnose 
and stage liver fibrosis, and were not affected by lamivudine and peginterferon a2b 
treatment. 
2. Methods and Materials 
2.1 Patient Materials 
Three hundred patients suffering from chronic hepatitis B (CHB) had liver 
biopsy performed from 1998 to 2005 in Prince of Wales Hospital. These include patients 
who had been recruited or screened for previous and ongoing therapeutic trials as well as 
patients who were suspected to have active liver disease through laboratory or 
radiological investigations. These patients had received either combination treatment of 
peginterferon and lamivudine, lamivudine or placebo treatment during the study period. 
Patients had received antiviral treatments for 1 year, and liver biopsy were collected 6 
months after the termination of treatment. Al l patients had paired liver biopsies 
performed before treatment regimen and after antiviral treatment. Blood samples had 
been collected by venipuncture between 9 and 11 am at the baseline visit within 4 weeks 
of liver biopsy. Residual serum samples were saved in -80 freezer for future study 
with written informed consent. Al l patients had compensated liver disease at recruitment. 
Liver biopsy was performed using 16G Temno needles (Bauer Medical, Clearwater, FL). 
The specimens were formalin-fixed, paraffin-embedded and stained with haematoxylin-
eosin. To ensure the accuracy of histological assessment, all liver biopsy specimens 
were at least 15 mm in length with a minimum of 5 portal tracts. Liver fibrosis was 
scored using Ishak scoring system (0-6) by a single histopathologist who was blinded to 
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the laboratory and glycomic data. Complete clinical database including demographic 
data and laboratory results were available for these patients. 
After screening, 122 patients had complete pre- and post-treatment samples; 27 
patients have only pre-treatment samples; 18 patients have only post-treatment samples. 
A total of 289 serum samples were used. A detail sample breakdown was given in Table 
8. Pre-treatment serum samples were used for the consolidation of the A^-glycomic 
profiles in liver fibrosis diagnosis, while the post-treatment serum samples were used to 
verify that those profiles were independent of antiviral drug treatments and to verify the 
diagnostic value of biomarkers. 
2.2 Total serum A^-glvcome profiling 
Two micro-liters of serum samples were digested with PNGase F to release the 
A^-glycans from the whole serum glycoproteins. The A^-glycans were cleaned by 
hydrophilic chromatography, spotted on a Gold chip, and covered with SDHB matrix. 
After vacuum drying, the A^-glycan samples were subjected to linear MALDI-TOF MS 
with the Enterprise Edition of ProteinChip PCS 4000 SELDI Readers (Bio-Rad 
Laboratories Inc., USA) to obtain a quantitative glycan profile with molecular mass 
ranging from 900 Da to 3500 Da. The common peaks among the A/-glycan mass spectra 
were identified and quantified using the ProteinChip® Data Manager Version 3.0.7.004 
(Bio-Rad Laboratories Inc., USA.). The peak intensities were normalized with the total 
ion current across all spectra, and subsequently with the total peak intensities within the 
corresponding spectrum. The normalized peak intensities of the duplicate measurements 






















































































































































































































2.3 Statistical Analysis 
2.3.1 Identification of Potential Diagnostic A/-Glvcans for Liver Fibrosis. 
In this part of the study, pre-treatment samples were used separately to identify a 
set of differential A^-glycans for detection of liver fibrosis. Differential A^-glycans found 
in post-treatment samples were compared with that of pre-treatment differential N-
glycans for the identification of treatment-independent A/^ -glycans. For each set of 
treatment samples, they were randomly divided into biomarker discovery group and 
validation group. For the 149 pre-treatment samples, 98 of them were grouped into 
biomarker discovery group; the remaining 51 were grouped into validation group. For 
the 140 post-treatment samples, 90 of them were grouped into biomarker discovery 
group; the remaining 50 were grouped into validation group. Only biomarker discovery 
sets were used during biomarker discovery phase. Validation sets were not involved in 
any biomarker discovery process to ensure the integrity of independent validation. 
Similar to the pilot study, two criteria were used to identify the A^-glycans 
associated only with liver fibrosis. First, the normalized peak intensities must be 
significantly higher/lower in patients with typical fibrosis than in individuals with 
minimal fibrosis. Second, the normalized peak intensities must correlate with the degree 
of fibrosis. The significance analysis of microarray (SAM) algorithm (Stanford 
University, 161, 162) and Mann-Whitney U test were used as independent 2-class 
comparison tests. In the SAM analysis, "2-classed, unpaired data" were selected as the 
data type, and 5000 permutations were performed on fibrosis group (Ishak score = 3,4， 
5, 6) and minimal fibrosis group (Ishak score = 0, 1, 2). Mann-Whitney U test was 
similarly applied on typical fibrosis group (Ishak score = 4，5, 6) and minimal fibrosis 
group (Ishak score = 0，1). Patients with intermediate fibrosis (Ishak score = 2，3) were 
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omitted in Mann-Whitney U test. Correlations between the degree of fibrosis (Ishak 
scores) and the peak intensities of the significant glycans were analyzed by the 
Spearman rank order correlation test. Mann-Whitney U test and Spearman rank order 
correlation test were carried out using SPSS 10.0 (SPSS Inc.). 
The Spearman rank order correlation test was used to examine correlation 
relationships between the A^-glycan peak intensities and the clinical/biochemical 
variables. The following 10 clinical variables were concerned: age (calculated to the date 
of liver biopsy), haemoglobin level，leukocyte count, platelet count, INR, total protein 
concentration, albumin concentration, bilirubin concentration, ALP and ALT. 
Only A^-glycans that showed significant difference between typical fibrosis and 
minimal fibrosis, correlation with Ishak score, and correlation with at least one clinical 
variable were selected as potential biomarkers and subjected to further analysis. 
2.3.2 Construction of iV-glvcan-based Diagnostic Model 
Log2 values of the normalized peak intensities were included as independent 
variables, and Ishak score was set as the dependent output variable. Forward stepwise 
linear regression analysis was performed using prediction values for constructing a 
diagnostic model to calculate the diagnostic index. Validation group was used to 
evaluate the performance of the diagnostic model in detecting significant liver fibrosis 
(Ishak score > 2) and liver cirrhosis (Ishak score > 4). Receiver Operating Characteristic 
curves was used to assess the sensitivity and specificity of the diagnostic models. The 
correlation of the model index with the Ishak scores was examined by the Spearman 
Correlation test. The difference in the model index between minimal and typical fibrosis 
groups was compared by Mann-Whitney U test. 
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2.3.3 Identification of Drug Treatment-Independent Diagnostic A^-Glvcans for Liver 
Fibrosis. 
In this part of study, we aimed to identify A^-glycans that had similar 
performance in detecting liver fibrosis before and after antiviral drug treatments. 
Differential A^-glycans that were commonly found in pre- and post-treatment biomarker 
discovery groups were selected and used to construct 3 models for biomarker discovery 
groups of pre-treatment samples, post-treatment samples and pooled pre- and post-
treatment samples respectively. Receiver Operating Characteristic curves was used to 
assess the sensitivity and specificity of the diagnostic models. The corresponding models 
were applied on validation groups of pre-treatment samples, post-treatment samples and 
pooled pre- and post-treatment samples respectively for independent validation. The 
correlation of the model index with the Ishak scores was examined by the Spearman 
Correlation test. The performance of these models would provide evidences to support 
the validity of drug treatment-independent A^-glycans. 
2.4 Validation of Fibro-Glvco Index 
The glycan peaks corresponding to the A^-glycan signature (4 glycans with m/z 
value of 1341.5, 1829.7, 1933.3 and 2130.3) identified in the pilot study were input into 
the linear regression equation for calculating the Fibro-Glyco Index of all samples. The 
correlation of the Fibro-Glyco Index with the Ishak scores of the liver histology was 
examined by the Spearman Correlation test. Receiver Operating Characteristics curve 
was applied to assess the diagnostic values, sensitivity and specificity of Fibro-Glyco 
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index in diagnosing significant liver fibrosis (Ishak score > 2) and liver cirrhosis (Ishak 
score > 4). 
3. Results 
In this section, pre-treatment and post-treatment samples were randomly divided 
into 2 groups: biomarker discovery group and validation group. There were small 
differences in the serological markers concerned between different groups. A summary 
was given in Table 9. Two-tailed Student T-test with Bonferroni Correction was used to 
compare the mean values of serological markers between groups. Since eleven 
serological markers were concerned in this study, Bonferroni corrected P value threshold 
was adjusted to 0.05/11 = 0.00455. 
In the pre-treatment and post treatment group, there were no significant 
differences in age, Ishak score and serological marker levels between biomarker 
discovery and validation group (Student T-test, all P values > 0.00455, N = 149). When 
comparing pre-treatment group with post-treatment group, there were significant 
differences in various serological markers, including platelet count (P = 0.002，N = 289), 
INR, albumin, ALP and ALT level (Al l P values < 0.001，N = 289). 
There were no significant differences in age, Ishak score, haemoglobin, 
leukocyte count, total protein concentration and bilirubin concentration between 
treatment groups and biomarker discovery/validation groups (all P values > 0.00455). 
These results suggested that our samples were randomized into different groups. 
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3.1 Serum A^-glvcome Profile and Liver Fibrosis-Associated Fingerprint 
The representative serum iV-glycome mass spectra of serum samples from a 
healthy individual, a patient with minimal liver fibrosis, and a patient with significant 
fibrosis in the range from 900 Da to 3500 Da were shown in Figure 14. By using the 
PCS 4000 ProteinChip Reader, most sialylated A^-glycan peaks observed were in full 
sodium salt forms, and the native protonated states of sialylated A^-glycan, while 
detectable, were less prominent. A total of 95 A^-glycomic features were identified in the 
mass spectra. A comparison of normalized peak intensities between pre- and post-
treatment group was given in Table 10. Statistical significant threshold was corrected to 
0.0005 by Bonferroni correction. Nine out of 95 peaks (9.5%) were showed to be 
statistically significant between pre- and post-treatment samples. 
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Mean (SD) Level of Pre-treatment Group Serological Markers 
A Biomarker Discovery Validation 
N = 98 N = 51 Sign. (2-tailed) 
Age 38.96 (10.68) ~ ~ 3 5 . 5 7 ( 1 1 . 4 1 ) 0 . 0 7 5 
Ishak Score 1.92 (1.58) 2.04 (1.81) 0.675 
Haemoglobin 14.85 (1.45) 14.61 (1.57) 0.348 
Leukocyte Count 5.95(1.57) 5.78 (1.48) 0.517 
Platelet count 178.99 (53.03) 199.10(62.41) 0.041 
INR 6.13 (11.62) 6.37 (12.01) 0.842 
Total Protein 76.81 (6.42) 77.57 (4.92) 0.459 
Albumin 39.63 (4.40) 39.80 (4.02) 0.817 
Bilirubin 10.63 (4.65) 11.20 (4.82) 0.489 
ALP 92.84 (32.37) 85.12 (25.58) 0.099 
ALT 151.57 (80.27) 159.22 (98.42) 0.611 
B Biomarker Discovery Validation 
N = 90 N = 50 Sign. (2-tailed) 
38.71 (10.91) 35.71 ( 1 0 . 4 6 ) 0 . 0 9 9 
ishak Score 1.80 (1.76) 1.79(1.68) 0.961 
Haemoglobin 14.78 (1.61) 14.84 (1.35) 0.825 
Leukocyte Count 6.08 (1.45) 6.22 (1.71) 0.595 
Platelet count 206.7 (52.87) 206.51 (63.02) 0.985 
INR 1.05 (0.07) 1.03 (0.05) 0.029 
Total Protein 78.33 (5.17) 77.81 (5.08) 0.554 
Albumin 43.73 (3.39) 45.11 (4.27) 0.035 
Bilirubin 11.06 (5.39) 12.49 (6.26) 0.150 
ALP 70.39(19.21) 72.53 (26.71) 0.294 
ALT 51.26 (70.08) 48.47 (47.14) 0.783 
Mean (SD) Level of Serological Markers 
C Pre-treatment Post-treatment 
N=:149 N = 140 Sign. (2-tailed) 
37.80 (11.02) 37.21 ( 1 0 . 7 5 ) 0 . 6 4 9 
Ishak Score 1.96 (1.66) 1.79 (1.72) 0.401 
Haemoglobin 14.77(1.49) 14.81 (1.48) 0.797 
Leukocyte Count 5.89(1.54) 6.15(1.58) 0.163 
Platelet count 185.87 (57.02) 206.61 (57.96) 0.002* 
INR 6.67 (12.11) 1.04 (0.06) <0.001* 
Total Protein 77.07 (5.94) 78.07 (5.11) 0.126 
Albumin 39.69 (4.26) 44.42 (3.90) <0.001* 
Bilirubin 10.53 (4.70) 11.77 (5.86) 0.130 
ALP 90.19(29.80) 72.46 (23.27) <0.001* 
ALT 154.19(86.65) 49.86 (59.52) <0.001* 
Table 9: Differences in serological markers between A) Pre-treatment biomarker 
discovery and validation group, B) Post-treatment biomarker discovery and validation 
group, and C) between pre- and post-treatment group. *P value < 0.00455. 
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Figure 14: The representative MALDI-TOF mass spectra of serum A^-glycome profile of 
(A) a chronic hepatitis B patient with significant fibrosis; (B) a chronic hepatitis B 
patient with minimal liver fibrosis, and (C) a healthy individual. The mass spectra were 
acquired by using PBS 4000 ProteinChip Reader. 
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Mean (SD) Level of Normalized Peak Intensities between Treatment Group. 
Pre-Treatment Post-Treatment 
g m/z Value N = 149 N = 140 Sign. (2-tailed) 
1143.5 0.151 (0.053) 0.174 (0.056) <0.0005 
1464.3 1.647 (0.673) 1.327 (0.561) <0.0005 
1642.4 8.250(1.094) 8.865 (1.079) <0.0005 
1890.0 2.684 (0.416) 2.887 (0.404) <0.0005 
1936.3 10.960(1.330) 11.780 (1.248) <0.0005 
2007.8 0.975 (0.193) 1.066 (0.209) <0.0005 
2035.8 0.587 (0.086) 0.539 (0.096) <0.0005 
2102.0 3.549 (0.639) 3.211 (0.552) <0.0005 
2413.8 1.867 (0.448) 1.689 (0.374) <0.0005 
Table 10: Differences in normalized peak intensities between pre- and post-treatment 
group. A total o f 95 A^-glycomic features were identified in the profile. Only statistically 
significant peaks were showed. A l l P value < 0.0005 (Student T-test, Bonferroni 
corrected). 
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3.2 Identification of Differential •/V-Glycans Biomarkers for Liver Fibrosis. 
3.2.1 Pre-treatment Group 
For pre-treatment sample biomarker discovery group, a total of 17 A^-glycans 
were identified after Mann-Whitney U test and Spearman Rank Order analysis; 12 of 
them (8 up-regulated and 4 down-regulated, N = 98) were found to be correlated with 
various serological markers and therefore selected as diagnostic biomarkers. The 
normalized intensities of 6 out of 12 A^-glycans also showed significant difference 
between minimal fibrosis (Ishak score = 0，1,2) and liver cirrhosis patients (Ishak score 
=5 , 6. Total N = 89). 
3.2.2 Post-treatment Group 
For post-treatment sample biomarker discovery groups, a total of 5 A^-glycans (3 
up-regulated and 2 down-regulated, N = 90) were identified and all of them showed 
significant correlation with various serological markers. Al l of them also showed 
significant difference between minimal fibrosis (Ishak score = 0，1, 2) and liver cirrhosis 
patients (Ishak score = 5, 6. Total N = 79). When comparing the diagnostic A^-glycans 
between treatment groups, 2 A^-glycans (m/z 1752.5 and m/z 1829.8) were found to be 
present in both groups, i.e. potential diagnostic A^-glycans unaffected by drug treatments. 
3.3 Correlation between Differential 7V-glvcans and Serological Markers. 
3.3.1 Pre-treatment Group 
In pre-treatment biomarker discovery group, normalized intensities of 12 N-
glycans were found to correlate with Ishak score, serological markers, or showed 
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significant difference between typical fibrosis and minimal fibrosis. A summary of these 
A^-glycans were given in Table 11. Ninty-six samples were involved in this analysis. 
Concerning liver function, 3 A^-glycans were correlated positively with albumin (r = 
0.278 to 0.435, all P values < 0.006); 3 A^-glycans were correlated negatively with 
albumin (r = -0.413 to -0.344，all P values < 0.001). Concerning the 6 A^-glycans that 
were correlated positively with liver damage, 5 of them were positively correlated with 
bilirubin concentration (r = 0.211 to 0.331, all P values < 0.037); 4 were correlated with 
ALP level (r = 0.211 to 0.374，all P values < 0.037). Only one A^-glycan with m/z 2202.8 
was correlated negatively with liver damage and inflammation (bilirubin level r = -0.322, 
P = 0.001; INR r = -0.221, P = 0.029). For blood clotting behaviour, 2 were correlated 
positively with INR (r = 0.205 to 0.241，all P values < 0.043); 3 were correlated 
positively with platelet count (r = 0.291 to 0.349，all P values < 0.004); all iV-glycans 
that were positively correlated with liver fibrosis were correlated negatively with platelet 
count (r = -0.454 to -0.204, all P values < 0.044). For white blood cell count, one N-
glycan was correlated positively with leukocyte count (r = 0.207，P = 0.041); 2 were 
correlated negatively with leukocyte count (r = -0.290 to -0.233，all P values < 0.021). 
The degree of liver fibrosis (Ishak score) was found to be positively correlated with 

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































3.3.2 Post-treatment Group 
In post-treatment biomarker discovery groups, normalized intensities of 5 N-
glycans were found to correlate with Ishak score, serological markers, and showed 
significant difference between typical fibrosis and minimal fibrosis. A summary of these 
A^-glycans were given in Table 12. Ninety samples were involved in this analysis. 
Concerning liver function, one A -^glyeans was correlated positively with total protein 
level (r = 0.256，P values = 0.032). Concerning the 2 A^-glycans that were correlated 
positively with liver damage, all of them were correlated with ALP level (r = 0.276 to 
0.318，all P values < 0.021); one of them were positively correlated with bilirubin 
concentration (r = 0.301, P = 0.011). A total of 4 A^-glycans were associated with liver 
inflammation; 3 of them were positively correlated with ALT level (r = 0.266 to 0.513, 
all P values < 0.026); the remaining one was negatively correlated with ALT level (r = -
0.373，P = 0.001). Two TV-glycans were correlated negatively with liver damage. One of 
them (m/z 1423.9) was correlated negatively with bilirubin level (r = -0.260，P = 0.030) 
while another one (m/z 912.3) was correlated negatively with ALP concentration (r = -
0.290，P = 0.015). For blood clotting behaviour, one 7V-glycan with m/z 1423.9 was 
correlated positively with platelet count (r = 0.316, P = 0.008); while A^-glycan with m/z 
1752.5 was correlated negatively with platelet count (r = -0.532, P < 0.001). For white 
blood cell count, A^-glycan with m/z 1752.5 was correlated negatively with leukocyte 
count (r = -0.412，P < 0.001). AA-glycan with m/z 1829.8 was marginally negatively 
correlated with leukocyte count (r = -0.232, P = 0.053). The degree of liver fibrosis 
(Ishak score) was found to be positively correlated with ALP (r = 0.320, P = 0.007), 
ALT (r = 0.269, P = 0.025) and INR (r = 0.292, P = 0.014)，and negatively correlated 
















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































3.4 Construction and Validation of Linear Regression Model for Detecting Liver 
Fibrosis in Pre-treatment and Post-treatment Groups 
3.4.1 Pre-treatment Group and Model Construction 
Twelve A^-glycans identified from the pre-treatment biomarker discovery group 
were subjected to linear regression analysis (N = 98)，and two TV-glycans (m/z 1601.5, 
m/z 2467.5) were selected as biomarkers with independent diagnostic values, and were 
used to predict degree of liver fibrosis in patients. The prediction algorithm was 
generated from pre-treatment biomarker discovery group, and applied on pre-treatment 
validation group which was not involved in any biomarker discovery process. The 
predicted degree of liver fibrosis was termed "Pre-treatment Fibro-Glyco Index". When 
applying such index on the pre-treatment biomarker discovery group, the area under 
ROC curve obtained was 0.84 (P < 0.001, Figure 15A). At 85% specificity, the 
sensitivity of the index was 57%. Positive LR was 3.80; negative LR was 0.51. 
3.4.2 Pre-treatment Group and Independent Validation 
When applied on pre-treatment validation group, Pre-treatment Fibro-Glyco 
Index was found to be significantly correlated with actual degree of liver fibrosis (r = 
0.470，P = 0.001，N = 51). The ROC curve area of the index in detecting liver fibrosis in 
validation group was 0.84 (P < 0.001，Figure 15B), which was the same as that of 
biomarker discovery group (Figure 15 A). At 85% specificity, the sensitivity of the index 
was 57%. Positive LR was 3.80; negative LR was 0.51. 
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Figure 15: ROC curves of the Pre-treatment Fibro-Glyco Index in the detection of 
significant liver fibrosis in A) Pre-treatment biomarker discovery group, B) Pre-
treatment validation group, and C) Post-treatment group. The 95% CIs of the AUG 
values are shown in parentheses. 
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When applied on post-treatment group, Pre-treatment Fibro-Glyco Index was also found 
to be significantly correlated with actual degree of liver fibrosis, although with lower 
correlation coefficient (r = 0.235，P = 0.005, N = 140). The ROC curve area of the index 
in detecting post-treatment liver fibrosis was 0.70 (P = 0.001，Figure 15C), which was 
lower than pre-treatment group. At 85% specificity, the sensitivity of the index was 44%. 
Positive LR was 2.93, negative LR was 0.66. 
3.4.3 Post-treatment Group and Model Construction 
Five A^-glycans identified from the post-treatment biomarker discovery group 
were subjected to linear regression analysis (N = 90), and two A^-glycans (m/z 1752.5, 
m/z 1829.8) were selected as having independent diagnostic values, and were used to 
predict degree of liver fibrosis in patients after treatment. The prediction algorithm was 
generated from post-treatment biomarker discovery group, and applied on post-treatment 
validation group which was not involved in any biomarker discovery process. When 
applying "Post-treatment Fibro-Glyco Index" on the post-treatment biomarker discovery 
group, the area under ROC curve obtained was 0.82 (P < 0.001, Figure 16A). At 85% 
specificity, the sensitivity of the index was 61%. Positive LR was 4.07; negative LR was 
0.46. 
3.4.4 Post-treatment Group and Independent Validation 
The predicted degree of liver fibrosis was termed "Post-treatment Fibro-Glyco 
Index". When applied on post-treatment validation group, Post-treatment Fibro-Glyco 
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Figure 16: ROC curves of the Post-treatment Fibro-Glyco Index in the detection of 
significant liver fibrosis in A) Post-treatment biomarker discovery group, B) Post-
treatment validation group, and C) Pre-treatment group. The 95% CIs of the AUG values 
are shown in parentheses. 
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Index was found to be significantly correlated with actual degree of liver fibrosis (r = 
0.260, P = 0.029, N = 50). The ROC curve area of the index in detecting liver fibrosis in 
validation group was 0.78 (P = 0.001，Figure 16B), which was lower than that of 
biomarker discovery group (Figure 16A). At 85% specificity, the sensitivity of the index 
was 50%. Positive and negative LRs were 3.33 and 0.59 respectively. When applied on 
pre-treatment group, Post-treatment Fibro-Glyco Index was also found to be 
significantly correlated with actual degree of liver fibrosis with higher correlation 
coefficient (r = 0.388，P < 0.001’ N = 149). The ROC curve area of the index in 
detecting pre-treatment liver fibrosis was 0.76 (P < 0.001，Figure 16C), which was 
higher than that in post-treatment group. At 85% specificity, the sensitivity of the index 
was 43%. Positive LR was 2.87，negative LR was 0.67. 
3.5 Performance of Common A/^ -glycans in Detecting Liver Fibrosis 
3.5.1 Pre-treatment Group and Model Construction 
Two A^-glycans (m/z 1752.5 and m/z 1829.8) in post-treatment panel were also 
found in treatment-naive samples. When using pre-treatment biomarker discovery 
samples for linear regression model construction, only one A^-glyeans (m/z 1752.5) was 
selected. The predicted degree of liver fibrosis was termed "Common Fibro-Glyco Index 
1". When applied on pre-treatment validation samples, Common Fibro-Glyco Index 1 
was found to be significantly correlated with actual degree of liver fibrosis (r = 0.344，P 
=0.013, N = 51). The ROC curve area of the index in detecting liver fibrosis in 
validation group was 0.76 (P < 0.001, Figure 17B), which was similar to that of 
biomarker discovery group (area under curve = 0.78, P < 0.001，Figure 17A). At 
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Figure 17: ROC curves of the Common Fibro-Glyco Index 1 in the detection of 
significant liver fibrosis in A) Pre-treatment biomarker discovery group, B) Pre-
treatment validation group, and C) Post-treatment group. The 95% CIs of the AUC 
values are shown in parentheses. 
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85% specificity, the sensitivity of the index was 57%. Positive LR was 3.80; negative 
LR was 0.51. When applied on post-treatment group, Common Fibro-Glyco Index 1 was 
also found to be significantly correlated with actual degree of liver fibrosis, although 
with slightly lower correlation coefficient (r = 0.320，P < 0.001’ N = 140). The ROC 
curve area of the index in detecting post-treatment liver fibrosis was 0.73 (P < 0.001’ 
Figure 17C), which was similar to pre-treatment group. At 85% specificity, the 
sensitivity of the index was 50%. Positive LR was 3.33; negative LR was 0.59. 
3.5.2 Post-treatment Group and Model Construction 
When using post-treatment biomarker discovery samples for linear regression 
model construction, two A^-glycans (m/z 1752.5 and m/z 1829.8) were selected and the 
algorithm generated was the same as Post-treatment Fibro-Glyco Index. The predicted 
degree of liver fibrosis was termed "Common Fibro-Glyco Index 2". When applied on 
post-treatment validation samples, Common Fibro-Glyco Index 2 had the same 
correlation characteristics as Post-treatment Fibro-Glyco Index (r = 0.260，P = 0.029，N 
=50). The ROC curve area of the index in detecting liver fibrosis in validation group 
was 0.78 (P = 0.001, Figure 18B), which was lower than that of biomarker discovery 
group (area under curve = 0.82，P < 0.001, Figure 18A). At 85% specificity, the 
sensitivity of the index was 50%. Positive and negative LRs were 3.33 and 0.59 
respectively. When applied on pre-treatment group, Common Fibro-Glyco Index 2 had 
the same correlation characteristics as Post-treatment Fibro-Glyco Index (r = 0.388, P < 
0.001，N = 149). The ROC curve area of the index in detecting pre-treatment liver 
fibrosis was 0.76 (P < 0.001, Figure 18C), which was higher than that in post-treatment 
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Figure 18: ROC curves of the Common Fibro-Glyco Index 2 in the detection of 
significant liver fibrosis in A) Post-treatment biomarker discovery group, B) Post-
treatment validation group, and C) Pre-treatment group. The 95% CIs of the AUG values 
are shown in parentheses. 
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group. At 85% specificity, the sensitivity of the index was 43%. Positive LR was 2.87, 
negative LR was 0.67. 
The relationship between the signal intensities of the A^-glycans mentioned above 
(m/z 1601.5, m/z 1752.5, m/z 1829.8, m/z 2467.5) and Ishak score were illustrated in 
Figure 19. 
3.5.3 Pooled Pre- and Post-treatment Group and Model Construction 
When using pooled pre- and post-treatment biomarker discovery samples for 
linear regression model construction, two "-glycans (m/z 1752.5 and m/z 1829.8) were 
selected with a different algorithm generated compared with Post-treatment Fibro-Glyco 
Index. The predicted degree of liver fibrosis was termed "Common Fibro-Glyco Index 
3". When applied on pooled pre- and post-treatment validation samples, Common Fibro-
Glyco Index 3 was found to be significantly correlated with actual degree of liver 
fibrosis (r = 0.321, P < 0.001’ N = 101). The ROC curve area of the index in detecting 
liver fibrosis in validation group was 0.77 (P < 0.001，Figure 20B), which was similar to 
that of biomarker discovery group (area under curve = 0.79，P < 0.001，Figure 20A). At 
85% specificity, the sensitivity of the index was 53%. Positive and negative LRs were 
3.53 and 0.55 respectively. 
3.6 Performance of Different Model in Detecting Liver Cirrhosis 
When applying Pre-treatment Fibro-Glyco Index on the pre-treatment validation 
group for detecting liver cirrhosis (Ishak score > 4)，the area under ROC curve obtained 
was 0.89 (P < 0.001)，with 63% sensitivity at 85% specificity (Figure 21 A). Positive LR 
was 4.20; negative LR was 0.44. 
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Figure 19: Representative mass spectra showing peak intensities of 4 diagnostic N-
glycans in the patients with different degrees of liver fibrosis. Al l were positively 
correlated with Ishak score. The molecular weights of the neutral molecules are marked 
in the mass spectra. 
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Figure 19 (con't): Representative mass spectra showing peak intensities of 4 diagnostic 
7V~glycans in the patients with different degrees of liver fibrosis. Al l were positively 
correlated with Ishak score. The molecular weights of the neutral molecules are marked 
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Figure 19 (con't): Representative mass spectra showing peak intensities of 4 diagnostic 
A^-glycans in the patients with different degrees of liver fibrosis. Al l were positively 
correlated with Ishak score. The molecular weights of the neutral molecules are marked 
in the mass spectra. 
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Figure 19 (con't): Representative mass spectra showing peak intensities of 4 diagnostic 
A^-glycans in the patients with different degrees of liver fibrosis. Al l were positively 
correlated with Ishak score. The molecular weights of the neutral molecules are marked 
in the mass spectra. 
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Figure 20: ROC curves of the Common Fibro-Glyco Index 3 in the detection of 
significant liver fibrosis in A) Pooled Pre- and Post-treatment biomarker discovery 
group and B) Pooled Pre- and Post-treatment validation group. The 95% CIs of the AUG 
values are shown in parentheses. 
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When applying Post-treatment Fibro-Glyco Index and Common Fibro-Glyco 
Index 2 on the post-treatment validation group for detecting liver cirrhosis (Ishak score > 
4)，the area under ROC curve obtained was 0.85 (P = 0.001)，with 63% sensitivity at 
85% specificity (Figure 2IB). Positive LR was 4.20; negative LR was 0.44. 
When applying Common Fibro-Glyco Index 1 on the pre-treatment validation 
group for detecting liver cirrhosis (Ishak score > 4)，the area under ROC curve obtained 
was 0.87 (P = 0.001)，with 63% sensitivity at 85% specificity (Figure 21C). Positive LR 
was 4.20; negative LR was 0.44. 
When applying Common Fibro-Glyco Index 3 on the pooled pre- and post-
treatment validation group for detecting liver cirrhosis (Ishak score > 4), the area under 
ROC curve obtained was 0.87 (P < 0.001)，with 81% sensitivity at 85% specificity 
(Figure 2ID). Positive LR was 5.40; negative LR was 0.22. A summary was given in 
Figure 21 and Table 13. 
3.7 Comparison of Fibro-Glvco Index in Pilot Study and Present Verification Study. 
FourA^-glycans (m/z 1341.4，m/z 1829.7，m/z 1933.3 and m/z 2130.3) were used 
to construct Fibro-Glyco Index in pilot study. From the mass spectra, only A^-glycans 
with m/z 1829.7，m/z 1933.3 and m/z 2130.3 were detected in the previous pilot study 
and the present study. Mass deviations between two studies were 0.1 Da (0.005%), 0.9 
Da (0.047%) and 0.2 Da (0.009%) respectively. Only TV-glycan with m/z 1829.7 was 
found to be a differential A^-glycan in both pre-treatment samples and post-treatment 
samples in the verification study (as m/z 1829.8). For all 3 "-glycans，none showed 
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Figure 21: ROC curves of different diagnostic model in the detection of significant liver 
cirrhosis in validation study. A) Pre-treatment Fibro-Glyco Index in detecting pre-
treatment validation group, B) Post-treatment Fibro-Glyco Index and Common Fibro-
Glyco Index 2 in detecting post-treatment validation group, C) Common Fibro-Glyco 
Index 1 in detecting pre-treatment validation group，and D) Common Fibro-Glyco Index 



































































































































































































































































































































































































































































































































































































































































significant correlation with degree of liver fibrosis in pre-treatment samples; only N-
glycan with m/z 1829.8 showed significant correlation with degree of liver fibrosis in 
post-treatment samples. In pilot study, A^-glycan with m/z 1829.7 and m/z 2130.3 were 
up-regulated in liver fibrosis, while m/z 1933.3 was down-regulated. In both pre- and 
post-treatment samples of the present verification study, only normalized peak 
intensities of A/-glycans with m/z 1829.8 was significantly up-regulated in fibrosis group. 
In the pre-treatment samples (n = 149)，none of the 3 A^-glycans were 
significantly correlated with albumin and total protein concentration. Therefore they 
were not related to liver function. Their correlation relationships with serological 
markers were summarized in Table 14. 
Comparison between spectra obtained from pilot study and verification study 
was showed in Figure 22. When Fibro-Glyco Index model was applied on our data set 
using only 3 parameters (normalized peak intensities of m/z 1829.7, 1933.3，2130.3)，the 
performance of the model in detecting liver fibrosis was markedly reduced, with ROC 
curve area of 0.67 (P < 0.001，Figure 23B). At 85% specificity, sensitivity of the index 
was 29%. Positive and negative LRs were 1.93 and 0.84 respectively. On the other hand, 
when we apply the 3-parameter Fibro-Glyco Index to the 46 samples in pilot study, the 
performance of such adjusted model in detecting liver fibrosis did not differ too much to 
the original model, with area under ROC curve of 0.92 (P < 0.001, Figure 23A). 
3.8 Structural prediction of diagnostic A^-glvcans 
A summary of the predicted structures of diagnostic A^-glycans in pre-treatment 
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Figure 22: Comparison of normal human serum TV-glycome profile obtained from pilot 
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Figure 23: ROC curves of the Fibro-Glyco Index using 3 parameters (normalized peak 
intensities of m/z 1829.7, 1933.3, 2130.3) in the detection of significant liver fibrosis in 
A) pilot study and B) validation study. 
134 
Mass Spearman Correlation 
Deviation with Ishak Score 
m/z Predicted Structures in Da (%) (P value) 
1143.5 N/A N/A -0.287 (0.004) 
1440.3 1.0(0.070) 0.249 (0.013) 
1601.5 G f ^ S h i h l l 0.2(0.012) 0.362 (<0.001) 
o - M - g 
O-W-O OR 
1642.5 o « 0.0(0.00) -0.314 (0.002) 
1658.3 “ N/A “ N/A — -0.235 (0.02) 
1684.5 “ OR 1.0 (0.057) 0.241 (0.017) 
〇 { l ^ 
©H£) 
1752.5 y>-m-m 1.0 (0.055) 0.415 (<0.001) 
1829.8 0.1 (0.007) 0.245 (0.015) 
: 2 1 5 8 . 2 N/A — N/A 0.323 (0.001) 
: 2 2 0 2 . 8 - N/A - N/A -0.214 (0.034) 
“ O B - Q A 
2467.5 • 0.8 (0.032) 0.402 (<0.001) 
二 2780.5 " N / A N/A 0.269 (0.007) 
Table 15: Predicted structures of 12 potential diagnostic A^-glycans in pre-treatment 
samples. 
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Mass Spearman Correlation 
Deviation with Ishak Score 
m/z Predicted Structures in Da (%) (P value) 
912.3 0.4 (0.048) -0.312 (0.009) 
1423.9 0.6 (0.043) -0.340 (0.004) 
1668.3 • • 0.8 (0.046) 0.388 (0.001) 
1752.5 J l ^ - m - m 1.0(0.055) 0.389 (0.001) 
+ 
1829.8 〇 { • • 0.1 (0.007) 0.353 (0.003) 




In this section, a new MALDI-TOF MS system with improved quantitative 
properties was used. The ProteinChip PCS 4000 SELDI Reader (Enterprise Edition) 
allows more sophisticated acquisition protocol and provides enhanced sensitivity when 
compared with the previous system (ProteinChip PBS-II Reader). Instead of dividing the 
sample spot vertically into 61 acquisition positions, PCS 4000 SELDI Reader divides the 
sample spot uniformly into 210 acquisition positions. Therefore, only one-third of the 
acquisition positions were needed for laser queries while the total number of spectra 
acquired was maintained. This not only avoided the variation of MS signals from 
different sample-matrix co-crystal as before, but also kept two-third of the intact co-
crystal for possible future analysis such as tandem MS fragmentation. From the result 
(Figure 22)，there were two obvious differences between the mass spectra obtained from 
pilot study (PBS II) and the present verification study (PCS 4000). First, the signal 
intensities of low abundance ion were markedly increased in PCS 4000 systems, for 
example m/z 1626.5, m/z 1642.8 and m/z 1788.7. This was due to enhanced sensitivity 
of the new MALDI-TOF system. This increase in signal intensities of low abundance 
ion was particularly useful in the verification study because from the result of pilot study, 
most of the diagnostic A^-glycans were of low abundance species with normalized signal 
intensities less than 6 except m/z 1933.3. It was possible that some low abundance N-
glycans might be missed due to their low signal-to-noise ratio (S/N ratio), or their m/z 
value might be detected with low precision due to peak broadening. The increase in 
signal intensities could partially avoid these two problems. Second, while both 
protonated and sodium salt form of sialylated 7V~glycans were co-dominant in PBS II 
system, only full sodium salt form was predominant in PCS 4000 system, for example 
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m/z 1932.7 (protonated form) and m/z 1954.7 (full sodium salt form). Since the 
preparation of TV^glycan and matrix chemicals were the same in both system, we 
suspected that the formation of sodium salt depends on the specification of instruments, 
for example the ionization procedure and ion detection. Since the signals of protonated 
and partial sodium salt species were suppressed and only full sodium salt species was 
dominant, the mass spectrum obtained was simplified and less overlapping of peaks was 
observed. Moreover, it was still possible to predict the structures of sialylated A^-glycans 
using the observed mass values minus multiple of 22. Overall, the new PCS 4000 
MALDI-TOF MS system had enhanced performance compared with the PBS II system. 
In the verification study, we aimed to apply total serum A^-glycome profile in 
detecting liver fibrosis in patients with CHB infection. The patient samples used in this 
study were either treatment-naive or lamivudine/peginterferon treated. Lamivudine is a 
nucleoside analog which was used to suppress HBV replication by inhibiting reverse 
transcriptase. Lamivudine was utilized with acceptable tolerability during hepatitis B 
treatment. However its merits were clouded by the emergence of drug resistant HBV 
after prolong treatment (192). Moreover, the sustainability of the treatment effect was 
low once the patient discontinued the lamivudine therapy (193). In response to the 
generation of lamivudine-resistant hepatitis B virus, novel nucleoside analogs such as 
adefovir and telbivudine were now under investigation. It was found by Yatsuji et al. in 
2008 that adefovir, in combination therapy with lamivudine, could suppress lamivudine-
resistant HBV with low incident of generating adefovir-resistant virus (194). On the 
other hand, monotherapy of telbivudine in Chinese was found to have higher antiviral 
and clinical efficacy with lower incident of generating drug resistant virus than 
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lamivudine (195). Nonetheless, since the the use of lamivudine was well established and 
thoroughly studied, it was still used as initial treatment (196). 
Interferon, on the other hand, is a class of cytokines that induce cellular immune 
response against foreign antigen. In order to increase its clearance half-life, it was 
conjugated to polyethylene glycol (PEG) to form pegylated interferon, or peginterferon 
for short. Previous study in 2008 by Everson et al. showed that peginterferon improved 
inflammation condition and fibrosis in patients with hepatitic C induced advanced 
fibrosis and cirrhosis (197). While some had suggested that interferon therapy in 
persistence HBV-infected patients might trigger hepatic decompensation (198)，Buster et 
al. in 2007 had proved that interferon therapy was relatively safe for CHB patients with 
advance fibrosis (199). Moreover, the interferon-lamivudine combination therapy had 
been subjected to investigation to see i f such approach could enhance the anti-viral 
effect and drug response in patients infected with HBV. Studies carried out by Chan et 
al. in 2005 and by Yilmaz et al. in 2007 had showed that combination therapy indeed 
had several advantages over lamivudine monotherapy in terms of virus suppression, 
reduction in lamivudine resistance and anti-viral efficacy (189, 200). 
Although being useful, study by Fattovich et al in 1991 had showed that 
interferon treatment on CHB patients had a risk of inducing the production of 
antinuclear antibody (ANA, 201), and Kansu et al. in 2004 also showed a similar surge 
in serum autoantibody in children with CHB receiving interferon treatment (202). On the 
other hand, Parana et al in 2006 had showed that peginterferon treatment induces 
production of autoantibodies in more than 50% of hepatitis C patients (203). However, 
these studies only showed an increase in autoantibody, but did not find significant risk of 
clinical autoimmunity associated with interferon treatment. Since antibody was a well-
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studied serum glycoprotein (61), the peginterferon treatment may introduce unknown 
false positive signal in the serum A^-glycome profile. 
In order to discover liver fibrosis-specific biomarkers, the biomarker candidates 
must not only associate strongly with degree of liver fibrosis, but also with serological 
markers, and the candidates should not be affected by drug treatments or different 
disease etiologies. In this study, we used the pre-treatment samples to identify diagnostic 
A^-glycans, and post-treatment samples to identify a panel of differential A -^glyeans after 
antiviral treatments. The iV-glycans commonly found in both panels would therefore 
have the characteristics of being diagnostic A^-glycans and with strong association with 
liver fibrosis after drug treatments. 
When comparing the level of serum biochemical markers between pre- and post-
treatment group in our study, there were statistically significant differences in platelet 
count, INR, albumin, ALP and ALT level. While the effect of drug treatment on liver 
histology and reversal of liver fibrosis was beyond the scope of this study, it nonetheless 
demonstrated the effect of drug treatment on serum biochemistry. When comparing the 
level of serum A^-glycome features between treatment samples, we have identified 9 
peaks in human serum 7V-glycome profile that showed statistical significant differences. 
This observation suggested that 9 features in the serum A^-glycome profile was altered 
after lamivudine-peginterferon treatment. However, only two peaks (m/z 1143.5, m/z 
1642.4) were showed to be correlated with degree of liver fibrosis and serological 
markers, and the remaining 7 features did not showed any relationship with degree of 
liver fibrosis and serological markers. A similar glycomic study was carried out using 
interferon y treated rodent fibrosis model (134)，however the group only showed changes 
in serum A^-glycome profile between normal and fibrosis group, but not those between 
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treatment group and treatment-naive group. Since no previous study was available for 
reference, and there were observable differences in serological parameters and N-
glycomic features, pre-treatment and post-treatment samples were analysed separately to 
avoid identification of treatment-related artifacts. 
In the pilot study, we aimed to demonstrate the feasibility of using serum N-
glycome profile in detecting liver fibrosis. In such a small scale study, the diagnostic 
model was validated by using LOOCV, using the same sample set for biomarker 
discovery and validation. While LOOCV performs well in avoiding the bias of testing 
hypothesis suggested by data (204), a complete independent validation data set was still 
desired. In this verification study, we used a larger data set to achieve complete 
separation of biomarker discovery and validation data set, which would avoid the 
aforementioned bias. The "Pre-treatment Fibro-Glyco Index" was shown to have an area 
under ROC curve of 0.84 in validation group, while the "Post-treatment Fibro-Glyco 
Index" had an area under ROC curve of 0.78. The result showed that when using total 
serum A^-glycome profile to detect liver fibrosis, the performance of such approach was 
better on pre-treatment samples than on post-treatment samples. This observation was 
consistent with our previous postulation that the serum A^-glycome profile was not only 
dependent on degree of liver fibrosis, but also on the drug treatment. Since the N-
glycome profile in post-treatment samples depends on both factors, it was not surprising 
that its performance in detecting liver fibrosis was not as good as that in pre-treatment 
sample, which depends on only the degree of liver fibrosis. On the other hand, it might 
due to the suppression of liver fibrosis associated A^-glycans by antiviral drug treatments. 
When applying models on the irrespective sample set (for example, applying 
"Pre-treatment Fibro-Glyco Index" on post-treatment sample set), the performance of 
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"Pre-treatment Fibro-Glyco Index" dropped drastically, the area under ROC curve 
dropped from 0.84 in validation set to 0.71 in post-treatment data set; while the 
performance (area under ROC curve) of "Post-treatment Fibro-Glyco Index" dropped 
from 0.78 in validation set to 0.76 in pre-treatment data set. From the result it was 
obvious that the diagnostic model developed from pre-treatment samples did not 
perform well on post-treatment samples, while the opposite performed comparatively 
well. This phenomenon could be explained by comparing the panels of differential N-
glycans in pre-treatment and post-treatment sample sets. The diagnostic A^-glycans of 
m/z 1601.5 and 2467.5 were used in the "Pre-treatment Fibro-Glyco Index", however 
these two A^-glycans were not found to be significantly associated with degree of liver 
fibrosis in post-treatment samples, which would explained the reduced accuracy of the 
index on post-treatment samples. On the other hand, the A/-glycans of m/z 1752.5 and 
1829.8 were used in the "Post-treatment Fibro-Glyco Index", and these two iV-glycans 
were also found to be significantly associated with degree of liver fibrosis in pre-
treatment samples. Although the normalized peak intensity ofTV-glycan m/z 1829.8 was 
not significant in distinguishing minimal and typical liver fibrosis (ROC curve not 
significant), that of A^-glycan m/z 1752.5 alone had an area under ROC curve of 0.77. 
Because A/-glycan m/z 1752.5 in "Post-treatment Fibro-Glyco Index" was commonly 
found to be significantly associated with degree of liver fibrosis in both treatment 
samples, the performance of "Post-treatment Fibro-Glyco Index" in pre-treatment 
samples was not as greatly reduced as that of "Pre-treatment Fibro-Glyco Index". Based 
on these results, it would appear that the performance of "Post-treatment Fibro-Glyco 
Index" was more stable in different samples than "Pre-treatment Fibro-Glyco Index". On 
the other hand, the more stable performance of "Post-treatment Fibro-Glyco Index" in 
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pre-treatment samples also suggested that the two A^-glycans of m/z 1752.5 and 1829.8 
may detect liver fibrosis independent of drug treatments. 
From the result, the same two //-glycans (m/z 1752.5 and m/z 1829.8) were 
common to both pre-treatment and post-treatment samples. In other words, this showed 
that these two A^-glycans were correlated with Ishak score, serological markers and 
showed significant difference between minimal and typical fibrosis regardless of drug 
treatments. When using pre-treatment samples to construct the linear regression model, 
only m/z 1752.5 was selected (Common Fibro-Glyco Index 1). This was consistent with 
our previous findings that only this A^-glycan showed significant classification efficiency 
in pre-treatment samples (area under ROC curve = 0.77). The performance of "Common 
Fibro-Glyco Index 1” was therefore similar to that of using A^-glycan m/z 1752.5 alone. 
When using post-treatment samples to construct the linear regression model, both N-
glycans were selected and the model generated was the same as that of "Post-treatment 
Fibro-Glyco Index". This was consistent with our previous findings since these two N-
glycans were also the only iV-glycan involved in constructing "Post-treatment Fibro-
Glyco Index". Therefore, when using the same set of training data, the model 
constructed and the performance of such model was expected to be the same as 
previously described. When using both pre-treatment and post-treatment samples to 
construct the linear regression model, again both A^-glycans was selected (Common 
Fibro-Glyco Index 3). However, the model constructed was different to that of Post-
treatment Fibro-Glyco Index, and the weighting on m/z 1752.5 was increased, while that 
of m/z 1829.8 was decreased. This adjustment was due to the inclusion of pre-treatment 
samples, in which A^-glycan with m/z 1752.5 had diagnostic value while m/z 1829.8 did 
not. When comparing the performance of Common Fibro-Glyco Index 3 with the other 2 
143 
models, it had higher area under ROC curve in both biomarker discovery group and 
validation group, and its performance was more stable in both treatments. This 
suggested that when using the common A^-glycans for model construction, the model 
generated would have a more stable performance before and after treatment, since the 
model had included two common differential A^-glycans that were specific to liver 
fibrosis and not affected by drug treatments. 
From the above results, we were confident that the 4 models developed were 
effective in detecting liver fibrosis either before or after drug treatments. Liver fibrosis 
involves disruption of liver architecture and tissue scarring, which would develop into 
liver cirrhosis and subsequently liver cancer i f left untreated. In our pilot study, the 
Fibro-Glyco Index was able to detect both liver fibrosis and cirrhosis with similar 
performance. It would be reasonable to postulate that i f our 4 models in verification 
study were indeed effective in detecting liver fibrosis based on fibrosis-associated N-
glycans, then these models would also be effective in detecting liver cirrhosis as well. 
Since liver cirrhosis represents a more severe type of liver fibrosis, there would be less 
ambiguity between minimal cirrhosis patients (Ishak score = 0 to 4) and typical cirrhosis 
patients (Ishak score = 5, 6)，and the models would be expected to have higher 
sensitivity and specificity in detecting liver cirrhosis. The performances of various 
models in the context of liver cirrhosis were summarized in Figure 21. From the result, 
the overall performance of various models was better than those in detecting liver 
fibrosis, which was consistent with our postulation. Moreover, the performance of "Pre-
treatment Fibro-Glyco Index" was the best, followed by Common Fibro-Glyco Index 3， 
Common Fibro-Glyco Index 1 and Post-treatment Fibro-Glyco Index. This trend was 
coherent to that of liver fibrosis detection. 
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In the pilot study, we had identified a panel of 17 differential A^-glycans that were 
significantly associated with degree of liver fibrosis. In the present verification study, we 
aimed to verify the diagnostic value of these A^-glycans by using larger sample size. I f 
these A^-glycans indeed were associated strongly with liver fibrosis in CHB patients, they 
were also expected to be found in verification study. Since all samples in the pilot study 
were treatment naive, we used pre-treatment samples in the verification study for 
comparison. As opposed of 17 differential A^-glycans in the pilot study, we had identified 
12 A^-glycans in the pre-treatment samples in the verification study. After comparing the 
two panels of differential A^-glycans in the pilot study and the present verification study, 
we had found 3 common differential A^-glycans in the two panels (m/z 1829.7,2159.0, 
2780.4). Therefore, we were not able to reproduce the result obtained in pilot study, and 
only 18% (3 out of 17) of the original differential A^-glycans remained in the differential 
panel of A^-glycans in verification study. While there were substantial differences 
between mass spectra obtained from PBS II reader and PCS 4000 SELDI reader as 
showed in Figure 22, the inconsistent results obtained from two studies were unlikely 
due to instrument bias. It was because 13 out of 17 differential 7V-glycans were also 
detected by the new PCS 4000 SELDI reader (except m/z 1341.4’ m/z 1363.8，m/z 
1444.7 and m/z 1488.6. Table 7). Therefore, while the relative peak intensities of mass 
spectrum obtained from the two instruments were different, the two instruments were 
able to detect most of the serum A^-glycans without much instrument-dependent artifacts. 
Such differences in differential A^-glycans between pilot study and verification study can 
be accounted for by the fundamental differences in the characteristic of samples. First, 
the inconsistency might be due to different sample preparation and histological staging. 
Although histological examination of liver biopsy was quite an established method for 
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the diagnosis of liver fibrosis (22, 23), there was still a certain degree of inter-observer 
variation. Since the patient samples in pilot and verification study were scored by 
different pathologists, there might be inconsistency in the assignment of the Ishak score 
to liver biopsy, even i f the true fibrosis stage of the biopsy was the same. This would 
cause systemic bias in the biomarker discovery and inconsistency in results. This 
variation also leaded to the statistical difference between samples involved in pilot study 
and verification study. We had compared the level of serological markers between the 
samples in pilot study and pre-treatment samples in verification study using Student T-
test with Bonferroni correction, and the result was summarized in table 17. It was worth 
noting that the mean value of degree of liver fibrosis, INR and ALT levels were 
statistically different between two sets of samples, while the mean age between samples 
was marginally the same. Since there was difference in degree of liver fibrosis between 
samples, the liver-fibrosis-associated A^-glyeans identified from the two samples might 
be different. Third, the differences between two studies may be due to the different in 
sample size and statistical power. In the verification study, the sample size concerned 
was approximately 3 times that of pilot study. This not only would allow identification 
of more subtle changes in the peak intensities, but also a higher confidence in the 
biomarker discovered since they would be less likely identified by chance as false 
positive. Also while the pilot study was a case-controlled study, samples in verification 
study were obtained from randomized clinical trial. Therefore, these would explain the 
reason why a different set of differential A^-glycans was identified in pre-treatment 
samples, while the total number of differential A^-glycans was reduced. 
The performance of Fibro-Glyco Index in the pilot study was better than various 
models in verification study in terms of area under ROC curve. The difference might be 
146 
due to the systemic bias and different statistical power as explained in the previous 
paragraph. Together with the result in verification study, the Fibro-Glyco Index 
developed in the pilot study might have included false positive A/-glycans in the 
diagnostic model which were specific to that particular set of samples. Moreover, while 
LOOCV was already implemented in order to avoid testing the hypothesis suggested by 
the data, still the panel of 17 differential A/-glycans was identified based on all the N-
glycome profiles. Therefore, LOOCV had avoided the self-validating problem of the 
linear regression model, but all the A^-glycan candidates of the model were based on the 
data itself. The bias of self-validation in the pilot study was only partly alleviated, but 
not completely eliminated. On the other hand, in the present verification study the 
validation sample sets were not involved in any biomarker discovery process. The 
samples for biomarker discovery and validation were completely separated, thus the 
verification study truly achieved an independent validation for the diagnostic model. 
This ensured that the evaluation results obtained from validation sets was unbiased and 
subjective. Overall, while the performance of various models in verification study was 
worse than that of Fibro-Glyco Index, they provided a more convincing and reliable 
detection scheme for liver fibrosis. 
In the pilot study, we had developed a Fibro-Glyco Index for the detection of 
liver fibrosis and cirrhosis. A total of 4 A^-glycans (m/z 1341.5, 1829.7, 1933.3 and 
2130.3) were utilized in the formula for the calculation of Fibro-Glyco Index. Also, we 
had suspected that an iV-glycan with m/z 1341.5 might be a liver-fibrosis-related artifact 
generated during MALDI-TOF MS analysis. We had applied the Fibro-Glyco Index 
formula in the verification study to see i f it could achieve a similar performance. 
However, when using the ProteinChip PCS 4000 SELDI reader in verification study, we 
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% 
Mean (SD) Level of Normalized Peak Intensities between Treatment Group. 
Serological Pilot Study Pre-Treatment~ 
Parameters N = 46 N = 149 Sign. (2-tailed) 
Ishak Score 3.43(1.88) 1.96(1.66) <0.001* 
Age 43.00(11.65) 37.80 (11.02) 0.006 
Haemoglobin 14.62 (1.67) 14.77 (1.49) 0.581 
Leukocyte Count 5.83 (1.59) 5.89 (1.54) • 0.801 
Platelet Count 180.78 (58.23) 185.87 (57.02) 0.599 
INR 1.12 (0.08) 6.67 (12.11) <0.001* 
Total Protein 75.98 (5.94) 77.07 (5.94) 0.279 
Albumin 41.28 (6.63) 39.69 (4.26) 0.056 
Bilirubin 11.41 (4.79) 10.83 (4.70) 0.461 
ALP 81.09 (24.97) 90.19 (29.80) 0.062 
^ 93.93 (79.16) 154.19(86.65) <0.001* 
Table 17: Differences in serological parameters between samples in pilot study and pre-
treatment samples in verification study. * - P < 0.00455 (Student T-test, Bonferroni 
corrected). 
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failed to detect one of the diagnostic A^-glycan with m/z 1341.5 in normal individual, 
minimal fibrosis patients or typical fibrosis patients. This provided another evidence to 
suggest that this A^-glycomic feature was a MALDI-TOF MS instrument and liver 
fibrosis related artifact, but not a genuine A^-glycan. Since one of the parameters was 
missing, we used an adjusted Fibro-Glyco Index using only 3 A^-glycomic parameters 
(m/z 1829.7，1933.3, 2130.3) to verify such model obtained in pilot study. When 
applying adjusted Fibro-Glyco Index formula on the verification study samples, the 
performance was significantly decreased compared with that of pilot study. The area 
under ROC curve in verification study was 0.67，compared with 0.92 of pilot study. The 
significant reduction of accuracy in verification study was largely due to the lack of 
association between degree of liver fibrosis and two out of three parameters (m/z 1933.3 
and 2130.3). Only A^-glyeans with m/z 1829.7 was significantly associated with degree 
of liver fibrosis in post-treatment samples. We believed that Fibro-Glyco Index might be 
over-trained in pilot study, which would explain such drastic different in performance 
when applied on another set of samples. 
Similar to the pilot study, we had predicted the structures of the diagnostic N-
glycans in the verification study. In the following section, we attempt to illustrate their 
possible origin. For the pre-treatment samples, two A^-glycans were utilized in the linear 
regression model of "Pre-treatment Fibro-Glyco Index" for the detection of liver fibrosis. 
The predicted structure of peak with m/z 1601.6 showed that it was a hybrid type 
triantennary A^-glycans. It was worth noting that this A^-glycan was found in human 
leukocyte common antigen CD45 molecule (205) and in rat hepatoma cell line (206). 
Previous study by Jung et al had showed that human leukocyte CD45 molecule might 
be enriched during viral hepatitis as population of CD45R0+ memory cells rise during 
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HBV infection (207), however this population surge was not sustained in chronic 
infection. Moreover, we believed that the quantity of this membrane glycoprotein and 
their level in human serum were too low to be detected by our technology. Previous 
studies had showed that concentration of various CD molecules in serum ranges from 0-
1 mg/L (CD80 in heathy individual, 208) to 9.8 mg/L (CD 163 in liver cirrhosis patients, 
209). 
Another AZ-glycan with m/z 2467.5 was also selected in the "Pre-treatment Fibro-
Glyco Index". The iV-glycan was identified as a sodium salt of a mono-sialylated, 
fucosylated complex type glycan with two or three antennaries. Although two isoforms 
were available, only the triantennary isoform was found in human species. The 
triantennary isoform was reported by Nakagawa et al. in 1995 to be conjugated to 
coagulation factor X in human plasma (210). It shall be noted that coagulation factor X 
also carries a similar A^-glycan with no fucose residue. As with other coagulation factor, 
coagulation factor X was synthesized by liver (211) and released into blood stream. 
Therefore, the up-regulation of the A^-glycan in liver fibrosis might be explained either 
by the increased production of factor X by liver, or the aberrant fucosylation event of 
factor X during liver fibrosis. 
For the post-treatment samples, again two A^-glyeans were utilized in the linear 
regression model for the detection of liver fibrosis after lamivudine and peginterferon 
treatment. Since the identities of the two diagnostic 7V~glycans in post-treatment samples 
were different to those of pre-treatment samples, it provided further evidence that there 
were intrinsic difference between the A^-glycome profile before and after treatment. One 
of the diagnostic A^-glycan had an m/z value of 1829.8, which was also found in the pilot 
study. Another diagnostic A^-glycan with m/z 1752.5 was predicted to be a sodium salt 
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form of a mono-sialylated, hybrid type biantennary glycans with molecular weight of 
1729.6 Da. Although to the best of our knowledge, no previous report had suggested that 
this A^-glycan was of hepatic origin, this A^-glycan was found to be associated with liver 
fibrosis before and after treatment. It should be pointed out that this A^-glycan had an 
unusual hybrid structure showing a truncated high-mannose branch on one of the 
antenna, which was found in human chorionic gonadotrophin (hCG) by Weisshaar et al 
in 1991 (212). Since hCG was a pregnancy-related hormone, it was unlikely to be the 
source of our diagnostic TV-glycan. However, Chui et al in 2001 had showed that 
reduced expression of a-mannosidase II，which was localized in Golgi apparatus (213), 
would reduce the level of complex type A^-glycan and increase the level of hybrid type 
A^-glycan in mammals (214). On the other hand, Matsuda et al. in 1991 had 
demonstrated that the glycosylation of hepatic glycoprotein was impaired during liver 
injury (215), and Jorge et al. in 2002 had identified a change in localization of Golgi 
apparatus in hepatocyte during biliary cirrhosis (216). These evidences suggested that 
the organization of Golgi apparatus and the glycosylation machinery that it carries might 
be disrupted during liver damage, which produced different types of truncated or 
incomplete A^-glycans. This would also provide another possible source for the "-glycan 
of m/z 1601.5, which was also a hybrid type iV-glycan with a high-mannose branch. 
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5. Conclusion 
In conclusion, we had identified 2 panels of differential 7V-glycans for pre- and 
post-treatment samples, and constructed 5 diagnostic models for detecting liver fibrosis 
in CHB patients. The area under ROC curve of different models for detecting liver 
fibrosis and cirrhosis was on average 0.79 and 0.87 respectively. When comparing the 
two differential panels, we had identified 2 iV-glycans that were commonly found in both 
set of samples. We had therefore consolidated the feasibility of using A^-glycomic 
profiling in the diagnosis of liver fibrosis and cirrhosis, and identified 2 features that 
may detect liver fibrosis independent of drug treatments. 
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General Discussion 
Chronic HBV infection was one of the major risk factors of developing liver 
fibrosis and subsequent cirrhosis (217). Liver fibrosis refers to the structural change of 
liver due to abnormal accumulation of ECM protein, activation of HSC, apoptosis of 
hepatocytes and disruption of liver architecture (11). The accumulation of ECM protein 
in liver was mainly due to repeated liver repair process mediated by HSC in response to 
chronic liver damage or inflammation. In normal circumstances, ECM was degraded by 
HSC through the action of matrix metalloproteinase. However during chronic 
inflammation and pathological fibrogenesis, action of MMP such as MMP-8 and MMP-
13 was inhibited by elevated expression of tissue inhibitor of matrix metalloproteinase-1 
(TIMP-1). Therefore, liver fibrosis is the clinical outcome of prolong fibrogenesis and 
reduced fibrolysis, initiated by chronic inflammation or damage (218). 
Because the pathology of liver fibrosis was mainly associated with accumulation 
of ECM, currently the gold standard of diagnosis is the histological examination of liver 
biopsy. However, liver fibrosis is a dynamic process involving unbalanced fibrogenesis 
and fibrolysis, liver biopsy could only provide a static picture of the disease progress. In 
order to monitor the progress of liver fibrosis in long term basis, histological 
examination of liver biopsy was not a preferred method since it was invasive and carries 
certain rate of complication. Since liver fibrosis, i f left untreated, would eventually 
develop into cirrhosis, and a small portion of patients would further develop HCC, 
continuous monitoring of disease progress is very important both for disease stage 
assessment and for drug response monitoring. Clearly, liver biopsy was not appropriate 
for this purpose. In light of this, we attempted to develop a non-invasive diagnostic test 
for liver fibrosis by using total serum A^-glycome profile. Our rationale was based on the 
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observation that liver is responsible for the production of a majority of serum 
glycoproteins, and the glycosylation pattern of serum glycoproteins was altered in liver 
fibrosis patients. 
In this study, we had identified 3 panels of differential A^-glycans: 1 panel in pilot 
study, and 2 panels for treatment naive and post-treatment samples in the verification 
study. In the pilot study panel, we had observed that 8 out of 11 predicted structures 
were either aberrantly glycosylated with a core fucose or a core bisecting GlcNAc, and 7 
out of these 8 aberrant A^-glycans were up-regulated with degree of liver fibrosis. This 
observation was coherent with those panels of treatment naive samples and post-
treatment samples in the verification study. In the treatment naive panel, 3 out of 7 
predicted structures were aberrantly glycosylated, and all 3 of them were up-regulated 
with degree of liver fibrosis; in the post-treatment panel, 3 out of 5 predicted structures 
were aberrantly glycosylated, and 2 out of 3 of them were up-regulated with degree of 
liver fibrosis. While some of the up-regulated A^-glycans did not had proximal fucose or 
a bisecting GlcNAc (for example, m/z 1363.8 in pilot study, Table 7; m/z 1440.3, m/z 
1601.5 and m/z 1752.5 in treatment naive panel, Table 15; m/z 1752.5 in post-treatment 
panel, Table 16)，they were all predicted to be hybrid type iV-glycans with at least 1 high 
mannose branch. Although there was yet no study targeting specifically the abundances 
of these two types of A^-glycans in normal human serum, several groups had reported 
that these two A^-glycans were rarely found in normal human serum. Morel le et al. in 
2006 did not find high mannose or hybrid A^-glycans in normal human serum using a 
similar MALDI-TOF MS technology (98), which was consistence with our result (Table 
5). 
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Because of these observations, we believed that A^-glycans with an increase in 
core fucosylation and addition of bisecting GlcNAc were strongly associated with liver 
disease status, and it could be utilized as a biomarker for liver fibrosis. Mooney et al in 
2006 had observed that the A^-glycan of alpha-1-acid glycoprotein was aberrantly 
fucosylated in the serum of liver fibrosis patients (219), and Sathish et al. in 2004 had 
showed that there was a significant increase in serum protein-bound fucose 
concentration in the serum of HBV-related cirrhosis patients compared with normal 
individual (220). For the modification of bisecting GlcNAc, Liu et al in 2007 had 
observed that serum A^-glycan species with bisecting GlcNAc was up-regulated in liver 
cirrhosis patients (97). These observations were consistence with studies carried out by 
Callewaert et al in 2004 and Morelle et al in 2006 (83，98). 
To the best of our knowledge, currently there was no definitive explanation 
regarding the up-regulation of A^-glycan species with core fucosylation and bisecting 
GlcNAc in liver fibrosis. In the following section, we aimed to provide our speculations 
of the mechanisms behind these two phenomena based on known literature. 
Core a 1-6 fucosylation is mediated by a-1, 6-fucosyltransferase (Fut8) in 
eukaryotes (221). An increase in expression of Fut8 was widely observed in various 
cancer and pathological conditions including HCC (65, 72, 222), pancreatic cancer (50), 
liver cirrhosis (39) and CDG (187). It also directs the secretion of hepatic glycoproteins 
into bile duct. It was believed that core fucosylation of A^-glycans on glycoproteins 
would interact with intracellular lectin-binding-domain-like carrier molecules associated 
with microtubule, which may direct the sorting of glycoproteins to the apical surface of 
hepatocytes (125). We speculated that since liver architecture was severely disrupted in 
liver fibrosis, the core fusosylated glycoprotein secreted through apical surface of 
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hepatocytes might leak into the blood stream. However, no definitive explanation was 
yet available to address such A^-glycan modification in liver diseases, and more work is 
needed to confirm our speculation. 
Addition of bisecting GlcNAc is mediated by A^-aceylglucosaminotransferase III 
(GnT III) in eukaryote (223), which catalyzes the addition of GlcNAc residue to the core 
mannose via p i -4 linkage. It was reported by Ishibashi et al in 1989 that GnT II I 
activity in liver tissue was elevated in liver cirrhosis and hepatoma patients (224). Such 
increase in activity could possibly be due to the promoter-activating effect of X protein 
produced by HBV (HBx), since Kang et al. in 2004 had demonstrated that the activity of 
GnT III in HBV transfected cells was strongly elevated when compared with HCC cell 
line (225). Together with the fact that all patients involved in this study has chronic 
hepatitis B infection, this suggested that the reason behind increased level of A^-glycans 
with bisecting GlcNAc in serum, which may be due to promoter-enhancing effect, is 
different to that of core fucosylation, which may be due to disruption of liver 
architecture. However, to the best of our knowledge, there was yet no study about the 
relationship between HBV and Fut8, and about the trafficking of A^-glycans with 
bisecting GlcNAc in liver. Further work is still needed to address the mechanism behind 
these phenomena. 
In this project, our technology was based on MALDI-TOF MS instrument, which 
characterize different A^-glycan species with unique m/z value. Mass spectrometric 
method was the most common in glycomic analysis, however there were still several 
limitations. First, mass spectrometry was not able to resolve isomeric A^-glycans, which 
have different structural formula and the same molecular weight. Different A^-glycans 
with equal molecular weight would be identified as one single species on the mass 
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spectra, and this would result in information loss. Secondly, mass spectrometry alone 
was not able to provide information regarding linkage information. Formation of 
different glycosidic bonds in A/~glycans was mediated by different glycosyltransferase. 
For example addition of core a l -6 fucosylation was mediated by Fut8 (221), while a 1-3 
fucosylation was mediated by a-1, 3-fucosytransferase (Fut6, 226). Although the two 
modifications were different in the glycosidic linkage, they would be represented by one 
single peak on the mass spectrum, given that the rest of the structure was the same. This 
results in missing not only structural information, but also the identity of the underlying 
glycosyltransferase responsible for that particular A^-glycan species. We utilized the 
acquired m/z values to predict the structure of different A^-glycans identified on the mass 
spectra. Because of the limitations mentioned above, we were not able to provide 
definitive account on the structure of A^-glycans. However, we were confident that our 
predicted structures were quite close to the real structures of these //-glycans. First, our 
predictions were based on literature support provided by CFG database. This provided 
evidences that those structures could be found in human serum. Therefore, the predicted 
structures not only match the m/z values acquired but also match the origin of our N-
glycans. Second, most of the up-regulated A^-glycans were predicted to be either core 
fucosylated or carrying a bisecting GlcNAc. This was consistence with previous 
research finding regarding total serum A^-glycome in liver fibrosis patients. Therefore, 
the predicted structures alsq match the pathological background of our samples. 
Nonetheless, the lack of definitive structural information was a major limitation of this 
study, and further analysis was required in order to obtain a full picture of the diagnostic 
A^-glycan identified. 
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A concrete structural elucidation was preferred in order to further characterize 
our biomarkers and validate our results. It could be achieved by using tandem MS/MS 
fragmentation analysis (98) or sequential exoglycosidase treatment (127). A wide range 
of different fragmentation method was used to characterize the structure and linkage of 
7V-glycans, including MALDI/Post source Decay (PSD) TOF-MS (227, 228), fast atom 
bombardment (FAB)-MS (229), IRMPD (100, 101, 230) and electron capture 
dissociation (ECD, 231). Lattova et al in 2004 had applied MALDI/PSD technology 
and fragmentation analysis to identify //-glycan from ovalbumin. A total of 20 A^-glycan 
structures were elucidated, although it did not completely avoid isobaric structural 
ambiguity (232). Angel et al in 1990 had applied FAB-MS to elucidate the structure of 
not only A^-glycans but also 0-glycans, and the linkage information was also acquired by 
sequence ions (233). Studies carried out by An et al in 2006 and Kirmiz et al. in 2007 
had applied IRMPD to identify the molecular structure of A^-glycans related to ovarian 
cancer and breast cancer respectively (100，101). Although from the result of literature 
search, ECD was not widely adopted for structural analysis of A^-glycans, Zhao et al 
recently had showed that ECD was able to provide structural information of 
permethylated iV-glycans together with collision activated dissociation (234). When 
comparing with exoglycosidase sequencing, one advantage of using MS fragmentation 
technique was its high-throughput performance. A large number of A^-glycan fragments 
could be analyzed in a short time relative to exoglycosidase sequencing method. 
Different algorithms were designed for identifying the parent 7V-glycan molecule from 
the fragment it generated, thus further facilitating the data analysis process. In 2003, a 
web-based database termed GlycoFragment was developed for generating all possible 
theoretical glycan fragments for each particular A/-glycan, allowing rapid fragment 
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matching and identification (235). A database search tool, GlycoSearchMS, was 
developed by the same group in 2004 in an attempt to compare and match the observed 
spectrum with the theoretical glycan fragment spectrum in the SweetDB database, which 
contains cross-reference data of glycans from other databases (236, 237). A similar 
online-portal was also developed in 2006 termed GLYCOSCIENCES.de (238). It can be 
seen that mass spectrometric method for A^-glycan structural analysis was already quite 
mature. In light of this, our future study wil l apply similar approach to confirm the 
predicted structures, most probably by using MALDI-TOF/TOF MS technology with 
collision induced dissociation. It was because MALDI-TOF MS was already the core of 
our technology. By using a similar instrument, our technology can be applied without 
large scale adjustment. MALDI-TOF/TOF MS had already been used by Maslen et al in 
2006 to identify glycan structures of phospholipase A2 (239). Moreover, several review 
articles were published describing such fragmentation analysis in depth (102, 105, 240). 
On the other hand, multiple reactions monitoring (MRM) can be used to detect A^-glycan 
with absolute structural specificity, and with absolute quantitative performance i f used in 
conjunction with stable isotope-labelled internal standard (241). The principle of MRM 
was to first select the parent ion (in our case intact iV>glycan) in the first mass analyzer, 
and after CID fragmentation select one of the fragment (A^-glycan fragment) in the 
second mass analyzer. Previous study by Anderson et al in 2006 had demonstrated that 
MRM could be used to identify and quantitate high to medium abundance plasma 
protein with good precision (242). In the future, we aimed to apply tandem MS with 
collision induced dissociation to elucidate the structure of A^-glycans. 
Although we had identified a panel of differential A^-glycans for liver fibrosis 
with different modifications, at this stage we can only postulate their potential biological 
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relationship with the pathology of liver fibrosis, and the cause of such modifications. 
Although there were reports suggesting the function of fucosylation (125) and the cause 
of addition of bisecting GlcNAc (223, 224, 225), there was yet no study showing their 
relationship with HBV-induced liver fibrosis. In the future we aimed to establish their 
relationship to the pathology of liver fibrosis. For these two abnormal modifications, we 
aimed to address the rationale of their up-regulation by investigating the expression of 
their respective glycosyltransferase in normal and fibrotic tissues. 
From literature search, we had identified Fut8 and GnT III as the enzymes 
responsible for the core fucosylation and addition of bisecting GlcNAc. A study by 
Kyan et al. in 2008 had measured the down-regulation of GnT V expression in testicular 
germ cell tumor by using sandwiched immunohistochemistry (243). On the other hand, 
Kang et al in 2004 had identified an up-regulation of GnT III in hepatocyte transfected 
with HBx by using Northern blot and Western blot against GnT III mRNA and protein 
respectively (225). We aim to first investigate the expression of Fut8 and GnT III in 
rodent fibrotic liver tissue. Human fibrotic liver tissue was not considered at this stage 
because liver fibrosis alone usually does not justify liver transplantation (244), which 
would make it difficult for us to obtain human fibrotic liver tissue. Moreover, rodent 
model of liver fibrosis was already established, and several studies were also carried out 
based on rodent model (134，245, 246). We will investigate the localization of Fut8 and 
GnT III in normal and fibrqtic liver by using both sandwiched immunohistochemistry 
assay to visualize Fut8 and GnT III protein expression, and confirm the result of the 
assay through Western blotting. The Western blot assay is to verify that there is no false 
positive in the immunohistochemistry assay. Instead of using Northern blot to measure 
glycosyltransferase mRNA levels, we will use quantitative real time PGR because of its 
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sensitivity, specificity and high-throughput performance. Shen et al in 2008 had applied 
quantitative real time PGR technique to measure the (3-1,4-galactosyltransferase I level 
in rodent skin tissue (247). 
Currently there are a number of serum-based non-invasive tests designed for 
liver fibrosis diagnosis (30, 248), most notably FibroTest (32), FibroSpect (34)，a linear 
regression model designed for CHB patients (249) and GlycoCirrhoTest (83). 
GlycoCirrhoTest was especially relevant since it was also serum TV-glycome based. 
FibroTest was a five-parameter serum based test designed to detect liver fibrosis 
in patients with HCV infection. It includes serum level of haptoglobin, a2-
macroglobulin, apolipoprotein A l , yGT and bilirubin. The logistic regression model was 
developed from a cohort of 205 patients as training group and 134 patients as validation 
group, with liver fibrosis stages scored using METAVIR system. The resulting model 
was found to have an area under ROC curve of 0.827 in detecting liver fibrosis, and 
0.923 for liver cirrhosis (32). In an independent validation study carried out in Australia, 
FibroTest gave an area under ROC curve of 0.739 in detecting liver fibrosis, which was 
relatively weaker than the original study (250). On the other hand, Callewaert et al. had 
compared the performance of FibroTest with their GlycoCirrhoTest. They had found 
that the area under ROC curve of FibroTest in detecting liver cirrhosis was 0.89，which 
was also weaker than the original study (83). 
FibroSpect was a three-parameter logistic regression model designed also for 
HCV infected patients. It was developed by using 294 training samples and 402 
validation samples, and it was based on the serum level of hyaluronic acid, TIMP-1 and 
a2-macroglobulin. The liver fibrosis stages of the samples were also evaluated by 
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METAVIR system. The FibroSpect model had an area under ROC curve of 0.831 in 
validation group，which was very close to that of FibroTest (34). 
In 2005, Hui et al. had developed a logistic regression model for the detection of 
liver fibrosis in patients with CHB infection (termed "CHB noninvasive model" for easy 
reference in this thesis). A total of 235 patients were involved, and was split into training 
group with 150 patients and validation group with 85 patients. Liver fibrosis stages of all 
patients were scored by Knodell system. Two models were developed, using 3 
parameters (body mass index, albumin level and bilirubin level) and 5 parameters (body 
mass index, ALP level, bilirubin level, albumin level and platelet count) respectively. 
These two models gave a very similar area under ROC curve of 0.765 and 0.768 in 
validation group respectively, which was similar to the independent validation result of 
FibroTest as mentioned above (249). 
Callewaert et al in 2004 had developed a GlycoCirrhoTest mainly for HCV 
patients by using the log ratio of 2 serum 尽glycans. Instead of using mass spectrometric 
method, they utilized DNA sequencer as a capillary electrophoretic equipment to 
analyze fluorophore-conjugated A^-glycans extracted from serum. The GlycoCirrhoTest 
developed had achieved an area under ROC curve of 0.87 in detecting liver cirrhosis, 
which was slightly lower than that of FibroTest. Two A^-glycans were utilized in their 
GlycoCirrhoTest: a biantennary complex type A^-glycan with core fucosylation and a 
bisecting GlcNAc, and a triantennary complex type A^-glycan. (83). Table 18 
summarized the performance of those above-mentioned studies together with Fibro-
Glyco Index, Pre-treatment Fibro-Glyco Index and Common Fibro-Glyco Index 3. 
It can be seen that most models utilized indirect serum biomarkers for the 


























































































































































































































































































































































































































































































































































































































































































































































































































































































































serum biomarkers. When comparing the performance of these models, FibroTest 
performance was the best in the context of both liver fibrosis and cirrhosis, although an 
independent validation study showed a reduction in accuracy. When examining the 
performance of various models in detecting both liver fibrosis and liver cirrhosis, the 
area under ROC curve was higher in detecting liver cirrhosis than for liver fibrosis. Our 
study was also consistent with this trend. This observation was also consistent with the 
postulation that liver cirrhosis represents a severe stage of liver fibrosis, and therefore 
there should be less ambiguity between normal individual and liver cirrhosis patients. 
However, since our study had not measured the serum level of haptoglobin, a2-
macroglobulin, apolipoprotein A l , yGt, hyaluronic acid and TIMP-1, we were not able 
to evaluate the performance of FibroTest and FibroSpect in our study. Nonetheless, 
various groups had independently evaluated the performance of such models (83，250, 
251)，which were in certain extent stable in different datasets. Overall, the area under 
ROC curve for detecting liver fibrosis in the validation samples were approximately 0.78; 
those for detecting liver cirrhosis were approximately 0.87. When examining the 
performance of the 6 diagnostic models in this study, it can be seen that the performance 
of Pre-treatment Fibro-Glyco Index and Common Fibro-Glyco Index 3 were relatively 
close to those values. Fibro-Glyco Index showed the worse performance among all 
models (AUROC = 0.67). 
When comparing our. models with various models developed by other research 
groups, the area under ROC curve were similar. Pre-treatment Fibro-Glyco Index had a 
similar performance as FibroTest and FibroSpect. Common Fibro-Glyco Index 3 had a 
lower performance than FibroTest and FibroSpect designed for HCV patients, but was 
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comparable with CHB noninvasive model and GlycoCirrhoTest which was designed for 
HBV-infected patients or based on glycomic technology. The result verified that the Pre-
treatment Fibro-Glyco Index had similar performance as those diagnostic models based 
on direct and indirect biomarkers. However, the comparison was based on figures 
reported by other research groups in previous publications using different sample sets to 
ours. We had not evaluated the performance of FibroTest, FibroSpect and GlycoCirrho 
Test on our samples. In order to make a more direct comparison, we would evaluate the 
performance of these tests on our samples, and to compare those results with our N-
glycomic models. 
In our study, approximately 200 CHB patients with various degrees of liver 
fibrosis were recruited. In both the pilot study and verification study, patients with 
minimal fibrosis (Ishak score < 2) were classified as normal control, and their serum N-
glycome profiles were compared with those with typical fibrosis (Ishak score > 2) for 
the identification of differential A^-glycans. Since no healthy individual without CHB 
was involved in this study, it was possible that the differential N-g\ycms identified were 
severe fibrosis-specific and not minimal fibrosis-sensitive. In the future, we wi l l also 
include a group of normal individuals with no HBV infection or apparent risk of liver 
fibrosis as a healthy control group. By including a group of genuine normal control, we 
wi l l be able to identify early stage sensitive A^-glycomic biomarkers to aid liver fibrosis 
diagnosis. — 
Using both treatment-naive and post-treatment samples, we had identified 2 
differential A^-glycans that were commonly found in both samples, suggesting that they 
were associated with degree of liver fibrosis and were not affected by drug treatments. In 
order to further validate this postulation and to evaluate the potential of using N-
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glycomic profiles for treatment monitoring, a more in-depth study focusing on the drug 
treatment response would be required. Currently liver biopsy and serum samples were 
collected 6 months after the termination of drug treatments, which may not be 
adequately long enough for liver fibrosis reversal to take place. This was reflected in our 
study by the difference in mean Ishak score in pre- and post-treatment patients, which 
showed no statistically significant difference. Moreover, most of our samples 
(approximately 75%) in verification study had minimal fibrosis only, which were not 
suitable for drug treatment monitoring. Also only 8 typical fibrosis patients showed 
improvement (Ishak score reduced by at least 2 grades) after treatment, which was not 
sufficient for statistical analysis. In light of this, we proposed that a further case-
controlled validation study should focus more on typical fibrosis patients, with a longer 
follow-up period after termination of treatments. The longer follow-up period should 
allow a better reversal of liver fibrosis in responding patients, and a more prominent 
change in serum A^-glycomic profile. In this future study, all the pre-treatment patients 
wil l be used to identify a panel of A^-glycomic biomarkers, which wil l be compared 
against post-treatment patients responding to drug treatments. The common A/-glycans 
obtained can then be validated via paired samples. The non-responding post-treatment 
samples wil l be used to identify A^-glycans that were associated with drug treatments. 
After this filtering, we should be able to identify iV-glycomic biomarkers suitable for 
drug treatment monitoring and specific to liver fibrosis. 
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Conclusion 
In conclusion, we had developed and optimized a high-throughput methodology 
for the quantitative profiling of both glycoprotein preparations and whole serum N-
glycomic using MALDI-TOF MS technology. When applying this technology on the 
serum of liver fibrosis patients with CHB infection，results of the pilot study showed that 
specific serum A^-glycan fingerprint could be used as a diagnostic marker. In a further 
study, we had used the same approach and identified two different panels of differential 
A^-glycans in patients with or without antiviral treatments. Two A^-glycans were found to 
be present in both panels, suggesting that they were specific to liver fibrosis and 
independent of drug treatments. Overall, our method was used to generate different 
diagnostic models for different patients. These models were able to detect liver fibrosis 
and cirrhosis in treatment naive patients with area under ROC curve of 0.84 and 0.89 
respectively; and those in post-treatment patients with area under ROC curve of 0.78 and 
0.87 respectively. These values were close to other non-invasive biomarkers such as 
FibroTest and FibroSpect. A majority of up-regulated iV-glycans related with liver 
fibrosis were found to be modified with core fucosylation or bisecting GlcNAc, which 
was consistent with other reports. 
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Original Data 
Original data are available upon request. 
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I. Symbol nomenclature 
The Nomenclature committee evaluated symbol nomenclatures in wide use and consulted with a variety of 
interested parties. The committee selected a version adapted by the Editors of "Essentials of Glycobiology" 
from that originally put forward by Stuart Kornfeld, and further modified it to fit Consortium needs based on 
the following criteria: 
• The nomenclature must be convenient for the annotation of mass spectra. To this end, it was decided 
that: 
- E a c h sugar type (eg sugars of the same mass: hexose, hexosamine and N-acetylhexosamine), 
should have the same shape. 
- I s o m e r s of each sugar type (eg mannose/galactose/glucose) should be differentiated by color or 
by black/white/shading. 
- W h e r e possible, the same color or shading should be used for derivatives of hexose (eg the 
corresponding N-acetylhexosamine and hexosamine). 
- U s i n g the same shape but different orientation to represent different sugars should be avoided so 
structures can be represented either horizontally or vertically. 
• The color version of the nomenclature should appear indistinguishable from the black and white version 
when copied or printed in black and white. 
• Because 10% of the population is color blind, the use of both red and green for the same shaped symbols 
should be avoided. 
• If desired, linkage information can be represented in text next to a line connecting the symbols (e.g. 
cx4，P4). 
Symbol nomenclature - color version printed in color: 
Hexoses! Circles 
N-Acetvlhexosamlnes: Squares 户广“/“厂 
Hexosamfnes: Squares divided diagonally 
• Galactose stereochemistry: with Black outline O CH S 
• Glucose stereochemistry: BLUE (0,0,250) with Black outline _ • 
• Mannose stereochemistry: GREEN (0,200,50) with Black outline 眷 • f S 
• Fucose: RED (250,0,0) with Black outline • 
• Xylose: (5-pointed star) ORANGE (250,234,213) with Black outline • 
Acidic Sugars (Diamonds) 
• NeuAc: PURPLE (200,0.200^ with Black outline • 
• NeuGc: LIGHT BLUE (233,255,255) with Black outline • 
• KDN: GREEN (0,200,50) with Pattern & Black outline • 
• GIcA: BLUE (0,0,250)/Upper segment with Black outline ^ 
• idoA: TAN (150,100,50)/Lower segment with Black outline • 
• GalA: RED (250,0,0)/Left segment with Black outline 令 
• ManA: GREEN (0,200,50)/Right segment with Black outline < • 
1 
Symbol nomenclature - color version printed in black and white: 
Hexoses: Circles 
N-Acetylhexosamines: Squares 
Hexosamlnes: Squares divided diagonally 
Print in 
black & white 
Printed on 2004 
• Galactose stereochemistry: with Black outline 0 D fSJ 
• Glucose stereochemistry: BLUE (0,0,250) with Black outline e 11 ~ 
• Mannose stereochemistry: GREEN (0.200,50) with Black outline 0 D LSJ 
• Fucose: RED (250,0,0) with Black outline 
• Xylose: (5-pointed star) ORANGE (250,234,213) with Black outline *' 
Acidic Sugars (Diamonds) 
• NeuAc: PURPLE (200,0,200) with Black outline 
• NeuGc: LIGHT BLUE (233,255,255) with Black outline <> 
• KDN: GREEN ( ,200,50) with Pattern & Black outline <> 
• GlcA: BLUE (O,O,250)/Upper segment with Black outline ~ 
·ldoA: TAN (150,100,50)/Lower segment with Black outline ~ 
• GalA: RED (250,O,O)/Left segment with Black outline 
• ManA: GREEN (O,20Q,50)/Right segment with Black outline ~ 
Symbol nomenclature - black and white version: 
Hexoses: Circles 
N-Acetylhexosamlnes: Squares 
Hexosamlnes: Squares divided diagonally 
• Galactose stereochemistry: White with Black outline 
• Glucose stereochemistry: Black with Black outline 
• Mannose stereochemistry: Gray with Black outline 
• Fucose: Gray with Black outline 
• Xylose: (S-pointed star) White with Black outline 
Acidic Sugars (Diamonds) 
• NeuAc: Black with Black outline 
o D rsJ 
e 11 ~ 
o D fSJ 
• NeuGc: White with Black outline <> 
• KDN: Gray with Pattern & Black outline <> 
• GlcA: Black/Upper segment with Black outline ~ 
• IdoA: Black /Lower segment with Black outline ~ 
• GalA: Black /Left segment with Black outline 
• ManA: Black/Right segment with Black outline 
2 
Printed on 2004 
II. Text nomenclature 
The committee recommends a “modified I UP AC condensed" text nomenclature which includes the anomeric 
carbon but not the parentheses, and which can be written in either a linear or 2D version. The Committee felt 
that: 
• Including the anomeric carbon is important, and is likely to become increasingly more so in the future as 
more complicated structures are discovered. 
• The presence of parentheses (which then necessitates the use of brackets to indicate branching 
structures) is unnecessarily cumbersome, particularly when representing the structure in 2D form. 
Example of chosen text nomenclature: 





III. Examples of symbol nomenclature used to illustrate N- and 0-linked glycans written in the 2D version of 
the text nomenclature. Note that symbol structures will be used to annotate data where linkages have not 
been defined (e.g MALDI profiling), and if linkages between monosaccharides are known, they can be 
added above or to the side of the line connecting the symbols if desired (e.g. a6 or p4). 
N-linked glycan: 
NeuAccx2-6Gaipi -4GlcNAc(31 -2Mana1 ^ ^ 
6 6 O 6 
Manful -4GlcNAc|51 -4GlcNAc-Asn ^ V 
NeuAc(x2-6Galp1 -4(3lcNAcpi -2Man(x1 Z X T 
0-linked Glycan: 
NeuAC(x2-3 Galf i l -4GlcNAcpi \ • 
^GalNAca-Thr • Q 






V > ？ , • 
b �..::: . ^ • i . 〉 . 广 . - , . - . . -
EiV • 
1 ； • ’ • : ' / 务 、 . ： ； ' : • ‘ 
• .  ,.、？「.〜.... 




• j^V" V 
li/i tV . • • , . 、 . . . . * , . . 、 • • 
-.” . . . - .、.. . - . . :‘-、’ 厂 - : . : . , : . . ‘ . , 
t f 〜-: .、.：•'：•。.-(——、 - ._.、、、- ‘ .‘.",‘•. 
‘ ‘‘ • ” , )、’’ . '、- ：、.、.’ 、‘ v i 
办，：、..“、..•-V； ： • f'--." t'' - • &广、.： “ r: ‘ .、... ..！ , •-.. 
… • br .r- ‘： -y - • , 
. ‘ . , , . U . . . . . . . . - , . 
.、，t 乂 .，v - ) ‘：r��:: V - … . - . . . 、. ‘ •••. ’、、： 
輪.，"i". 乂.-.‘.、.…、卜人-.:“.. ,.、 
麥丨 * . .、."U;〔’ '‘.I、、“..‘',_、： .. - “ 
^fpSt' ^ h l i i i^Af 、 
‘ 《 * 1 ^ . ^ 
t^ ikf"^ ^ J；：、 
^JPl；?!";令科漆《一 贫?(V、 ： -v,’.： “ 
Jf ， J 卜 ‘ ‘ S “ 
f . % 、 • ' . . . - . , • . ‘ . - ’ . . 
u c 、/n 、、、”；>.?:‘.,•、 
" " « <-:、.L 〜.••.,.:•:、:.-...产. > 」 
m ^ ' . " ‘ 、‘ ‘ 
K ^ 二:.一 ’… 
Clinical Chemistry 53:7 . ‘ 
1254-1263 (2007) Proteomics and 
Protein Markers 
High-Throughput Quantitative Profiling of Serum 
N-Glycome by MALDI-TOF Mass Spectrometry 
and N-Glycomic Fingerprint of Liver Fibrosis 
R I C H A R D K . T . K A M / ' ^ T E R E N C E C W . P O O N / - ^ ' ^ " H E N R Y L . Y , C H A N ” N A T H A L I E W O N G , 
A L E X Y . H U I , " a n d J O S E P H J . Y . S U N G ^ ' ^ 
Background: The use of MALDI-TOF mass spectrome- Conclusion: This is the first study to illustrate the 
try (MS) in quantitative glycan profiling has not been quantitative aspect of MALDI-TOF MS in N-glycome 
reported. In this study, we attempted to establish a profiling and the first study to reveal the potential value 
high-throughput quantitative assay for profiling serum of the serum N-glycan profile for identifying liver 
Af-glycome, and we applied the new assay to identifying fibrosis. 
serum N-glycans for diagnosis of liver fibrosis and • 2007 American Association for Clinical Chemistry 
cirrhosis. 
Methods: N-glycans from whole serum proteins in 2 /xL N-glycan is a group of carbohydrate side chains co-
serum were released by enzymatic digestion, cleaned up valently linked to the asparagine residues of glycopro-
by hydrophilic chromatography, and subsequently teins. N-glycan is one of the major information-rich bi-
quantitatively profiled with a linear MALDI-TOF MS omolecules comparable to nucleic acid and proteins ( 1 ) . 
system, which was originally designed for quantitative N-glycan aberrations are associated with many diseases 
proteomic profiling. Serum N-glycome profiles from 46 including congenital disorders in glycosylation (CDG)5 
patients with chronic hepatitis B infection and with ( 2 , 3 ) , chronic alcohol abuse ( 4 ) , and liver cancer ( 5 , 6 ) . 
different degrees of liver fibrosis were examined. Such aberrations can be found in the patients' sera ( 7 - 1 0 ) . 
Results: The intra- and interassay CVs of peak intensi- Glycomics studies at the whole-tissue level provide a 
ties of the standard N-glycans were <8% and <17%, general overview on the glycome, the total glycosylation 
respectively. When the assay was applied to the analysis pattern of glycoproteins, lipids, or other types of biomol-
of serum N-glycome profiles, 17 peaks were found to be ecules. Some laboratories have attempted to release all 
potential biomarkers for detection of liver fibrosis/ glycans attached to whole serum proteins (the serum 
cirrhosis. Linear regression analysis revealed that 4 glycans/glycome) and compare the profiles of disease 
peaks of 1341.5, 1829.7, 1933.3, and 2130.3 m/z (all P and control cases ( 1 1 - 1 4 ) . Potential diagnostic serum 
<0.005) had complementary value in detecting liver glycan markers have been identified for liver cirrhosis 
fibrosis and included them, but not any serological ( 1 1 , 1 2 ) , ovarian cancer ( 1 3 ) , and breast cancer ( 1 4 ) . 
markers, in the diagnostic model. Leave-one-out cross- Capillary electrophoresis has been applied to profile 
Validation showed the diagnostic model could identify the serum N-glycome (11) and can quantify carbohydrate 
significant fibrosis (Ishak score 乏3) and cirrhosis (Ishak molecules with high reproducibility at a CV <5% ( 1 5 ) . 
score ^5), both at 85% accuracy. Compared to mass spectrometry (MS), however, capillary 
• electrophoresis has relatively lower throughput. Recently, 
Fourier transform ion cyclotron resonance MS has been 
''Li Ka Shing Institute of Health Sciences, ^ Department of Medicine and used ( 1 3 , 1 4 ) , but information about its quantification 
Therapeutics, Centre for Emerging Infectious Diseases, and Department of performance h a S nO t been available. T h e MALDI-TOF 
Ariatomkal and Cellular Pathology, The Chinese University of Hong Kong, 
Prince of Wales Hospital, Shatin, Hong Kong SAR. 
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^iences, Department of Medicine and Therapeutics, The Chinese University of 
Hong Kong, Prince of Wales Hospital, Shatin, N.T., Hong Kong SAR. Fax ^ Nonstandard abbreviations: CDG, congenital disorders in glycosylation; 
^2-2648-8842; e-mail tcwpoon®cuhk.edu.hk. MS, mass spectrometry; ALP, alkaline phosphatase; AFP, a-fetoprotein; DHB, 
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Pre\nously published online at DOI: 10.1373/cliiichem.2007.085563 GlcNAc, N-acetyl-glucosamine; APTT, activated partial tliromhoplastin time. 
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mass spectrometer, a relatively cheaper instrument, has programs designed for quantitative proteomic profiling, 
been used for characterization of carbohydrate structure Fig. 1 (see the Data Supplement that accompanies the 
for many years ( 1 2 , 1 6 ) . In the past 5 years, MALDI-TOF oulirie version of this article at http:/ /www.clinchem. 
MS-based instruments, such as SELDI ProteinChip sys- org/content/vol53/issue7) is the schematic diagram 
tern ( 1 7 , 1 8 ) and the ClinProt system ( 1 9 ) , have been used showing the design of the assay, 
for quantitative profiling of the serum proteome. 
The feasibility of using MALDI-TOF MS for quantita- DETACHMENT OF AF-GLYCANS FROM WHOLE SERUM 
tive profiling of the glycome remained uncertain. In this PROTEINS 
study, we attempted to establish a high-throughput quan- We denatured 2 fxL of serum at 56 °C in 20 ；xL of 12.5 
titative assay for profiling the serum N-glycome by using ntmol/L sodium phosphate buffer (pH 8.3) containing 2.5 
the MALDI-TOF MS function and spectrum analysis mL/L j3-mercaptoethanol (Sigma-Aldrich) and 1.25 g/L 
programs of the SELDI ProteinChip system. We also used sodium dodecyl sulfate (Sigma-Aldrich) for 1 h and then 
the new assay to search for serum N-glycans, the concen- added 5 juL of 100 mL/L Triton X-100 (Sigma-Aldrich) to 
trations of which were altered in patients with liver neutralize the denaturing effect of the sodium dodecyl 
fibrosis, to serve as an example of the clinical potential of sulfate. We then added 25 ju,L of 50 minol/L sodium 
the assay. phosphate buffer (pH 8.3) containing 0.5 U of peptide:N-
glycosidase F (PNGase F; EC 3.5.1.52; Sigma-Aldrich). The 
Materials and Methods digestion mixture was incubated at 3 7 � C for 24 h. 
PATIENT MATERIALS 
Liver biopsies were obtained from consecutive patients MICROSCALE PURIFICATION OF SERUM N-GLYCOME BY 
with chronic hepatitis B in the Prince of Wales Hospital, HYDROPHILIC CHROMATOGRAPHY 
Hong Kong, in 2002 and 2003. Patients included those A method originally developed for purification of glyco-
who had been recruited or screened for other therapeutic peptides ( 2 0 ) was modified in this study to purify N-
trials, as well as patients who were suspected of having glycans. We equilibrated 10 mg of preswollen Sepharose 
active liver disease on the basis of laboratory or radiologic 4B gel (GE Healthcare Life Sciences) twice with 0.5 mL of 
investigations. No patients were undergoing treatment at binding solution (butanol:ethaiiol:7 mniol/L manganese 
the time of liver biopsy or had compensated liver disease chloride solution = 5:1:1, vol/vol/vol). We diluted 8 /xL 
at the time of recruitment. After obtaining informed of the enzymatic digest with 200 fxL of binding solution, 
consent, we collected fasting blood samples by venipuiic- mixed this with the gel in a 0.5-mL microcentrifuge tube, 
ture before liver biopsy. Serum was stored at -70 ° C and incubated the mixture on a blood-tube rotator at 
Randomly selected serum samples from 46 patients [35 room temperature for 30 min. The whole content was then 
males and 11 females; mean (SD) age, 48.3 (9.2) years] transferred to a Spin-X column (Corning) and washed 4 
Were archived for this study. The same set of samples had times with 0.5 mL of washing solution (butanol:etliaiiol: 
been subjected to proteomic profiling in our previous water = 5:1:1, vol/vol/vol). Finally the N-glycans were 
study ( 1 8 ) . Age was calculated to the date of biopsy. Use eluted with 200 j l l L of 100 mL/L ethanol, followed by 
of these clinical samples for biomarker discovery was centrifugal vacuum drying. The N-glycans were redis-
approved by the university ethics committee. The data of solved with 5 /jlL of 100 mL/L ethanol as the purified 
the histological staging (Ishak score reflecting the degrees N-glycan preparation and stored at -30 before MS 
of liver fibrosis) and hematologic and biochemical tests analysis, 
[complete blood screens, coagulation tests, bilirubin, total 
protein, albumin, alanine transaminase, alkaline phospha- MALDI-TOF MS-BASED N-GLYCOME PROFILING ASSAY 
tase (ALP), and ^-fetoprotein (AFP)] were retrieved from N-glycan samples and matrix chemical were added on an 
the database of our previous study ( 1 8 ) . Ten patients had 8-spot gold ProteinChip array (Ciphergen Biosystems) by 
minimal fibrosis (Ishak score = 1), 9 had mild fibrosis undertaking a sandwich spotting approach. Super-2,5-
(Ishak score = 2 ) , 10 had moderate fibrosis (Ishak score = dihydroxybenzoic acid (DHB) in the presence of NaCl 
3 or 4), 8 had severe fibrosis and incofhplete cirrhosis was used as the matrix chemical. A stock solution of 
(Ishak score = 5), and 9 had probable/definite cirrhosis super-DHB (1.35 g/L DHB, 0.15 g /L 2-hydroxy-5-me-
(Ishak score = 6). thoxybenzoic acid, 10 mmol /L NaCl in 100 mL/L etha-
nol) was prepared, stored at -30 °C, and 6.7-fold diluted 
DESIGN OF AN ASSAY FOR QUANTITATIVE PROFILING with Mil l iQ water on the day of MS analysis. First, 0.5 /xL 
OF SERUM N-GLYCOME of super-DHB was spotted and vacuum-dried. Then 0.5 
队glycans from whole serum proteins in 2 /xL serum were /xL of the purified N-glycan preparation was spotted and 
released by enzymatic digestion, cleaned up by hydro- vacuum-dried, followed by sequential addition and vac-
philic chromatography, and then quantitatively profiled uum drying of 0.5 /xL of 500 mL/L acetomtrile and 0.5 fiL 
With a linear MALDI-TOF MS system, which was origi- of super-DHB. Finally, 0.5 /xL of 500 mL/L ethanol was 
nally designed for quantitative proteomic profiling. The spotted over the spotting area and vacuum-dried to 
iiiass spectra were analyzed witli the existing computer achieve a homogeneous layer of aiialj^te-matrix cocrystals. 
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The gold ProteinChip arrays were read over the 900-4000 normalized peak intensities must be significantly higher/ 
.w/z interval on the ProteinChip PBS n reader of a Protein- lower in patients with typical fibrosis/cirrhosis than in 
Chip Biomarker System. The ProteinChip reader was individuals with minimai fibrosis, and (b) the normalized 
equipped with a nitrogen laser operating at 337 nm peak intensities must correlate with the degree of fibrosis, 
wavelength and at 5 microjoule pulse. The mass spectra The significance analysis of microarray algorithm (Stan-
were acquired at a positive ion mode and an optimized ford University) (17, IS, 21) was used to identify the 
interval of 1200-3000 m/z. Mass spectrum of each glycan glycans that were significantly higher/lower in patients 
sample was a mean of 610 mass spectra obtained over the with fibrosis/cirrhosis by comparing the N-glycome pro-
sample spot at 61 acquisition positions. The mass spec- files of the cases with minimal fibrosis (Ishak score = 1) 
trum of each sample was smoothed, baseline-subtracted, with those for cases with typical fibrosis/cirrhosis (Ishak 
externally calibrated with the standard N-glycans (see score >3) at a median false discovery rate of 2.5%. In the 
Table '1 in the online Data Supplement), and finally significance analysis of microarray analysis, "2-classed, 
internally calibrated with peaks at 1626.5, 2269.0, and unpaired data" were selected as the data type, and 5000 
2947.6 m/z. The glycan peaks with signal-to-noise ratio >3 permutations were performed. Correlations between the 
among the mass spectra were identified and quantified by degree of fibrosis (Ishak scores) and the peak intensities of 
use of Biomarker Wizard software (Ciphergen Biosys- the significant glycans were analyzed by the Spearman 
terns). The peak intensities were normalized with the total rank order correlation test, 
ion current and subsequently with the total peak inten-
sity. On the mass spectra, each nonsialylated glycan CONSTRUCTION OF GLYCAN-BASED DIAGNOSTIC 
appeared as a single peak with an m/z value equivalent to MODEL 
the average molecular mass plus 1.0 mass unit (mass of a Logj values of the age, potential diagnostic glycans, and 
proton). For the sialylated glycans, sodium salts were serological markers [total protein, albumin concentration, 
formed and detected as a group of consecutive peaks with international normalized ratio, activated partial thrombo-
a step-wise increment of 22 m/z (see Fig. 2 in the online plastin time (APTT), alanine transaminase, total bilirubin, 
Data Supplement). For a sialylated glycan with n sialic ALP, AFP, hemoglobin, leukocyte count, and platelet 
acid residues, n + 1 consecutive peaks were detected. The count] were included as independent variables, and Ishak 
normalized peak intensities of all consecutive peaks were score was set as the dependent output variable. Forward 
Slimmed to obtain the normalized peak intensity for the stepwise linear regression analysis was performed using 
sodium-free parent glycan. Each sample was analyzed in SPSS (SPSS Inc.) to select the variables with independent 
duplicate. Mean values of the duplicates were used in prediction values for constructing a diagnostic model to 
subsequent data mining. calculate the Fibro-Glyco index. Leave-one-out cross-val-
idation was performed to evaluate the performance of the 
EVALUATION OF QUANTITATIVE PERFORMANCE OF diagnostic model in detecting significant liver fibrosis 
THE MALDI-TOF MS-BASED N-GLYCOME PROFILING (Ishak score S:3) and cirrhosis (Ishak score >5), as we 
ASSAY previously described (18). 
Four standard N-glycaiis (CalBiochem) were used during 
evaluation. Structural information of the standard N- STATISTICAL ANALYSES 
glycans is listed in Table 1 in the online Data Supplement. The Spearman rank order correlation test was used to 
When the reproducibility of the normalized peak intensi- examine correlation relationships between the N-glycan 
ties was examined, 3 (M3N2, MANS and A2) of the peak intensities and the clinical/biochemical variables, 
standard N-glycans was fixed at 10 pmol. Intraassay CV The sensitivity and specificity were calculated according 
Was determined from 32 identical sample-matrix spots iii to the standard formulas. ROC curves were constructed 
One single day by use of the same preparations of matrix for differentiating patients with or without significant 
chemic^ and reagents. For the interassay CV, the stan- liver fibrosis (Ishak score >3) and for differentiating 
dard glycan mixture was measured in duplicate for 12 patients with or without liver cirrhosis (Ishak score >5). 
consecutive days by using different bafches of matrix The likelihood ratios (LRs) were calculated by use of the 
chemical and reagents, which were prepared freshly on standard formulas: positive LR (LR+) = sensitivity/ 
the day of experiment. Linearity relationships between (100% - specificity); negative LR (LR-）= (100% -
the quantity and normalized peak intensity of each of 4 sensitivity)/specificity, 
standard N-glycans were evaluated by varying amounts 
from 5 to 20 pmol while fixing the amount of the other 3 Results 
^-glycans at 10 pmol . QUANTITATIVE PERFORMANCE OF THE MALDI-TOF 
MS-BASED N-GLYCOME PROFILING ASSAY 
IDENTIFICATION OF POTENTIAL DIAGNOSTIC GLYCANS A representative mass spectrum of 4 standard N-glycans 
扣R LIVER FIBROSIS/ CIRRHOSIS all at 10 pmol is shown in supplementary Fig. 3. For all 3 
As in our previous study (18), we used 2 criteria to standard N-glycaiis, the intraassay CVs of the normalized 
identify the glycans associated only with disease, {a) the peak intensities were <8% and the interassay CVs were 
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<17% (Table 1). Linearity study showed that the normal- resulting in 10 glycans significantly correlated with liver 
ized peak intensity was directly proportional to the rela- function. Concerning liver inflammation, only the 2606.9 
tive quantity of a glycan, with an value 20.95 for all m/z glycan was negatively correlated with alanine 
4 standard glycans (see Fig. 4 in the online Data traiisaminase concentration (r = -0.366; P - 0.012). 
Supplement). Concerning liver damage, 1 glycan was positively corre-
lated with total Wlirubin {r = 0.319； P = 0.031), whereas 1 
SERUM N-GLYCOME PROFILE AND LIVER FIBROSIS— glycan was negatively correlated (r = -0.316; P = 0.032). 
ASSOCIATED FINGERPRINT Noiie of the glycans were correlated with ALP. Three 
The representative serum N-glycome mass spectra of glycans were positively correlated with AFP (r = 0.327 to 
serum samples from a healthy individual, a patient with 0.431; all P values <0.05). As a result, 76% (13 of 17) of the 
minimal liver fibrosis, and a patient with significant liver-fibrosis-associated glycans potentially reflected the 
fibrosis are shown in Fig. 1, A-C. Fig. I D shows that when physiological state of the liver. Finally, it is well known 
heat-inactivated PNGase F was used to release the N- that platelet count is negatively correlated with degrees of 
glycans, no significant peaks were detected. This finding fibrosis. We found that 8 glycans were correlated with the 
indicates that the majority of the peaks in the mass spectra platelet count (all P values <0.05). Therefore, 82% (14 of 
were contributed by the N-glycaiis released from the 17) of the glycans forming the liver fibrosis fingerprint 
whole serum proteins. We observed that 5 freeze-thaw were significantly correlated with the serologic markers 
cycles did not significantly affect the serum N-glycome that directly reflect the liver physiology and/or with 
profiles (see Fig. 5 in the online Data Supplement). those that are well known to be altered in patients with 
We found that 55 glycans were matched among the liver fibrosis (Table 2). 
serum samples. At a median false-discovery rate of 2.5%, 
we identified 15 iV-glycans that were significantly higher LINEAR REGRESSION MODEL FOR DETECTING LIVER 
and 8 N-glycans that were significantly lower in the FIBROSIS AND CIRRHOSIS 
patient group of typical fibrosis /cirrhosis. Among these Among all the dependent variables (potential diagnostic 
23 significant /V-glycans, 13 were positively correlated glycans, serological markers, and age), only N-glycans of 
with the degree of fibrosis, and 8 were negatively corre- 1341.5, 1829.7, 1933.3, or 2130.3 m/z (all P <0.005) were 
lated (all P values <0.05; Fig. 2). Therefore, only 21 selected as biomarkers with independent diagnostic val-
glycaiis were significantly associated with liver fibrosis. ues and included in the linear regression model for 
ROC curve analyses showed that 17 of these liver fibrosis- calculating the Fibro-Glyco index. Leave-one-out cross-
associated glycans had potential value in the detection of validation showed that the Fibro-Glyco index signifi-
either liver fibrosis and/or liver cirrhosis (all P values cantly correlated with degrees of liver fibrosis (r = 0.784; 
<0.05). The 1829.7 nt/z glycan [area under the curve P = 0.01). Furthermore, the index was useful in the 
(AUC) = 0.90] was the best marker for detecting signifi- detection of liver fibrosis and cirrhosis. The ROC curve 
cant liver fibrosis, and the 1444.7 m/z glycan (AUC = 0.83) areas for the Fibro-Glyco index in detection of liver 
Was the best marker for detecting liver cirrhosis. The fibrosis and in detection of liver cirrhosis both were 0.91 
results for the 17 potential diagnostic glycans are listed in (Fig. 3). At 84% specificity, the sensitivity for detecting 
Table 2. liver fibrosis was 85%, the overall accuracy was 85%, and 
the LR+ and LR- were 5.4 and 0.18, respectively. At 83% 
CORRELATIONS BETWEEN THE N-GLYCAN PEAK Specificity, the sensitivity for detecting liver cirrhosis was 
INTENSITIES AND SEROLOGICAL MARKERS 88%, the overall accuracy was 85%, and the LR+ and LR-
Among the 17 potential diagnostic glycans, 5 were corre- were 5.1 and 0.14, respectively, 
lated with albumin concentration (r = 0.417 to 0.490 and 
-0.292 to -0.348; all P values <0.05); 5 were correlated Discussion 
with total protein (/• = 0.329 to 0.351 and -0.292 to -0.343; Although MALDI-TOF MS has been widely used to 
all P values <0.05); 1 was positively correlated with APTT characterize the structure of glycans, this is first study 
(r = 0.326; P = 0.027), and 3 were negatively correlated indicating that MALDI-TOF MS is also applicable to 
(r = -0.322 to -0.356; all P values <0.05); 4 were quantitative profiling of a complex mixture of glycans. To 
correlated with international normalized ratio {r = 0.304 achieve this quantitative capability, we took 2 important 
to 0.403 and -0.380 to -0.450; all P values <0.05), measures, one to ensure a homogeneous layer of glycaii-
matrix cocrystals and the other to scan the glycan-matrix 
spot to obtain 610 mass spectra, the mean of which was 
TaWe 1. Intra- and Interassay reproducibility of the MALDI- ^sed as the final mass spectrum for each glycan sample. 
TOF MS-based A^gtycome profiling assay. Previously, we showed that both measures were unpor-
a^ndard AAgiycan Int哪say CV, % Interassay CV, % fant to obtain a quantitative mass spectrum for profiling a 
U J ， 8.67 17.11 mixture of protein/peptide molecules (22). 
A2 8 In the present study, using the serum A/-glycome 
： ： profiling assay, we successfully identified a panel of 
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Fig. 1. The representative MALDI-TOF mass spectra of serum AZ-glycomes of a chronic hepatitis B patient with minimal liver fibrosis [A), a chronic 
hepatitis B patient with significant fibrosis (fi), and a healthy individual (C). 
When inactivated PNGase F was used to release serum A/-glycans (D), no significant peaks were detected. 
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Fig. 2. Representative mass spectra showing peak intensities of 2 diagnostic /V-glycans in the patients with different degrees of liver fibrosis. 
The 1933.3 m/z glycan and 2130.3 m/z glycan were negatively and positively associated with liver fibrosis, respectively. The molecular weights of the neutral 
molecules are marked in the mass spectra. 
serum N-glycans as potential markers for detecting liver model can be used to detect liver fibrosis/cirrhosis with 
fibrosis and liver cirrhosis; 82% (14 of 17) of the glycans other underlying causes, such as chronic hepatitis C 
with potential diagnostic values were significantly corre- infection and chronic alcohol abuse, 
lated with the serological markers that directly reflect N-glycaiis are different from peptides or proteins in 
liver physiology and/or with those that are well known to terms of sequence-structure analysis. Because human N-
be altered in patients with liver fibrosis. These findings linked glycans all contain the same chitobiose core [2 
also serve as indirect evidence indicating that identified /V-acetyl-glucosamines (GlcNAcs) attached to a triman-
diagnostic glycans have clinical meanings associated with nose] and are synthesized by a well-defined pathway, an 
the disease being studied. accurate mass measurement will generally permit predic-
Callewaert et al. (11) applied the DNA sequencer to tion of structure ( 2 3 , 2 4 ) . We attempted to predict the 
profile sialidase-treated N-glycans from the whole serum structures of the 4 major diagnostic glycans (1341.5, 
proteins in patients with and without liver cirrhosis. The 1829.7,1933.3, and 2130.3 m/z) from their mean m/z values 
present study strongly suggested that the serum N-gly- by searching the Consortium for Functional Glycomics 
come profile is useful in predicting not oiily liver cirrhosis database and using Expasy GlycoMod ( 2 3 ) with an ac-
but also liver fibrosis. As far as we know, this is the first ceptable error tolerance <0.05%. The predicted structures 
study demonstrating such clinical importance in humans. of the 4 glycans were successfully matched to those that 
Because only 46 patients were examined in this study, we had been observed in human (Fig. 4). 
are undertaking a similar study with a much larger With the predicted structures, we found that 3 diag-
sample size to confirm the clinical value of the present nostic N-glycans (1341.5,1829.7, and 2130.3 m/z) showing 
diagnostic model. Further studies are also needed to positive correlations with fibrosis stages contain a proxi-
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Detection of Liver Fibrosis Detection of Liver Cirrhosis 
1.00«, I 1 . 0 0 - , 
r ^ ^ [ 7 
.75. I .75. H 
> > 
.500 邑 .50. 1 
^ AUC =0.912 (0.831 -0,994) ^ AUC = 0.911 (0.829 - 0.993) 
Sensitivity: 85% Sensitivity: 88% 
Specificity: 84% Specificity: 83% 
,25. Accuracy: 85% .25. Accuracy: 85% 
0.00 0.00, 
oto S ^ I i i lo olo S 11 rto 
1 - Specificity 1 - Specificity 
Fig. 3. ROC curves of the Rbro-Glyco index in the detection of significant liver fibrosis (A) and cirrhosis (B). 
The 95% CIs of the AUC values are shown In parentheses. 
, Deviation from ^ , . 
AT-glycan Predicted Structure(s ) Theoretical Correlation with 
Measured m/z value , , liver fibrosis stages 
m/z value ( % ) ‘ 
HSOJ - H - Q 牟 
1341.5 0.3 (0.022) Positive 
1829.7 or 0.0 (0.000) Positive 
1933.3 0.5 (0,026) Negative 
2130.3 » • > 0.7 (0.033) Positive 
Pig. 4. Predicted structures of the 4 serum AZ-glycans included in the diagnostic model. 
Black diamonds, sialic acid; white circles, galactose; black squares, GlcNAc; gray circles, mannose; gray triangles, fucose. 
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ll 10 Abstract Abbreviation 36 
11 Introduction Glycans have unique characteristics that are HPLC high-performance liquid chromatography 38 
12 significantly different from nucleic acids and proteins in terms LC liquid chromatography 40 
13 of biosynthesis, structures, and functions. Moreover, their MS mass spectrometry 42 
14 isomeric nature and the complex linkages between residues MALDI-TOF matrix-assisted laser desorption/ionization 44 
15 have made glycan analysis a challenging task. Disease MS time-of-flight mass spectrometry 45 
16 development and progression are usually associated with CDG congenital disorders of glycosylation 48 
17 alternations in glycosylation on tissue proteins and/or blood CE capillary electrophoresis 50 
18 proteins. Glycans released from tissue/blood proteins hence HCC hepatocellular carcinoma 52 
19 provide a valuable source of biomarkers. In this postgenome 
20 era, glycomics is an emerging research field. Glycome refers 
to a repertoire of glycans in a tissue/cell type, while glycomics 
22 is the study of glycome. In the past few years, attempts have Introduction 55 
23 been made to develop novel methodologies for quantitative 
24 glycomic profiling and to identify potential glycobiomarkers. Glycosylation is one of the most common posttraiislational 56 
25 It can be foreseen that glycomics holds the promise for modifications in eukaryotes, and a majority of cellular 57 
26 biomarker discovery. This review provides an overview of the proteins are glycosylated through either N- or 0-glycosylation 58 
打 unique features of glycans and the historical applications of or through glycophosphatidylinositol anchor pathway that 59 
站 such features to biomarker discovery. connects the protein with two fatty acid chains. Other 60 
扣 Future Prospective The concept of glycomics and its recent important glycoconjugates include glycosphingolipids, 61 
恥 advancement and future prospective in biomarker research lipopolysaccharides, and peptidoglycans. The attachment of 62 
are then reviewed. Above all, there is no doubt that polysaccharides or glycans to biomolecules depends on the 63 
拟 glycomics is gaining momentum in biomarker research. physiological status of the cells [1] and the protein sequence 64 
[2]. Glycosylation changes have been identified in various 65 
Keywords Glycomics. Glycome • Glycoprotein • diseases, ranging from systemic genetic diseases, like 66 
I Glycobiomarker • Quantitative profiling • Glycosylation • congenital disorders of glycosylation (CDG) syndrome [3], G7 
站 Mglycan • 0-glycan • Biomarker research to localized malignancy, like ovarian cancers [4]. There has 68 
been a long history in applying glycobiomarkers for disease 69 
r' “ diagnosis and prognosis. Because of their diverse structures 70 
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77 analytical technologies, glycomics and glycoproteomics is cannot be addressed by using conventional analytical 127 
78 gaining momentum in biomarker researches. approaches in genomics and proteomics. 128 
79 While genomics or proteomics have been relatively well Glycosylation alters the biochemical properties of a 129 
80 established and commonly applied to biomarker discovery glycoprotein in a number of ways, including an isoelectric 130 
81 [5，6], biomarker research is relatively unexplored through point [8], conformational stability [9], thermal and pH 131 
82 glycomics perspective. This review will give an introduc- stabilities [10，11]’ susceptibility to inorganic solvent and 132 
83 tion of the characteristic of glycosylation and the historical proteolysis [12], and a lectin-binding behavior [13]. In 133 
84 applications of glycobiology to biomarker research. The general, glycosylation increases the thermal stability and 134 
85 concept of glycomics, its differences from glycoproteomics, reduces the susceptibility of protein to proteolysis, as 135 
86 its recent advancement and future prospective in biomarker demonstrated by various deglycosyiated glycoenzymes 136 
87 research, and the technologies for quantitative profiling of [14]. However, the removal of glycosylation does not 137 
88 tissue glycome are then reviewed. Given the board always change the biochemical properties of different 138 
89 spectrum of glycomic studies in various diseases, it would glycoproteins in the same way [14]. Therefore, functional 139 
90 be impossible to provide an in-depth review for every changes brought about by glycosylation not only depend on 140 
91 aspect in this review article. The focus of this article will be the structure of a glycan, but also on the characteristics of 141 
92 mainly on the applications of TV-linked and 0-linked the protein concerned. It is almost impossible to predict the 142 
93 glycans in biomarker discovery. functional changes brought by the glycans based solely on 143 
their glycan structures. Moreover, a single glycoprotein 144 
molecule may have several glycosylation sites with various 145 
94 Overview of Biochemical and Functional susceptibilities to glycosylation and may carry different 146 
95 Characteristics of Glycan glycan chains independently, leading to a considerable 147 
number of glycoforms with subtle differences in their 148 
96 Compared with DNA molecules and polypeptides, glycans properties. For example, serum haptoglobin (Hp) is a 149 
97 attached to glycoconjugates have three fundamental differ- tetramer composed of two alpha subunits of 9.1 kDa and 150 
98 ences, which are (1) non-template-based synthesis, (2) two beta subunits of 40 kDa. The carbohydrate content of 151 
99 branching primary structures, and (3) variable linkages Hp is found exclusively as 'complex' AMinked glycans on 152 
100 between the basic units, i.e., monosaccharides. In humans, the beta subunit only [】5]. There are four AMinked 153 
101 the major glycan basic units include mannose (Man), glycosylation sites on the beta subunit. The glycans are 154 
102 galactose (Gal), A^-acetylgalactosamine (GalNAc), glucose either biantennary or triantennary, both terminating with 155 
103 (Glc), A^-acetylglucosamine residue (GlcNAc), sialic acid sialic acid residue(s). Fucose is linked to the core GlcNAc 156 
104 (or called //-acetyl neuraminic acid, NeuSAc), and fucose residue at either alpha-1,6 position or alpha-1,3 position 157 
105 (Fuc). In contrast to the production of DNA molecules or [16]. In our recent study, we observed a total of 18 158 
lOf) polypeptides, which requires the presence of complemen- glycoforms with slight differences in molecular weight 159 
107 tary DNA strands or mRNAs, there is no template or blue- (ranging from 35 -44 kDa) and p/ value (ranging from 4.6- 160 
108 print molecule for the production of oligosaccharides to be 5.8) [17]. Given such complicated relationships between 161 
109 based upon. The synthesis of a glycan depends on the protein biochemical properties and glycosylations, it is 162 
110 activity of a set of glycosidases and glycosyltransferases in inevitable in glycoproteomics to isolate and study structures 163 
111 rough endoplasmic reticulum and Golgi apparatus and the of glycan motifs. This is especially important in biomarkers 164 
target molecule. To date, it is still impossible to predict research because glycosylation is usually tissue or disease 165 
113 the structure(s) of the glycosylation side chain(s) based on specific [18，19]. These allow identification of glycopro- 166 
the protein sequence. While the primary structures of DNA teins with tissue-specific glycosylations or tracing back the 167 
molecules and proteins are linear and relatively straightfor- origin of disease-related differential glycoproteins. 168 
ward, the branching property allows glycans to have 
exceedingly a large number of isomeric primary structures 
even if only six basic units are concerned [7]. In contrast to A^-linked and O-Iinked Glycosylations 169 
彻 DNA molecules and proteins, the bonding between two 
1 如 monosaccharide residues can have a variety of configura- There are two major types of glycoprotein glycosylation 170 
tions and linkages. There are two different stereochemical concerned and studied extensively in biomarker discovery: 171 
configurations of glycosidic bonds——an alpha linkage and a AMinked and 0-linked glycosylations. It is because they are 172 
123 beta linkage. The only difference between the alpha and commonly associated with secretory glycoproteins found in 173 
beta linkages is the orientation of the linked carbon atoms. the blood. Glycosylphosphatidylinositol (GPI)-anchored 174 
彻 Furthermore, each carbon in a monosaccharide can partic- glycoproteins, on the other hand, are bound to plasma 175 
ipate in such bonding. This flexibility and complexity membrane by two fatty acid chains and less readily detected 176 
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177 in body fluids. The structural and physiological character- and invertebrates. Sialic acid can link up with the terminal Gal 230 
178 istics of these two types of glycans are more diverse than in a2-3 or otl 6 configuration, depending on the cell-type, 231 
179 those of GPI-anchored glycoproteins. tissue-type, developmental stages, and environmental factors 232 
180 TV-linked glycan is covalently bonded with the amide [26]. cx2 -8 linkage is also found in the terminal polysialic acid 233 
181 group on asparagine residue of proteins. The asparagine chain in AMinked and 0-linked glycans and in ganglioside 234 
182 residue is located in a consensus Asn-X-Ser/Thr sequence in [27, 28]. The presence of sialic acid on plasma membrane 235 
183 which X can be any amino acid except proline. In some rare increases the hydrophilicity and negative charges of the cell 236 
184 cases, the serine or threonine residue can be replaced with a and masks the Gal residue in the internal sequence to avoid 237 
185 cysteine, giving an Asn-X-Cys glycosylation site, as found in binding of it with specific receptors [26]. It is also commonly 238 
186 epidermal growth factor receptor [20], a minor glycosylation expressed in microbial pathogen as a molecular mimicry, as 239 
187 site in human transferrin [21] and CD81 molecules [22]. N- sialic acid is heavily related with cell surface glycoproteins 240 
188 glycans can be classified into three classes based on the and cell-cell recognition system [26’ 29]. 241 
189 composition and sequence of oligosaccharides: high man-
190 nose, complex, and hybrid. The high-mannose AMinked 
191 glycan is composed of mainly polymannosyl residues in all 
192 branches. The complex-type glycans have a characteristic N- Historical Development and Clinical Application 242 
193 acetyllactosamine Gal(Pl 4)GlcNAc in every branches. of Glycobiomarkers 243 
194 While the hybrid-type glycan carries both high-mannose 
195 branches and complex branches. Regardless of class, all N- Glycosylation changes have been identified in various 244 
196 linked glycans share the common tri-mannosyl core Manal- diseases, ranging from systemic genetic diseases like 245 
197 6(Majial-3)MaiT(3 l-4GlcNAc(31 4GlcNAc. Each mannose CDG syndrome [3] to localized malignancy like ovarian 246 
198 residue of the tri-mannosyl core at the nonreducing termini cancers [4]. There has been a long history in applying 247 
199 can be extended in an independent manner by oligomannose glycobiomarkers for disease diagnosis and prognosis. 248 
200 (high-mannose type) or N- acetyllactosamine (complex Glycans with specific sequence are recognized as 249 
201 type), or linked up with two more branches (antennae). antigens in immune system. Besides the ABO blood group 250 
202 A single A/'-glycan can therefore carry up to four branches antigens, one of the famous examples is the Lewis antigen 251 
203 (tetra-antennary). The branching mannose residue in the (Le) present on the plasma membrane of red blood cells. 252 
204 core is susceptible to the addition of bisecting GlcNAc Lewis antigen belongs to a type of cell adhesion molecules 253 
205 through |31~3 bond through the action of •/V-acetylgiuco- expressed by leukocytes and some circulating cancer cells. 254 
206 saminyltransferase-Ill, while the asparagines-linked Lewis antigen is recognized by selectin, a family of lectins 255 
207 GlcNAc may be fucosylated through the (xl-6 bond through expressed by vascular endothelial cells, and assists the 256 
208 the action of a 1 -6-fucosyltransferase [23’ 24]. adhesion of leukocytes and cancer cells to endothelia. Four 257 
209 0-linked glycans, on the other hand, have more complex types of Le antigen are identified: Le^ (Gal(31-3(Fucal-4) 258 
210 and less defined structures than AMinked glycans. 0-linked GlcNAc), Le'' (Fuca 1 -2Gal (31 -3(Fucal -4)GlcNAc), Le" 259 
glycan is linked to the hydroxy 1 side chain group on the (Gal|31 4(Fucal -3)GlcNAc), and Le^ (Fucal-2Gal(31-4 260 
212 serine or threonine residue in the protein. The two most (Fucocl-3)GlcNAc). Le®, Le", and their sialylated 261 
213 contrasting differences between O- and A -^linked glycans are (Neu5Acal-3Gal|31- 4(Fucal-3)GlcNAc) and sulphated 262 
214 the absence of common tri-mannosyl core and a consensus (S043-0Gal(31-4(Fucal-3)GlcNAc, and NeuSAcal- 263 
215 amino acid sequence on the glycosylation site. In most of the 3Gal (31 - 4( Fuca 1 -3)(S046-0)GlcNAc) variants are com- 264 
O-linked glycoproteins, the glycans are mucin type that monly associated with cancer cell adhesions. Previous 265 
carries the core sugar GalNAc, followed by a Gal, GalNAc, studies have shown that inhibition of Le® and Le" antigen 266 
or GlcNAc residue. Unlike AMinked glycans, O-linked expressions in cancer cells greatly reduce their adhesion to 267 
219 glycans are less branched and usually carry, at most, two endothelial cells or selectin-expressing cells in vitro, and 268 
antennae, branching at the core GalNAc by Gals. the expression of sialyl Le" and sialyl Le" is associated with 269 
In both types of glycosylations, the main monosaccharide tumor progression and metastasis [30]. Because of the 270 
222 residues encountered are usually hexoses and their A^ -acetylated connection between sialyl Lewis antigen and tumorigenicity, 271 
223 derivatives, including GlcNAc and A^-acetyllactosamine. it is not surprising that the expression of sialyl Le" is a useful 272 
Pentoses are rarely found in human glycosylation system prognostic factor in cancers, for example, for colorectal 273 
except xylose in O-linked glycans, and their presences are carcinomas [31-33]. Helicobacter pylori also expresses Le" 274 
usually allergenic [25]. Sialic acid, or A^-acetylneuraminic and Le^ antigens on its cell surface as part of the 275 
acid, is another important constituent of glycans. It is a nine- lipopolysaccharide to mimic the cell-surface glycoconjugate 276 
找8 carbon acidic monosaccharide usually found at the termini of molecules of human gastric endothelial cells [34]. They are 277 
various glycans and on the plasma membrane of vertebrates responsible for the adhesion of H. pylori, the infection and 278 
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279 colonization of which cause chronic gastritis and gastric other pathological conditions. As tumor cells have different 332 
280 cancer. glycosylation machinery, it is hypothesized that identifica- 333 
281 The glycosylation of immunoglobulin (Ig) is also of tion of tumor-specific glycoforms should improve the 334 
282 great interest. Immunoglobulin is a well-known circulating specificity of a tumor marker. This hypothesis has been 335 
283 glycoprotein found in serum. It is glycosylated at a supported by various studies showing that identification of 336 
284 conserved location in heavy chains and at a less conserved tumor-specific glycoforms can improve the diagnostic value 337 
285 location in light chains. Immunoglobulins are produced and of serum AFP. AFP is an A/-glycosylated serum glycopro- 338 
286 secreted specifically by Ig-secreting cells and play impor- tein carrying a biantennary complex type glycan [49] and is 339 
287 tant roles in the immune system. Glycosylation plays a a well-documented upregulated biomarker for hepatocellu- 340 
288 critical role in modulating the structure and function of Igs. lar carcinoma (HCC). However, it was also found to be 341 
289 Alterations in glycan structures of Ig has been observed in a elevated in chronic liver diseases, reducing its specificity in 342 
290 variety of autoimmune diseases, such as rheumatoid diagnosis HCC. By using lectin-afFinity electrophoresis, an 343 
291 arthritis and systemic lupus erythematosus [35，36], as well elevated level of core alpha 1 ~6-fucosylated AFP glycoform 344 
292 as immune-related diseases like IgA nephropathy [37]. called AFP-L3 can differentiate between chronic liver 345 
293 Abnormal hypogalactosylated 0-glycosylation on the Fc diseases and HCC, demonstrating the application of altered 346 
294 region in IgA molecules is known to cause mesangial IgA glycosylation in biomarker discovery [47, 50]. Apart from 347 
295 deposition in kidney in IgA nephropathy, leading to AFP-L3, a monosialylated glycoform of AFP termed 348 
296 glomerular damage [37]. msAFP was also found to be able to differentiate between 349 
297 The majority of serum glycoproteins are of hepatic early stage HCC with nondiagnostic AFP level and liver 350 
298 origin. The close relationship between liver and serum cirrhosis patients with similar total serum AFP level [51]. 351 
299 glycoproteins suggests that liver abnormalities associated These studies have shown that, although total serum AFP 352 
300 with aberrant glycosylations can be reflected by the alone was not sufficient to differentiate HCC and chronic 353 
301 changes in serum glycoprotein glycosylation patterns. The liver diseases, the qualitative and quantitative information 354 
302 degrees of fucosylation on certain serum glycoproteins, of the iV-glycosylation pattern of serum AFP have signif- 355 
303 such as haptoglobin [38]，cholinesterase [39], and alpha-1 icantly improved the performance of AFP as a HCC- 356 
304 acid glycoprotein [40], were increased in liver cirrhosis. specific biomarker. Besides AFP, it has been reported that 357 
305 Microheterogeneity with concanavalin A affinity of serum serum levels of fucosylated glycoforms of alpha-1 anti- 358 
306 transferrin was observed in patients with alcoholic liver trypsin and transferrin in patients with HCC are signifi- 359 
307 disease [41]. Altered glycosylation pattern of serum cantly higher than with liver cirrhosis [52, 53, 54]. 360 
308 transferrin can be observed in patients with alcohol abuse. Haptoglobin is a serum glycoprotein carrying sialylated 361 
309 Carbohydrate deficient transferrin is a well-established complex type biantennary jV-glycan. Changes in the 362 
310 biomarker for detecting alcohol abuse [42-44]. haptoglobin glycosylation pattern have been studied as 363 
311 Alternations in glycosylation of glycoproteins and early as 1992 in ovarian cancer [36] and in canine diseases 364 
312 glycolipids are common in various cancers, and a consid- in the past decade [55’ 56]. Serum haptoglobin level was 365 
313 erable amount of them play important roles in carcinogen- found to be elevated in serum of HCC patients [17], and the 366 
•^ 14 esis, such as tumor progression, tumor cell differentiation, fucosylated glycoform of haptoglobin with altered sialyla- 367 
^15 cell -cell interaction, and tumor cell adhesion and metastasis tion was found to be associated with tumor progression, 368 
316 [45-48]. For examples, downregulation of beta-1,3-//- enhancing its value as HCC biomarker [17]. Recently, 369 
317 acetylglucosaminyl-transferase-T2 expression was observed aberrantly glycosylated haptoglobin has been shown to be a 370 
in invasive human bladder transitional cell carcinomas potential biomarker for other cancer types, including non- 371 
compared with their noninvasive counterparts, suggesting small cell lung cancer [57], prostate cancer [58], and 372 
that downregulation of this glycosylation enzyme may be pancreatic cancer [59]. 373 
321 
involved in cancer progression [45], In colorectal cancers, 
mRNA expressions of various glycosyltransferases are 
significantly altered [46]. Elevated mRNA expression of Glycomics—An Uprising Approach for Biomarker 374 
alpha 1-6 flicosyltransferase in human hepatoma tissues was Discovery 375 
associated with the production of tumor-specific fucosy-
处6 lated alpha-fetoprotein (AFP) glycoform [47]. The changes Glycome refers to a repertoire of glycans in a tissue/cell 376 
' 力 o f glycosylation machinery in the cancer cells can be type. Glycomics is the study of glycome. Glycomics is 377 
处8 reflected in the blood circulation by tracing the changes in becoming a hot research field in the recent years. There 378 
处9 the glycosylation of the proteins released by the tumor [48]. have been considerable advances in mass spectrometry 379 
’"^恥 The poor specificity of a tumor marker is often because (MS) technologies and oligosaccharide analysis technolo- 380 
晰 of the fact that it is also produced by normal cells under gies, including techniques in derivatization, fluorescent 381 
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382 labeling, capillary electrophoresis (CE), and high-performance mics and high-throughput MS approaches. To achieve this, 432 
383 liquid chromatography (HPLC), making glycomics study HGPI has attempted to develop a common data and 433 
384 possible. Recent advances of analytical technologies also analytical standard method of jV-glycans for various 434 
385 allow more effective differentiation of isomeric and anomeric diseases. Ultimately, a common database platform will be 435 
386 glycans, which can visualize the glycome with higher developed. Since October 2004, several projects were 436 
387 resolution. Similar to genomics and proteomics studies, carried out by HGPI, including the development of a 437 
388 glycomics studies rely on high-throughput screening to standard methodology for glycome analysis of glycans 438 
389 identify a panel of distinguishable glycomic features simulta- carried by human transferrin and IgG and the development 439 
390 neously. Glycomics study usually involves a large-scale of a diagnostic program for CDGs. The result of method 440 
391 systemic analysis of glycan pools, which usually contain development was noteworthy. It made a comprehensive and 441 
392 several subtypes such as AMinked and O-linked glycans and quantitative comparison between the merits and drawbacks 442 
393 glycans from glycolipid. Among these glycan subgroups, of different analytical approaches [61]. The ongoing CDG 443 
394 their structural properties, such as sequences and extent of program, on the other hand, aims to complement traditional 444 
395 branching and sialylation, differ from each other significantly methods for classification of the symptom through genetics 445 
396 as mentioned above. The analytical approaches for these and to discover new subtypes of the symptom. This 446 
397 subgroups hence are also different. anticipation by the global proteomics community clearly 447 
398 Moreover, as mentioned in the last section, glycans have illustrates the worldwide awareness of the importance of 448 
399 been recognized as a valuable source of biomarkers for glycomics in biomarker research. 449 
400 various diseases. Glycomic analysis allows rapid global In August 2007，the National Cancer Institute (NCI), 450 
401 comparison of glycome within body fluids or tissues of which is part of the National Institutes of Health in the 451 
402 interest, which would allow identification and application USA, had funded a new US$ 15.5-million 5-year initiative 452 
403 of a new type of biomarkers for cancer diagnosis and to consisting of seven projects on glycomic biomarker research 453 
404 monitor cancer development and treatment. With the with aims to discover novel cancer biomarkers and to 454 
405 establishment of powerful high-throughput technologies, improve preexisting ones. All seven projects (Table 1) are 455 
406 the analysis of glycome—a complex mixture with signifi- focused on either serum glycomic biomarkers or anti-glycan 456 
407 cant biological importance—has become a surmountable autoantibodies. Majority of these projects focused mainly on 457 
408 task. Unlike genomic or proteomic biomarkers, which cancers with poor prognosis, including pancreas cancer and 458 
409 directly or indirectly rely on transcriptional or translational breast cancer. This campaign has highlighted the importance 459 
410 information, glycomics allows biomarker researches to of glycomics in biomarker discoveiy and the advent of 460 
411 focus solely on the posttranslational events within the cells. glycomics in this postgenome era. 461 
412 It should be pointed out that there are several differences 
413 between glycoproteoniics and glycomics. Glycoproteomics 
414 aims to enrich, quantify, separate, and identify low Recent Applications of Glycomics to Biomarker 462 
415 abundant glycoproteins with specific glycosylation. There- Discovery 463 
416 fore, glycoproteomics focuses on a subset of proteome 
417 characterized by the presence of glycosylation on proteins, Owing to technological limitations to elucidate the complex 464 
418 and proteins remain the main subject of study [60]. In information of various glycans including sequences, struc- 465 
419 glycoproteomics study, a specific glycofonn of a glycopro- tures, and quantities, early studies of glycosylation 466 
420 tein, such as monosialylated AFP, will be identified as a remained at the level of separation of protein glycoforms 467 
421 biomarker. Glycomics, on the other hand, focuses on based on isoelectric focusing or lectin-affinity electropho- 468 
422 structures and sequences of glycan motifs, and the resis and subsequent identification by immunoblotting [42- 469 
423 conjugated molecules are not the main concern. The focus 44，50]. Recently, the development and maturation of more 470 
424 of this review is mainly on the applications of glycomics to sophisticated analysis platforms like MS and bioinformatics 471 
425 biomarker discovery, while glycoproteomics is not covered. allow more in-depth studies and high-throughput analyses 472 
^ on glycosylations. These have accelerated the utilization of 473 
glycosylation as a new source of biomarkers, as differential 474 
幻6 Human Proteome Organization Human Disease glycans can now be assessed more accurately and precisely 475 
427 Glycomics/Proteome Initiative at a larger scale. Aberrant glycosylation has gained much 476 
attention in biomarker researches, especially in liver 477 
Human disease glycomics/proteome initiative (HGPI) was diseases and cancers. 478 
launched by Human Proteome Organization. The major aim Except for the use of lectin microarrays, in most cases, it 479 
430 of HGPI is to identify disease-related glycobiomarkers in is inevitable in glycomic study to deglycosylate the 480 
biological fluids mainly by undertaking functional glyco- glycoconjugate of interest (glycoprotein, glycolipid, or 481 
Clin Proteom 
t l . l Table 1 The seven biomarker discovery projects funded by NCI by targeting glycans (information source: lUtp://www.nih.gov/news/pr/aug20()7/ 
nci-2l.htm) 
t l . 2 Project title Objectives of project 
Discovery and clinical validation of cancer Determine the diagnostic or prognostic anti-glycan autoantibody signatures 
biomarkers using printed glycan array in patients. For breast cancer, determine how many years before diagnosis that 
t l . 3 progression to cancer can be predicted 
t】 .4 Immunogenic sugar moieties o f prostate cancers Identify anti-glycan autoantibody signatures in prostate cancer patients 
Early cancer detection and prognosis through Identify biomarkers from glycans released from serum glycoproteins and 
t l . 5 glycomics develop high-throughput platforms to measure biomarkers suitable for the clinic 
Glycan markers for the early detection of Identify breast cancer biomarkers based on aberrant glycan modifications on 
t l . 6 breast cancer defined amino acid residues of serum glycoproteins 
Tumor glycomics laboratory for discovery o f Identify glycoprotein and glycolipid biomarkers for pancreatic cancer in pancreatic 
t l . 7 pancreatic cancer markers ductal fluid that can also be found in serum. Develop assays for promising biomarkers 
Autoantibodies against glycopeptide epitopes as Determine autoantibody signatures to mucin glycopeptides in pancreatic and breast 
t l . 8 serum biomarkers of cancer cancer patients 
NeuSGc and anti-Neu5Gc antibodies for detection Expand on research showing that cancer patients express cell surface glycans 
of cancer and cancer risk containing the sialic acid A^-glycolylneuraniinic Acid (NeuSGc) and produce 
t l . 9 autoantibodies to these structures 
482 lipopolysaccharide) and to retrieve the free glycan mole- sequencer as a CE instrument and subsequently used to 493 
483 cules for downstream analysis. The whole workflow can be detect liver cirrhosis [18’ 62]. Four glycomic features were 494 
484 roughly divided into three parts: deglycosylation, purifica- found to be significantly different in liver cirrhosis patients 495 
485 tion, and quantitative analysis (Fig. 1). compared with control, and all upregulated features were 496 
486 The number of glycomic researches and glycobiomarker shown to be fucosylated and carry a bisecting GlcNAc. Log 497 
487 studies has been gradually rising in the beginning of this ratio of two of these features gave a receiver operating 498 
488 century. A brief summary of all articles published in characteristic (ROC) curve area of 0.87 in classifying mild 499 
489 relation with glycomics was given in this review to provide fibrosis and compensated liver cirrhosis. In 2007，the same 500 
490 an overview of this growing field. In 2004, the global approach was applied to identify A^-glycomic changes in 501 
491 pattern of desialylated AMinked glycans from whole serum HCC patients with hepatitis B virus-induced liver cirrhosis 502 
492 proteins was successfully profiled by using a DNA [63]. Two fucosylated glycomic features, one of them 503 
Q 2 Fig. 1 Three parts of the |Glycoprote in samples / serum / t i s s u e s ^ 
I workflow: deglycosylation, “ ~ -i 1 
j purification, and quantitative 
analysis ^ ^ ^ ^ ^ ,-
I 1 Trypsinization 
Fluorcsccncc labeling of 
proteins I cells / 




^ Sample clean up Fluorescent labeling of glycans 
Lcctin I I MALDI-TOF M S / | | H PLC / Capillary Electrophoresis 
Microarray Tandem MS — r 
^ ^ 7 
Data mining, statistical analysis, structural 
prediction, biomarker discovery, ctc. 
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504 carrying bisecting GlcNAc, were found to be associated Technologies for Quantitative Profiling of Tissue 557 
505 with HCC. The log ratio of these two features gave an ROC Glycome 558 
50G curve area of 0.81 in diagnosing HCC, which is comparable 
507 with that of using AFP. Quantitative profiling is essential for the identification of 559 
508 Apart from CE, a matrix-assisted laser desorption/ differential features in biomarker discovery. Among the 560 
509 ionization time-of-flight (MALDI-TOF) MS has been technologies mentioned above, HPLC and CE are well 561 
510 successfully applied to obtain the quantitative profiles of known for their quantitative performance. The detection 562 
511 jV-linked glycans from the whole serum proteins without methods of glycans in these systems are based on the 563 
512 the need of desialylation and has been applied to identify measurement of fluorescent signal of the derivatized 564 
513 potential A^-glycomic biomarkers for liver fibrosis and liver glycans. As long as there is neither detector saturation nor 565 
514 cirrhosis [19]. A'-glycans were released from whole serum substrate bias during derivatization, the signal intensity 566 
515 proteins by PNGase F digestion and were purified by should be proportional to amount of analytes. CE has been 567 
516 hydrophilic chromatography. Finally, they were profiled by demonstrated to be quantitative in analyzing native and 568 
517 linear MALDI-TOF MS. A total of 17 differential N- derivatized glycosaminoglycans [68]. 569 
518 glycans were identified that correlated with degree of liver The quantitative aspect of glycan analysis in MALDI- 570 
519 fibrosis. Four of these A^-glycans were selected by using TOF MS is affected by various parameters including 571 
520 linear regression for the construction of diagnostic model. analyte derivatization, types of laser, spotting protocol, 572 
521 By using linear regression, a diagnostic model was choice of matrix, and acquisition protocol of spectrum. 573 
522 constructed from the potential diagnostic A'-glycans. It gave Structure of glycans, on the other hand, does not signifi- 574 
523 an ROC curve area of 0.91 for detecting liver fibrosis and cantly affect the quantitative performance of MALDI-TOF 575 
524 0.911 for detecting liver cirrhosis in the pilot study. In a MS [69], although it has been suspected that an extra 576 
525 similar study [64], the //-glycans released were purified by antenna may promote postsource decay [61]. To obtain a 577 
526 HPLC on graphitized carbon columns, and subsequently quantitative profile of glycome by MALDI-TOF MS, 578 
527 subjected to either desialylated or methyl-esterified before methyl-esterification of the sialic acid residues is usually 579 
528 MALDI-TOF MS analysis. MALDI-TOF MS was also required to prevent the loss of sialic acid during MS 580 
529 used in conjunction with a novel type of sepharose beads to analysis. However, our recent study has been that sialylated 581 
530 profile total serum A^-glycan [65]. The sepharose bead was glycan could be already quantified in the presence of 582 
531 flinctionalized with a hydrazide polymer to facilitate the 10 mM NaCl, but without the need of methyl-esterification 583 
532 immobilization of free glycans through hydrazone bond, [19], In proteomic study, it had been shown that the 584 
533 which allowed on-beads methyl-esterification of sialic acid. reproducibility of MALDI-TOF mass spectra was greatly 585 
534 The technology was applied to study three types of affected by the spotting methods, such as direct mixing, 586 
535 diseases: CDGs, HCC, and prostate cancer. It was able to overlaying, and sandwiching [70]. Similarly, such parameter 587 
S3f) identify serum glycomic features that could differentiate should also dictate the quantitative performance of MALDI- 588 
537 type 1 and type 2 CDG from healthy normal controls and TOF MS in glycan analysis. 589 
538 HCC from health normal controls. The method also The reproducibility of the signal intensity of a glycan 590 
1 539 allowed analysis of total cellular glycan profiles of human depends on (1) the quality of the glycan-matrix co-crystal on 591 
540 prostate cancer cells and normal human prostate epithelial the sample spot and (2) the laser scanning protocol. The 592 
cells. variation of signal intensities can be minimized by obtaining 593 
Apart from 7V-glycans, total serum O-glycomic pattern more mass spectra over different areas on the sample spot and 594 
was also profiled by MALDI-Fourier transform ion cyclo- averaging the resulting spectra. From a multi-institutional 595 
tron resonance (FTICR) MS and applied to discover study, the intra-assay and inter-assay coefficients of variation 596 
biomarkers for ovarian cancer [66]. A unique serum O- percentages of glycans released from human IgG were below 597 
546 glycomic profile containing 16 cancer-specific signatures 10% and 4.2% for major species and 34% and 13% for minor 598 
was obtained from patients with ovarian cancer. Infrared species [61]. In a separate study, the intra-assay and inter- 599 
548 multiphoton dissociation was applied, to glycan sequencing. assay coefficients of variation percentages of three different 600 
The diagnostic features identified in the spectra were standard glycans were below 9% and 18%, respectively [19], 601 
站0 confirmed to be oligosaccharides but not peptides. Later, This suggests that the quantitative performance of MALDI- 602 
站 1 the same approach was applied to search for potential TOF MS is comparable to chromatography. However, the 603 
biomarkers for breast cancer in mouse and human [67]. multi-institutional study clearly illustrated that there were 604 
553 Principle component analysis of the O-glycomic profiles considerable variations between different centers [61]. More 005 
’ h a d successfully distinguished breast cancer samples from efforts have to be made to standardize the protocols and 606 
’ n o r m a l samples. A summary of the above studies was given instrumentation to obtain comparable mass spectra from 607 
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609 TOF MS is its incapability to provide concrete structure microarray, the structure of the glycan can then be 662 
610 information of the glycan detected, although it is possible to interpreted based on the interaction pattern. Moreover, 663 
611 predict structures of glycans based on molecular weights lectin microarrays can be used to study glycan- lectin 664 
612 obtained from MS [19]’ In the future, a similar approach interaction in a high-throughput manner [83]. 665 
613 could be carried out with a MALDI-TOF/TOF MS system to Because the affinity of lectins to glycans was relatively low 666 
614 allow direct structure analysis by tandem MS. Besides a to 10" ^ M) compared with antibody-antigen inter- 667 
615 combined use of MALDI and TOF MS, MALDI has been action to 10"'^M), various techniques have been 668 
616 combined with FTICR MS to obtain quantitative glycomic developed to avoid loss of analytes during washing and to 669 
617 profiles [66，67]. However, the reproducibility of the probe such weak interactions such as the evanescent-field 670 
618 MALDl-FTICR MS in quantitative glycomic profiles has fluorescence detection [83] and the ratiometric approach [84]. 671 
619 not been systematically evaluated. An evanescent field is a weak electric field that only 672 
620 Comparable to gene expression microarray and antibody propagates wavelength distance from the sensor surface. It 673 
621 microarray, lectin microarray was a newly developed allows real-time detection during the interaction event 674 
622 technology for glycomics and glycoproteomics studies. between lectins and glycans, thus omitting the need of 675 
623 Lectins are highly specific carbohydrate-binding biomole- washing. While the ratiometric approach utilizes dual fluores- 676 
624 cules that recognizes glycans by their structural informa- cence colors similar to DNA microarrays for different 677 
625 tion. Different types of lectins recognize different samples, allowing ratiometric comparison between glycomes. 678 
626 oligosaccharide structures, terminal residue, and linkage This approach was also shown to be able to analyze complex 679 
627 [7 .1 ]. For example, galectins are specific toward Gal residue mixture including the total glycome of whole-cell lysates [84]. 680 
628 [72]; siglecs are a group of I-type lectins, which mediate The quantitative performance of lectin microarray has been 681 
629 glycan recognition via Ig-like domains [73], and selectins well evaluated [82]. The signal intensity was linear for 682 
630 are expressed by leukocytes and endothelial cells to glycoproteins in the range of 50 to 300 |xg/ml. Coefficient 683 
631 recognize sialyl Lewis antigens [74]. Lectins have been of variation of signal intensities was within 10% to 20% [83]. 684 
632 widely used to study and isolate glycoproteins. Lens Although lectin microarray also detects fluorescence 685 
633 ciilinaris agglutinin lectin, which binds specific to alpha- signal associated with the glycans, there are several ways 686 
634 1,6 fucosylation at proximal core GlcNAc, has been applied that are different from the approaches based on HPLC or 687 
635 to isolate fticosylated AFP glycofomis associated with CE. Firstly, in the lectin microarray technology, fluorescent 688 
636 HCC [75]. Ricinus communis agglutinin lectin, which binds tags could be attached to protein portions of the glyco- 689 
637 |3-Gal, was applied on monitoring the desialylation of conjugates, instead of the glycan molecules. Hence, the 690 
638 glycoproteins in murine B16 melanoma cells [76] and on glycoproteins or glycoconjugates can be applied directly to 691 
639 investigating the degree of galactosylation of glycoproteins the array without deglycosylation and desialylation. This 692 
640 in human astrocytoma [77]. Sambucus nigra agglutinin simplifies the experimental process and allows more 693 
641 lectin, which recognizes alpha 2,6-linked sialic acid, was labeling options and downstream analysis as well as 694 
642 used to measure the degree of alpha 2,6-sialylation of simultaneous analysis of 0-linked, N-linked, and glycolipid 695 
643 glycoproteins in human colon cancer [78]. Binding of Helix glycans [82]. Secondly, lectin microarray belongs to the 696 
644 pomatia agglutinin lectin, which recognizes GalNAc, to type of competition assays. Different glycoproteins having 697 
645 human cutaneous malignant melanoma was found to be the same glycan structures will compete for the same group 698 
646 associated with metastasis formation [79]. Peanut lectin, of lectins. It is not uncommon that different glycoproteins 699 
647 which binds Gal (31-3 GalNAc, was used to measure levels are labeled with a different number of fluorescent tags, 700 
648 of mucin-type 0-glycan in the human benign and malignant leading to variations in the signal intensities between 701 
649 colorectal tissues [80]. experiments. Furthermore, a single lectin molecule can 702 
650 In the lectin microarray technology, a panel of lectins is bind to glycan molecules with different structures, but at 703 
1 immobilized onto solid support in a microarray format. This different affinities. When a mixture of glycoproteins or 704 
652 allows simultaneous detection of glycans based on their glycoconjugates is subjected to a lectin microarray analysis, 705 
interaction with different lectins. ..Lectin microarray was a highly complex pattern of competition and interaction 706 
first developed in 2004 [81]. It has been shown that a lectin among glycans and lectins will result. 707 
655 microarray spotted with nine lectins was already capable of 
656 giving distinct glycoprofiles for different glycoproteins 
[82]. In the experiment, lectin microarray was exposed to Future Prospective 708 
fluorescence-tagged glycoproteins, followed by washing 
659 and scanning. The experiment outcome was a pattern of As glycosylation changes have been associated with a wide 709 
恥0 lectins that interact with the glycans of glycoproteins. When range of diseases, it can be foreseen that glycomics holds 710 
恥 1 a purified glycan or glycoprotein is analyzed with the lectin the promise for biomarker discovery. Currently, HPLC and 711 
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